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                                                             ABSTRACT  
Prostate tumor cells over-express a prostate-speciﬁc membrane antigen (PSMA) 
that can be used as a marker to select these cells from highly heterogeneous clinical 
samples, even when found in low abundance. In this study, anti-PSMA aptamers were 
immobilized onto the surface of a capture bed poised within a PMMA, microchip, which 
was fabricated into a high-throughput micro-sampling unit (HTMSU) used for the 
selective isolation of rare circulating prostate tumor cells resident in a peripheral blood 
matrix. The HTMSU capture bed consisted of 51 ultra-high-aspect ratio parallel 
curvilinear channels with a width similar to the prostate cancer cell dimensions. Using a 
linear velocity (2.5 mm s-1) for optimal cell capture in the aptamer tethered HTMSU, a 
recovery of 90% of LNCaP cells (prostate cancer cell line; used as a model in this 
example) was found. Due to the low abundance of these cells, the input volume 
required was 1 mL and this could be processed in 29 min using an optimized linear ﬂow 
rate of 2.5 mm s-1. Captured cells were subsequently released intact from the afﬁnity 
surface using 0.25% w/v trypsin followed by counting individual cells using a contact 
conductivity sensor integrated into the HTMSU that provided high detection and 
sampling efﬁciency (100%) and did not require staining of the cells for enumeration. 
Next, an alternative fluidic device was designed and fabricated to select E. coli 
O157:H7 cells from water samples using antibody-based positive selection followed by 
the accurate identification and quantification via RT qPCR. The assay offers the ability 
to evaluate recreational water quality without the need for bacterial cell culturing. Due to 
the smaller size of these cells (1-2 μm) compared to CTCs (20 μm), fluidic transport 
properties of E. coli cells were characterized and found to depend less on centrifugal 
forces to increase the encounter rate of the cells with the surface-immobilized 
antibodies used for their selection compared to the larger CTCs.  Through fundamental 
studies to optimize the transport rate, E. coli cells could be recovered at 72%, with the 
RT qPCR assay limit-of-detection equal to ~6 cells.  The enrichment procedure provided 
many advantages compared to existing EPA methods for E. coli analysis; (i) recognizes 
O157 antigens from intact and virulent cells and in stressed and non-culturable cells, 
which also can produce Shiga-like toxins; (ii) cells enriched on-chip were free from 
potential interferences that may hamper the nucleic acid-based measurements; and (iii) 
preconcentrate cells by nearly 105 from samples that are 100 mL in total volume.  
xxi 
 
Finally, I report on a microfluidic technique for selective isolation, enumeration, 
and electrokinetic enrichment of low-abundance (~10 cells mL-1) circulating tumor cells 
(CTCs) directly from whole blood. Enriched CTCs can then be genetically profiled for 
marker mutations which can provide important clinical information. In here I integrated 
high-throughput CTC selection ability of HTMSU with electrokinetic enrichment step for 
pre-concentration of selected CTCs for molecular profiling of rare genetic mutation in 
genomic DNA. SW620 cells (colorectal cancer cell line) over-express the integral 
membrane protein EpCAM, and as such could be immuno-specifically selected using 
the HTMSU activated with the EpCAM antibodies. Selected CTCs were then 
enzymatically released intact from the antibody capture surface and hydrodynamically 
transported through a pair of Pt electrodes for conductivity-based enumeration without a 
need for fluorescent labeling. Following enumeration, CTCs were hydrodynamically 
transported at a flow rate of 1 µL min-1 to an on-chip electro-manipulation unit. At an 
electric field strength of 100 V cm-1, the negatively charged CTCs migrated against both 
the EOF and hydrodynamic flow and were enriched in the anodic receiving reservoir to 
a final volume of 2 µL. The collected CTCs could then be genetically profiled to search 
for point mutations using a PCR/LDR/capillary electrophoresis assay.  
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CHAPTER 1 MICROSYSTEMS FOR CAPTURE OF LOW-ABUNDANT CELLS 
 
1.1 Low-Abundant Cells 
What distinguishes a low-abundance cell from one that is not, and what 
applications require the ability to analyze low-abundance cells? On the basis of the data 
presented in Table 1.1, we consider any sample containing less than 1,000 target cells 
mL−1 to contain low-abundance cells. Typical examples of low-abundance cells are 
circulating tumor cells (CTCs), circulating fetal cells, and stem cells. The abundance of 
these cells, as well as others, is highly variable and depends upon factors such as the 
age of the sample, the stage of the disease, and the cellularity, which is defined as the 
state of a tissue or cell with regard to the degree, quality, or condition of cells present.1 
However, environmental samples containing biopathogens are categorized on the basis 
of the effective infectious dose level that can lead to the outbreak of disease (Table 1.1). 
 The ability to select and enumerate low-abundance cells and their subsequent 
analyses have many important applications (Table 1.1), such as cancer research,2 
forensic science, homeland security, space exploration, environmental analysis,3 
isolation and characterization of intact fetal cells in maternal blood for noninvasive 
prenatal diagnosis,4 use of stem cells for cell-based therapies,5 detection of CTCs in 
blood for differential diagnosis and prognosis,6–11 and detection of T lymphocytes for 
determining the progression rate of human immunodeficiency virus infections12,13 or 
autoimmune disease.14 Another fast-growing area requiring low-abundance cell analysis 
is the isolation and detection of pathogens and protozoan parasites such as Escherichia  
coli O157:H7, swine influenza  virus, and  Cryptosporidium  in  various  food  and  water   
                                                 
 Reproduced with permission from Annual Reviews of Analytical Chemistry 
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Table 1.1 Low-abundance cell types (<1000 targets mL−1) and methods for their selection 
Rare cell type Resident material 
      Cell 
abundance 
(cells mL
-1
) 
Isolation method Ref. 
 
C
T
C
 Lung, Breast, 
Prostate, Pancreatic, 
Colon, Cervical, 
Bladder 
Peripheral, Cord 
blood, Bone marrow, 
Lymph Fluid, 
Thymus, Urine 
<0.7 
MACS, FACS, 
Immunoaffinity columns 
(6,9, 
42, 
18) 
F
e
ta
l 
 
Trophoblasts, 
Lymphocytes, 
Nucleated 
Erythrocytes 
Maternal and cord 
blood 
1-15 
MACS, FACS, Charge flow 
separation, Density 
gradient centrifugation 
(DGC) 
(83) 
  
  
S
te
m
  
 
 
Multipotent Stem Cells 
 
 
Peripheral, Cord 
blood 
Bone marrow 
400 
MACS, FACS 
Immunoaffinity columns,           
                DGS 
(19-
22) 
S
o
m
a
ti
c
  
Sperm Vaginal swab 380  
Differential extraction, 
FACS  
 (84) 
In
fe
c
te
d
  
HIV infected T cells 
S. spp infected 
lymphocytes 
Peripheral blood 
Lymph 
300 
MACS, FACS 
Immunoaffinity columns 
ELISA 
(23, 
24) 
(88) 
B
a
c
te
ri
a
l E. hirae, E. gallinarum 
E. casseliflavus,               
S. pneumoniae 
E. coli O157:H7*, 
V. Cholerae* 
Waste, River, 
Drinking Waters 
0.01-1 
Bacteria Culture, 
ELISA, PCR/RT-PCR 
(94, 
25) 
(26) 
V
ir
u
s
e
s
 
Adenoviruses* 
Enteroviruses* 
Hepatitis A and E* 
Waste, River, 
Drinking Waters 
0.01-1 
Viral cultures, 
Immunoaffinity column, 
 RT-PCR, ELISA 
(26) 
Dengue 
Swine flu 
Bovine Diarrhea 
Peripheral Blood 
Lymph 
1000 
610  
10 
(25) 
 
(64) 
P
ro
to
z
o
a
 
/H
e
lm
in
th
e
s
 
C. parvum 
C. cayetanensis, 
E.histolytica, N. fowleri 
D. medinensis, S. spp. 
Waste, River, 
Drinking Waters 
0.01-1 
Fluorescence antibody, 
Filtration, PCR/RT-PCR, 
ELISA 
(26) 
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samples.15–17 
The challenge in any analytical strategy for low-abundance cells begins with the 
selection of the target cells from a heterogeneous population in which the target is a 
minority. For example, in the case of CTCs, in 1 mL of whole blood there are more than 
109 red blood cells (RBCs) and typically one to five CTCs, requiring an enrichment 
factor less than 109. For the isolation of low-abundance cells, four important metrics 
must be considered: (a) throughput, the number of cell-identification or -sorting steps 
per unit time; (b) recovery, an indicator of the fraction of target cells collected from the 
input sample; (c) purity, which depends on the number of so-called interfering cells 
excluded from the final analysis; and (d) viability, that is, whether the isolated cells 
retain their biological function after the selection process.27,28 Additionally, highly 
efficient quantification of the number of enriched low-abundance cells must be provided 
in most cases.29  
1.2 Methods for Low-Abundant-Cell Selection  
Two basic formats can be used for selecting low-abundance cells from mixed 
populations: macro and microscale formats. Macroscale formats provide high 
throughput for selecting low-abundance cells due to their ability to process large input 
volumes quickly, whereas microscale formats typically lack that ability (see Figure 
1.1).30 High-throughput processing is required due to the necessity for sampling large 
input volumes to generate a high statistical confidence for successfully securing the 
target cells from the processed sample. Throughput is directly proportional to (a) the 
cross-sectional area of the conduit through which the sample is delivered and (b) the 
rate of sample delivery. The input sample volume required  for the  assay is  determined  
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Figure 1.1 Sample-processing time as a function of the fluidic conduit cross-sectional area at 
three different linear velocities: 1, 10, and 100 mm s−1. 
by the frequency of rare cell appearance. For example, at 5 cells mL−1, a sampling 
volume of 1 μL would produce a probability of only 0.5% of finding the target cells in that 
volume.  Because low-abundance cells appear at frequencies less than 1,000 cells 
mL−1, high-volume sampling (≥1 mL) is required to increase the probability of isolating 
these rare events. If cross-sectional dimensions of 35 μm×35 μm were employed for a 
fluidic conduit to exhaustively search for rare cells, and if the transport rate through the 
conduit were 10 mm s−1 with a required input volume of 1.0 mL, the sampling time 
would be approximately 278 h. For a single rectangular conduit with dimensions of 150 
μm×35 μm under conditions similar to those given above, the sampling time would be 
reduced to ∼5.6 h. If the 150 μm×35 μm conduits were highly parallelized through the 
incorporation of 51 conduits, the processing time would drop to 0.12 h (Figure 1.1). 
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1.2.1 Macroscale Techniques for Selecting Low-Abundant Cells 
Commonly used macroscale formats for enriching low-abundance cells include (a) 
magnetic capture that employs micrometer-sized ferromagnetic beads coated with 
molecular recognition elements, typically referred to as immunomagnetic-assisted cell 
sorting (IMACS);35-37 (b) size-based separations that use nuclear-tracked 
membranes;38,39 (c) fluorescence-activated cell sorting (FACS);40,41 and (d) reverse-
transcription polymerase chain reaction (RT-PCR) of messenger RNAs (mRNAs), which 
are used as surrogates for cell identification.42 In the following sections, we briefly 
discuss these macroscale processing techniques. 
1.2.1.1 Immunomagnetic-Assisted Cell Sorting  
CellSearch® procedure and OncoQuick® system are two commercially available 
immunomagnetic isolation kits for selecting CTCs from peripheral blood samples.43 Both 
kits employed anti-epithelial cell adhesion molecules (EpCAM) antibodies for selecting the 
cancer cells. Both procedures employed density gradient centrifugation followed by a series 
of washes in order to remove the red blood cell (RBC) fraction from the whole blood sample 
prior to magnetic isolation of the low abundance cells. Centrifugation of the RBC depleted 
sample is next performed at 800×g for 10 min to remove the blood plasma. The resulting 
cellular pellets are resuspended in 10 mL of buffer, and incubated with carboxylate-
functionalized ferromagnetic particles that are coated with anti-EpCAM. 
Immunomagnetically-labeled cells are concentrated using an external magnetic field (see 
Figure 1.2). Following magnetic isolation, the processed sample is incubated with leukocyte 
specific anti-cytokeratin antibodies labeled with Alexa Fluor 555, nuclear specific 4‘,6-
diamidino-2-phenylindole (DAPI), and a CTC specific anti-EpCAM antibody conjugated to a 
fluorescein derivative. Under these conditions, white blood cells and tumor cells harbor blue  
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Figure 1.2  (A-C) Schematic of the immunomagnetic-assisted cell-sorting process. Blue and tan 
circles represent normal and circulating tumor cells, respectively. (D) Schematic of a 
fluorescence-activated cell-sorting instrument. 
fluorescing nuclei; however, the fluorescent signatures of the FITC derivative selectively 
placed a green ―halo effect‖ about the blue nuclei of the CTCs. The orange fluorescent halo 
from the Alexa Fluor 555 about the nuclei of the leukocytes is used for exclusion. The CTC 
recovery rates data is significantly better using the CellSearch system (60% recovery) 
compared to the OncoQuick system (26% recovery). In addition, the CellSearch system 
requires a smaller input volume compared to the OncoQuick system. The non-metastatic 
samples with both kits show the detection of at least one CTC in the blood of healthy 
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individuals in 12% of these samples analyzed. For the confirmed metastatic cancer cases, 
CellSearch is capable of producing positive responses in 54% of these samples resulting in 
a relatively high rate of false negatives.43 The OncoQuick system demonstrated poorer 
detection accuracy as only 23% of the samples are reported positive for metastatic disease. 
In 5 of the 6 varieties of cancer studied, CellSearch is twice as effective as OncoQuick at 
detecting metastatic disease and CellSearch is also found to be more sensitive in common 
positive tests often identifying more CTCs within similar amounts of peripheral blood. 
1.2.1.2 Size-Based Selection  
Tracked polycarbonate membranes with varying pore sizes (8–14 μm) are 
employed to filter large (9.0–18 mL) blood samples spiked with known quantities of 
CTCs.36 Prior to filtration using the membrane, the samples are diluted at a 1:1 (v/v) 
ratio of spiked blood:PBS containing an anticoagulant EDTA. Simple gravimetric 
filtration through these polycarbonate membranes is sufficient to reduce the erythrocyte 
content by >105 cells mL-1. After the initial filtration using the polycarbonate filter, the 
isolated cells are washed and incubated for 1 h with anti-pan-cytokeratin directed 
against cytokeratin 5, 6, 8, 17 and 19)-FITC. After a wash to remove the unbound anti-
cytokeratin antibodies, nuclei-specific propidium iodide is added, and an additional 
incubation of 30 min performed. The cells retained by the polycarbonate membrane are 
analyzed using a combination of laser scanning cytometry (LSC) and microscopy. After 
analysis, all the cytokeratin positive cells are relocated and examined ―by eye‖ to 
exclude any false- positive events. Only positive cells with the appropriate 
nuclear:cytoplasmic ratio are counted as positive events.  
 False positives are evident in the case of MCF-7 cells, and the authors attributed 
this to the presence of adhesion molecules on the cells‘ periphery. The most prominent 
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reduction in leukocyte frequency is demonstrated for 9 mL blood samples that originally 
contained 5×107 leukocytes, which is reduced to 7,000 leukocytes after the filtration 
step. These membranes are demonstrated to isolate nearly 85–100% of the CTCs, but 
significant numbers of white blood cells are also retained due to their similar size with 
respect to the CTCs complicating the enumeration process. Also, the process requires 
pre or post treatment of retained cells with a variety of fluorescent stains before the LSC 
could be utilized.   
Microarrays are also used in the isolation of target cells. Various ―cluster of 
differentiation‖ (CD) antigens are affinity-captured onto the arrays containing 
immobilized antibodies.40 The arrays contain several surface-immobilized antibodies 
directed toward target antigenic species, which are used to spatially isolate cells. These 
methods are limited by slow mass transport but are promising for multiplexed analyses; 
the array elements are not individually addressable making collecting isolated cells from 
a multiplexed analysis difficult due to the single chamber of the arrays. Most often in 
order to isolate a particular phenotype, subsequent processing is required. Belov et al. 
presented an array technique based on cluster of differentiation in leukemia.40 The CD 
antigens can be used to phenotype leukocytes based on characteristic abnormal 
patterns of antigen expression. Microarray technology is also used to screen HIV 
positive blood against normal as well as blood from those undergoing therapy and those 
deemed long term non-progressors.41 
1.2.1.3 Fluorescence-Activated Cell Sorting  
FACS can be used to select low-abundance cells from mixed populations by 
monitoring the presence of antigenic species indigenous only to the target cells (see 
http://www.abcam.com/technical). FACS samples individual cells in a high-throughput 
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fashion (∼50,000 cells s−1) by monitoring the fluorescence signature elicited by each cell 
type (Figure 1.2D). For example, FACS has been used to detect and enumerate an 
immortalized breast cancer cell line (BT-20 cells) that was seeded into peripheral blood 
mononucleated cells (PBMCs) at frequencies of 10−5, 10−6, and 10−7.37 The flow cytometer 
employed three excitation wavelengths, 325, 488, and 633 nm, allowing for discrimination 
between the PBMCs and the BT-20 cells. A panel of fluorescently labeled antibodies 
allowed the BT-20 cells to produce distinct colors for their identification from the PBMCs. 
BT-20 cells were also characterized by a cocktail containing three anti-cytokeratin 
antibodies, each tagged with a different-colored dye. Through the use of a color-
discrimination algorithm, BT-20 cells were detected with a 20% recovery for frequencies at 
10−5 and 10−6. The challenges associated with this assay format were the extensive 
amount of time required for the immunofluorescent staining (∼20 h), the need to remove 
the RBCs from the blood sample prior to processing, and the extensive equipment required 
for the measurements. The recovery was low due to the loss of target cells during removal 
of the RBC fraction and the extensive staining and processing steps required. For this 
approach to reliably assess rare CTCs at frequencies of 10−7 in the presence of PBMCs, 
∼200 mL of blood would be needed. 
1.2.1.4 Molecular Methods  
Another approach employed for the analysis of low-abundance cells in clinical or 
environmental samples is RT-PCR, in which mRNAs are used as markers to report on the 
presence of specific low-abundance cells. For example, reports have documented RT-
PCR‘s ability to detect low-abundance cells in 106 PBMCs via an appropriate marker 
panel.38 Gene expression–based assays have high sensitivity but can generate poor 
selectivity, which can lead to false-positive results. Also, as with many low-abundance cell–
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based assays for whole blood, the RBC fraction must be removed with, for example, Ficoll-
Hypaque density-gradient centrifugation (DGC), which can reduce cell recovery. Notably, 
these assays are prone to high interlaboratory variability.39 
1.2.2 Challenges Associated with Macroscale Methods for Low-Abundant-Cell 
Selection 
 
Enrichment of target cells via macroscale systems typically employs either positive 
selection (for example, IMACS or FACS) or negative selection. Negative selection gives 
low purity (0.01%–0.1%) due to insufficient removal of interfering cells.42 When the sample 
matrix is whole blood, negative selection performed on the basis of size is often marred by 
interferences resulting from leukocytes, due to the similarity in size between these cells and 
the CTCs, for example.45,46 Attempts to further preconcentrate targets and remove WBCs 
introduce a significant risk of target loss. For example, monocytes were found to interfere 
with the selection of comparably sized stem cells.47  
The challenges associated with positive selection using IMACS or FACS assays are 
the extensive amount of time required for the immunofluorescent staining (∼20 h) and, in 
many cases, the need to remove the RBCs from a blood sample prior to processing. 
Furthermore, semi-automated processes requiring operator intervention and the variability 
in reagent and laboratory protocols lead to poor interlaboratory standardization and data 
collection, assessment, and management.48 Additionally, downstream processing of the 
collected rare cells requires samples with high purity that are in a viable form (i.e., following 
cell culturing). For example, the magnetic field used for IMACS may produce perturbations 
on stem cell differentiation.49 Finally, in the case of positive selection, the recovery can 
depend upon the expression level of the antigenic membrane protein used for their 
selection.9  
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Many macroscale techniques also rely on DGC preselection. Differences in density 
between cell types can be small, and individual cell types can be heterogeneous in size 
and density.50 Consequently, particular cell types can distribute throughout a density-
gradient medium, rather than precisely segregate at a discrete area; this results in reduced 
recovery of the desired cells and/or contamination with undesired cell types.45 Procedures 
such as DGC that enrich for low-abundance blood cell types, such as hematopoietic 
progenitor cells, can lead to significant loss or reduced yields due to poor segregation with 
potential interfering cells. For example, conventional density-gradient methods to isolate 
progenitor cells (e.g., CD34+ hematopoietic stem cells) from umbilical cord blood results in 
significant loss of the desired stem cells.46 
1.3  Microsystems for Low-Abundant-Cell Selection 
Microsystem technologies allow the dissemination of new sample-processing 
capabilities to a broader user community due to their potentially smaller footprint, lower 
power consumption, reduced reagent requirements, and process automation, as compared 
with their benchtop counterparts. Additionally, improved performance is fundamental to 
high-sensitivity cellular analysis technologies.53,54 In particular, microsystem platforms 
enable one to handle small numbers of cells without loss. Such a task is difficult to achieve 
with instruments such as conventional flow cytometers, which typically require a starting 
population of more than 100,000 cells.55 Furthermore, low-abundance cell–selection 
mechanisms such as affinity, physical characteristics, dielectrophoresis (DEP), and 
magnetic interactions can be integrated into a microsystem, along with downstream 
molecular processing of the intracellular contents of the selected cells, to provide important 
clinical or environmental information. The challenge for imposing low-abundance cell–
selection assays to microsystems is sampling; to generate a high statistical probability of 
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selecting the low-abundance cells, large input volumes (>1 mL) must be processed, and 
most microsystems cannot handle large-volume inputs in reasonable times (i.e., they have 
poor throughput; see Figure 1.1). Therefore, novel design approaches must be 
implemented to accommodate the necessary sampling volume. In the following sections, 
we review microfluidic-based systems for selecting low-abundance cells. 
1.3.1 Low-Abundant-Cell Selection via Immunoaffinity Interactions 
Affinity-based selection of low-abundance cells is often employed in 
microsystems. This approach exploits the specific but noncovalent interactions between 
a ligand, such as an antibody, aptamer, or peptide, and a target-specific receptor, such 
as a membrane protein.56 Affinity-based cell selection via microsystems can be carried 
out by either positive or negative selection. Negative selection requires the complete 
removal of the nontarget cells with minimal target-cell capture and is an attractive 
approach when the specific markers for target cells are not fully known. In contrast, 
positive selection involves directly capturing the target cell through the use of a 
membrane protein(s) unique to that cell type.9  
In most cases, cell selection involves a solid phase in which (a) the recognition 
element(s) is covalently tethered to the surface of a fluidic conduit and (b) the sample 
containing the low-abundance cells is moved through this conduit to invoke the 
selection process. The operational criteria mentioned in Section 1 are important to this 
phase, as are (a) nonspecific interactions, (b) target cell–recognition element adhesion 
strength, (c) conduit architecture, (d) recognition element immobilization chemistry, and 
(e) ligand surface density.  
As noted in Section 1, throughput—namely, the number of cell-identification or -
sorting steps per unit time—is a critical metric to optimize. One can improve throughput 
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by increasing the transport rate of sample through the selection conduit. However, cell 
recovery can degrade at certain transport rates, indicating that there is an optimal flow 
rate at which the system can be operated. The analytical model used to explain this 
observation is based on cell adhesion between a surface-tethered antibody and a 
moving antigen.57 This model describes a two-state process. The first state accounts for 
transport of the solution-cell antigen to the surface-bound antibody, which describes the 
encounter rate (ko). The second state gives the probability (P) that an association event 
will occur during the time the antigen is in close proximity to the tethered antibody. The 
encounter rate, ko, increases linearly with flow velocity, whereas P decreases. These 
states can be used to calculate the rate of capture per antigen-antibody pair (kf, s
−1) via 
the following equation:57 
                                                kf =ko P        (1) 
P can be estimated from Equation 2, 
                                              P=ᴧδ/(1+ᴧδ)  (2) 
where δ is the dimensionless Damkӧhler number (calculated from a2kin/D; kin is the 
intrinsic antigen-antibody reaction rate; a is the encounter radius) and ᴧ is the 
dimensionless encounter time [calculated from ז/(a2/D); ז=8a/(3Uπ); U is the cell-
translational velocity; D is the cell diffusion coefficient].33,57 Equation 1 indicates that the 
recovery increases with translational velocity due to increases in ko but that, beyond an 
optimal velocity, the recovery degrades due to insufficient reaction time (i.e., lower P). 
 Critical to affinity-based cell selection that uses surface-immobilized recognition 
elements and flow processing is the adhesion force (FA) between the cell and the 
antibody-decorated surface, which must be greater than the shear force (FS) generated 
by the solution flow to prevent target cell loss. FA can be determined from the bond 
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strength between a single antigen-antibody complex (fc), the cell-contact area with the 
recognition surface (Ac), and the number of receptors poised on the surface within the 
contact area of the cell (Cs). FA is calculated from
33 
                                                     FA=fc×Ac×Cs  (3) 
If the cell is assumed to be a nondeformable object once it adheres to the capture 
surface, the contact area can be calculated from Equation 4,58 
                                          Ac=π{rpsin[cos
−1(rp –h‘+h)/rp]}
2 (4) 
where rp is the cell radius and h and h’ represent the characteristic cell-separation 
distances from the surface upon binding. When the FS generated by the flow is equal to 
or greater than FA, the cell can be removed from the surface. The velocity-dependent FS 
can be determined from Stoke‘s law,59 
                                                        FS=6πηrpνc , (5) 
where rp is the cell radius, η is the solution viscosity, and νc is the critical linear velocity 
that can induce cell detachment.  
The application of mAB based microsystem for CTCs selection kept pace with 
their increasing availability. Monoclonal antibody-poised microsystem was designed by 
Du et al. to recognize and select cervical cancer cells (HCCC) in a mixed cell 
population.60 The channel dimensions of microsystem were rather large, 500 µm×500 
µm, and  2.0 cm long. The anti-α6-integrin antibody was immobilized on the surface 
against overexpressed α6-integrin antigen on cervical cancer cell membrane. The 
capture efficiency of 30% was obtained at average velocity of 1.3 mm s−1 and surface 
antibody concentration of 1:50, while normal cell capture efficiency was less than 5% 
reported indicating insufficient separation efficiency with low purity to track rare cell 
events. It is found that separation purity and cancer cell capture efficiency were altered 
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by the specificity of the antibody, flow rate and surface immobilized antibody 
concentration. Increasing the flow rate caused both increased dissociation of antigen 
and decreased antigen–antibody interaction time. The high non-specific binding of 
normal cells at low flow rates were observed and it was likely a result of the high surface 
to volume ratio of the microchannel. 
Nagrath et al.9 developed a microsystem for selecting CTCs directly from 
peripheral blood. The CTCs originated from solid lung, colorectal, breast, prostate, brain, 
and neck tumors and were selected through use of anti-EpCAM monoclonal antibodies 
tethered to the walls of a microfluidic channel and posts. The device contained 78,000 
microposts that were 100 μm tall and 100 μm wide with a total surface area of 970 mm2 
(Figure 1.3). Anti-EpCAM monoclonal antibodies provided the specificity for CTC 
recovery from unfractionated blood because EpCAM is specifically overexpressed by 
adenocarcinomas.9,33 The essential parameters that determined recovery by the CTC 
chip were flow velocity, shear force, and cellular EpCAM expression level, as noted in 
Equations 1–5. At a flow rate of 1 mL h−1, 65% of the CTCs were recovered, and 98% of 
the cells remained viable. As the processing flow rate was increased to 3 mL h−1, the 
recovery was reduced to 25%, as shown in Figure 1.3E. Enrichments from whole blood 
provided ∼50% purity, and as a result the CTCs had to be differentiated from the major 
impurity, leukocytes, through use of fluorescently labeled cytokeratin and CD45 
antibodies (Figure 1.3G-N). The same CTC chip was also used to select low-abundance 
lung cancer cells from whole blood.59 Extensive clinical studies have been successfully 
completed with the use of this CTC chip. For example, with this chip CTCs were 
isolated in 100% of patients with early-stage prostate cancer. Furthermore, the potential 
utility  of   this   CTC  chip  in  monitoring  response  to   anticancer   therapy   was   also  
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Figure 1.3  Isolation of circulating tumor cells (CTCs) from whole blood, performed with a 
microfluidic device (CTC chip) fabricated in silicon via reactive ion etching. (A) The workstation 
setup for CTC isolation from whole blood. (B) The CTC chip with microposts etched into the 
silicon. (C) Micrograph of whole blood flowing through the CTC chip. (D) An image of a captured 
NCI-H1650 lung cancer cell spiked into blood (pseudo-colored red). The inset shows a high-
magnification view of the captured cell. (E) CTC recovery as a function of flow rate. (F) 
Regression analysis of capture efficiency for various target-cell concentrations in whole-blood 
samples versus lysed-blood samples. (G-N) High-magnification images of captured CTCs and 
hematologic cells stained with 4‘,6-diamidino-2-phenylindole (DAPI), cytokeratin, and CD45. 
Merged images identify CTCs in panels G, I, K and M and hematologic cells in panels H, J, L, 
and N. 
investigated. In a small cohort of patients with metastatic cancer who were undergoing 
systemic treatment, temporal changes in CTC numbers correlated well with the clinical 
course of the disease.9,59  
 Adams et al.33 introduced a microchip-based high-throughput microsampling unit 
(HTMSU) capable of selecting very low abundance CTCs from whole blood in a single 
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step. The HTMSU was fabricated from poly(methylmethacrylate) (PMMA) via 
microreplication and consisted of 51 ultrahigh–aspect ratio, parallel, curvilinear channels 
and a Pt-conductivity sensor to allow for cell enumeration (Figure 1.4). The capture 
channels were functionalized, via a carboxylate scaffold, with anti-EpCAM monoclonal 
antibodies. The authors found that the CTC-capture efficiency varied with channel width; 
the highest recovery (97%) was obtained for channels that had similar widths (35 μm) to 
the CTC dimensions (15–30 μm) (Figure 1.4F). The device was capable of high-
throughput operation at an optimal linear fluid velocity of 2 mm s−1 in each channel (51 
parallel channels), allowing 1 mL samples to be exhaustively interrogated in ∼37 min. 
The captured CTCs were subsequently removed from the capture surface via trypsin 
and were quantitatively counted one at a time via conductivity detection. 
 Microsystems have also been applied to immunoassay-based recognition for 
pathogen detection. Static forward light scattering was investigated for the analysis of 
bovine viral diarrhea virus in a complex matrix mimicking a body fluid.61 The assay was 
based on the use of microparticles coated with antibodies directed against bovine viral 
diarrhea virus, and the reaction was monitored in a Y-shaped poly(dimethylsiloxane) 
(PDMS) fluidic device with optical fibers oriented at a 45◦ angle to measure light scatter 
from single virus cells. Bovine viral diarrhea virus concentrations of 10 TCID50 mL
−1 
(where TCID50 stands for 50% tissue-culture infectious dose) were detected with this 
microfluidic chip. Application of antigen/antibody-recognition strategies for low-
abundance-cell selection is, in some cases, limited by the availability of antibodies 
directed against membrane proteins uniquely found on the target rare cells.62 
Additionally, most   positive selection tools require surface immobilization of the 
antibody, which can result in reduced recovery or  adhesion  strength  between  the  cell 
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Figure 1.4  Schematic of a microchip-based high-throughput microsampling unit (HTMSU) 
fabricated in poly(methylmethacrylate) via microreplication for selection of circulating tumor cells 
(CTCs). (A) An AutoCAD® diagram of the sinusoidally shaped capture channels with bright-field 
optical micrographs showing (B) the integrated conductivity sensor consisting of cylindrical Pt 
electrodes with a 75 μm diameter and a 50 μm gap; (C) the single port exit, where the HTMSU‘s 
width tapers from 100 μm to 50 μm and the depth tapers from 150 μm to 80 μm over a 2.5 mm 
region that ends 2.5 mm from the Pt electrodes; (D) the sinusoidal cell-capture channels (5x 
magnification); (E) three-dimensional projection of the topology of the HTMSU obtained at 2.5 
μm resolution via noncontact optical profilometry (arrows, Pt electrode conduits); and (F) the 
capture efficiency of CTCs in spiked whole-blood samples as a function of the cells‘ translational 
velocity. The microchannels were 35 μm wide (red down triangles, sinusoid; purple circles, 
straight) and 50 μm wide (blue up triangles).  
 
and the surface-tethered antibody due to the stochastic nature of the immobilization 
chemistry. Antibodies may also show variation in antigen binding, exhibit instability 
when bound to solid surfaces, and have limited binding sites.63 Finally, environmental 
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factors may affect antibody-antigen interactions.64,65 Therefore, alternatives to 
antibodies for low-abundance cell selection have been investigated.  
Aptamers, single-stranded nucleic acid oligomers, possess highly specific 
recognition affinities to molecular targets through interactions other than classical 
Watson-Crick base pairing.66 Compared with antibodies, aptamers have lower molecular 
weights, remain stable during long term storage, sustain reversible denaturation, have 
low toxicity, and can be produced against targets via highly automated technologies 
[e.g., SELEX (systematic evolution of ligands by exponential enrichment)].67 Additionally, 
their immobilization chemistry is highly oriented: End-point attachment occurs 
exclusively through the 5‘ or 3‘ end of the aptamer, which bears a functional group. 
These advantages make aptamers highly desirable as potential molecular recognition 
elements for low-abundance-cell selection.68 
Aptamers have been employed in a microsystem for the capture of prostate 
cancer cells that used a LNCaP cell line as a model. This cell line overexpresses a 
prostate-specific membrane antigen (PSMA) that was used as a marker for the 
selection of these cells.69 Nuclease-stabilized and in vitro–generated PSMA aptamers 
were immobilized onto ultraviolet-modified PMMA capture channels (Figure 1.4A-D). 
The authors used carbodiimide-coupling chemistry and the appropriate linker structure 
to enhance the accessibility of the surface-bound aptamer to the solution borne cells 
(Figure 1.5A). Following selection and isolation, the captured cells were released from 
the capture surface via enzymatic digestion of the extracellular domain of PSMA for 
subsequent conductivity enumeration. CTCs possess unique electrical properties that 
arise from their characteristic chemical composition (compared with those of 
erythrocytes. 
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Figure 1.5  (A) Chemical steps for the immobilization of aptamers to the surfaces of a 
poly(methylmethacrylate) (PMMA)-based high-throughput microsampling unit (HTMSU) used for 
the positive selection of LNCaP cells. (B) Conductometric responses generated for 1.0 mL of 
whole blood seeded with 20±1 LNCaP cells (red) and 0 LNCaP cells (blue), at a linear flow 
velocity of 2.5 mm s−1, processed with an HTMSU. The arrows designate peaks that were 
identified as LNCaP cells on the basis of a signal-to-noise threshold of 3. 
For example, the overexpression of membrane glycoproteins—such as PSMA 
and EpCAM, which are associated with many tumor or cancer cells—results in an 
increase in the number of negatively charged sialic acid molecules that cap the 
extracellular domains of these integral membrane proteins.58 As shown in Figure 1.5B, 
only positive signals were designated as LNCaP cells due to their electrical properties. 
The system required no sample pretreatment and provided high throughput (processing 
time for 1 mL was 29 min), a recovery of 90%, and a purity of 100%. 
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1.3.2 Low-Abundant-Cell Selection via Physical Criteria 
Differences in cell size, density, shape and deformability can be exploited in 
microsystems to select low-abundance cells on the basis of mechanical restriction.71,72 
Such microsystems are relatively easy to build with common microfabrication 
technologies.19  
Forensic DNA analysis of sexual assault evidence requires separation of DNA 
from epithelial (victim) and sperm (perpetrator) cells collected on vaginal swabs. 
Because the cells in sexual assault evidence are rarely viable, biological adhesion is 
less likely, but adsorption to the glass is possible and could be used to selectively 
isolate the epithelial cells from solution using microsystem, either alone or in conjunction 
with the sedimentation rate differences.19 Specific gravity differences are small but 
perceptible, with sperm cell density on the order of 1.12 g mL-1 73 and epithelial cell 
densities in the range of 1.04-1.08 g mL-1.74 These values characterize differences in 
the rate at which cells would settle to the bottom of the inlet reservoir. The microsystem 
prepared by Horsman et al. contained a straight channel with the dimensions of 2.5 cm 
long, 50 µm deep and 90 µm wide at half-height. The larger surface area of the 
epithelial cells and their high concentration of cell surface binding proteins, which are 
capable of specific interaction with surfaces, present the possibility for binding to glass 
substrates. Because, the method does not use mobilization of the epithelial cells, 
clogging of the microchannel by epithelial cells, was not encountered here. Separation 
speed and throughput was low, because the flow rates achievable using gravity forces 
were slow, not easily controlled. It was demonstrated that increasing the flow rate to 
achieve a faster separation can dislodging the epithelial cells from the reservoir. A 20 
min separation (~380 sperm cells) provided sufficient material for DNA extraction and 
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PCR amplification of a 380-bp fragment of β-globin, which is a representative human 
gene. Though the system generated 100% theoretical purity, the real life forensic 
samples are contaminated with bacteria and purity of separation can be deteriorated 
and bacteria can interfere with effective counting of sperm cells using optical means. 
The size and deformation characteristics of fetal nucleated red blood cells 
(fNRBCs) were used to isolate them from maternal blood.19 fNRBCs range between 9 
and 12 μm in size and were demonstrated to deform and pass through fluidic obstacles 
fabricated in PDMS that were as small as 2.5 μm×5 μm. WBCs ranging in diameter 
between 10 and 20 μm could not deform and thus were retained by the fluidic  channels 
of similar dimensions. The authors19 isolated low-abundance fNRBCs from umbilical 
blood that was preconcentrated using DGC. Unfortunately, the low processing rate of 
<0.35 mL h−1 posed a major challenge to this system, given that ∼10 mL of blood had to 
be processed to accommodate sampling these low-abundance cells. 
A series of massively parallel microfabricated sieving structures were used to 
separate neuroblastoma (NB) tumor cells from blood constituents on the basis of size 
characteristics.72 The reported devices consisted of four successively narrowing regions 
of channels. The size-based selection of tumor cells was carried out through the use of 
diluted blood (1:10) (v/v) containing the NB cells. As the NB cells traversed the device, 
they were retained in the 10 μm×20 μm channels, but other blood cells migrated to the 
output. It was observed that in shallow channels NB cells tended to adhere to the walls 
upstream of where freely moving cells were retarded. A shorter (3.5 cm) device with 
deeper (20 μm) channels reduced the device flow resistance and adhesion problems. 
Experiments that used undiluted whole blood (2 mL) took approximately 3 h to analyze. 
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The authors72 noted that the enriched cells obtained from the device had low purity and 
that the interfering cells were composed of residual erythrocytes and leukocytes. 
1.3.3 Low-Abundant-Cell Selection via Dielectrophoresis 
DEP uses the electrical polarization of cells in nonuniform fields to induce 
translational motion and/or reorientation of the cells.75 The induced polarization depends 
on multiple factors related to the cells‘ condition, such as bilipid membrane 
characteristics, internal structure, and size of the nucleus.76 DEP has been used to 
study the physiology of bacterial,77 yeast,78 plant,79 and mammalian cells80 and to 
investigate cellular alterations accompanying physiological changes, such as mitotic 
stimulation and induced differentiation. The variability in particular cells‘ response to 
electric fields can be used not only to differentiate cell types but also to distinguish the 
activation states of similar cells.81 DEP devices can differentiate among cell types by 
changing the field frequency or amplitude.82-84  
The DEP force (FDEP) acting on a cell can be calculated via
85 
                                     FDEP=2πεM rp
3Re[fCM (ω)]∇E
2
RMS, (6) 
where εM is the permittivity of the suspending medium, rP is the cell radius, ERMS is the 
electric field strength, and Re[fCM(ω)] is the real part of the dipolar Clausius-Mossotti 
factor. This factor is the relative polarization of the cell versus that of the surrounding 
medium and is given by85 
                              fCM (ω)=[ε∗C(ω)−ε∗M (ω)]/[ε∗C+2ε∗M (ω)]  (7) 
where εC∗ and εM∗ are the complex permittivities of the cell and medium, respectively. 
The DEP forces can be either negative, Re[fCM(ω)]<0 (i.e., the cell is repelled by a 
region of higher electric field), or positive, Re[fCM(ω)]>0 (i.e., the cell is attracted to a 
region of higher electric field). As shown by Equations 6 and 7, the polarizability of the 
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cell is frequency dependent; thus, changing ω can result in the selection of certain cell 
types. 
 A dielectric affinity column was used to select tumor cells (MDA231) from diluted 
blood,86 from which the cells were captured by balancing gravity, DEP, fluid drag, and 
hydrodynamic lift effects (Figure 1.6) and released by reducing the frequency of the 
applied electric field. Efficient selection was obtained when (a) the product of the cell 
radii and dielectric polarizability was sufficiently different and (b) the ratio of fluid velocity 
to the square of the applied voltage was within the specified range, determined by the 
type of cell. The column sorted cells at a rate of ∼103 s−1; larger devices increased this 
rate by two orders of magnitude. The viability of the excluded cells was 98%, indicating 
that the cell-membrane barrier function was maintained. The total number of cells 
analyzed with this device in a single run was 1.2×106, and the ratio of tumor cells to 
normal hematopoietic cells was 1:3.  
The electrical conductivity of RBC membranes increases sharply when they 
become infected with malarial parasites such as Plasmodium falciparum. When 
challenged by a suspension in a low-conductivity medium, infected cells lose internal 
ions, whereas uninfected cells retain them.24 The resulting dielectric differences 
between infected and noninfected cells were exploited in order to sort these cells via 
DEP.24 Parasitized cells were isolated by steric dielectric field–flow fractionation (DEP-
FFF) and were focused at the center of a spiral electrode array, identified, and counted. 
The spiral microelectrode array had a 2 mm2 surface area and was composed of five 
complete turns of four parallel spiral elements. On the spiral array, cells were 
distinguished through differences in their DEP properties. More than 99.5% of the 
25 
 
normal erythrocytes were trapped, and 90% of the parasitized cells were 
preconcentrated 50- to 200-fold.  
 
Figure 1.6 Dielectrophoretic separation of MDA231 human metastatic breast cancer cells from 
diluted peripheral blood. (A) Initial separation of cells in the chamber inlet well after the electrical 
sweep signal was applied. (B) Blood cells focused into bands that flowed between the electrode 
tips, leaving the cancer cells behind. (C) Cancer cells that remained on the electrode tips after 
the blood cells were swept downstream through the dielectrophoresis column. (D) Close to the 
chamber outlet well, where only blood cells in focused bands were moving.  
 
Using a similar approach, Reichmuth et al. developed a microfluidic chip with an 
integrated membrane for simultaneous concentration and detection of swine influenza 
virus with necessary sensitivity for diagnosis.87 The membrane was created in a small 
section (100 µm wide×25 µm deep×150 µm long) of the microchannel. The  
Immunoassays recognized the membrane viral proteins using antibodies. Open channel 
electrophoresis was used to detect by observing formation of an antibody–antigen (virus 
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particle) complex. The size-exclusion properties of the in situ polymerized 
polyacrylamide membrane were exploited to simultaneously concentrate viral particles 
and separate the virus/fluorescent antibody complex from the unbound antibody. The 
filtration step eliminated the need for washing, commonly required with surface-based 
immunoassays and increased the speed of the assay. With integrated preconcentration, 
a LOD of 610 TCID50 mL
−1 could be obtained for <50 µL sample in less than 6 min. The 
most common failure mode of the chip was accumulation of dust or other particulates at 
the membrane element. Therefore, sample prepreparation is required to remove large 
particles (> micrometer-size). 
Differences in cell-dielectric properties were exploited to separate and identify 
cells without extensive cell manipulation.88 For applications such as stem cell research, 
it is highly preferable that the isolated cells be unlabeled and minimally manipulated to 
preserve their integrity. Vykoukal and coworkers89 applied DEP-FFF for the rapid, label-
free enrichment of progenitor cells from a stromal vascular fraction. Different cell types 
were  driven   to  different  flow  lamina   in  a  DEP-FFF  separator  on  the basis  of  the 
aggregate effect of their density and specific dielectric properties. Low-abundance 
putative progenitor cells, NG2 cells (<2% in the starting mixture), were enriched up to 
14-fold, yielding 28% NG2+ cells in the most enriched fraction. This device is therefore 
ideally suited for batch-mode isolation and recovery of moderate quantities of cells 
(<106 cells per run).  
Although these approaches are applicable to many cell-processing problems, 
they demand that the dielectric properties of the target cells be significantly different 
from those of the interfering cells. For this reason, DEP/gravitational field–flow 
fractionation (DEP/GFFF), which has a potentially higher discriminatory ability, has been 
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developed.90,91 GFFF is a process by which particles are allowed to settle while under 
the influence of an axial flow.92 In DEP/GFFF, the balance of DEP and gravitational 
forces controls cell position in the gravitational flow profile.91 This technique was applied 
to the separation of a breast cancer cell line (MDA435) from RBCs.92 Results suggested 
that the MDA435 cells could be separated from erythrocytes in a 10 μL sample 
containing a total of ∼50,000 cells. The enriched fractions of the MDA435 cells and 
erythrocytes were reported to be >98% and >99%, respectively. 
1.3.4 Low-Abundant-Cell Selection via Magnetic Interactions 
Target cells can be specifically labeled with antibody-conjugated magnetic beads, 
and the selection and enrichment of the low-abundance cells can be achieved through the 
use of a magnetic field. Using this principle, Lee and coworkers27 developed an integrated 
system capable of selecting RNA viruses, such as dengue virus and enterovirus, through 
use of antibody-conjugated magnetic beads and one-step RT-PCR in an integrated 
microfluidic system. The target virus in the sample was captured with modified magnetic 
beads and manipulated via microelectromagnets (Figure 1.7A). The integrated microfluidic 
system performed the entire process automatically with a rotary micropump and 
microvalves for fluid control. Following isolation, the viruses selected were subjected to 
thermolysis, RNA extraction, and RT-PCR on a single chip. The authors‘ results were 
similar to those obtained with benchtop instruments (Figure 1.7B). 
 Furdui and Harrison adopted this technique in order to enrich Jurkat cells (T cell 
leukemia) from blood.93 The model samples contained Jurkat cells to erythrocyte cells 
ratios of 1:10,000 with a total of 1-2×1010 RBCs mL-1 with a Jurkat cell frequency of 1×106 
mL-1. The magnetic beads were initially functionalized with protein A prior to incubating with   
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Figure 1.7 (A) Schematic of an integrated reverse-transcription polymerase chain reaction (RT-
PCR) chip with a cell-selection unit for the magnetic capture of target cells. A microtemperature 
module, a bead-collection module, and a microfluidic control module are integrated into the chip. 
(B) A mixture of dengue virus (102 PFU) and enterovirus 71 (102 PFU) was incubated with 
antidengue antibody (lanes 1 and 2) or antienterovirus 71 antibody-conjugated magnetic beads 
(lanes 3 and 4); RT-PCR was then performed with dengue group–specific primers (lanes 1 and 
3) or enterovirus 71–specific primers (lanes 2 and 4). The lanes marked with the letter L 
represent signals generated from DNA size markers. Results on the left and right are from a 
benchtop instrument and the integrated chip, respectively.  
 
anti-human CD43. The results of the incubation yielded antibody-functionalized beads, 
where the antibodies were bound to protein A via their Fc domain. A magnetic zone was 
used to selectively isolate the magnetic particles bound to the target cells in the microfluidic 
device. Subsequent to a rinsing step, the captured cells were eluted after removal of the 
magnetic field and initiation of hydrodynamic pumping. Following optimization, the authors 
were able to isolate 37% of the spiked T-cells with a throughput that corresponded to 3 μL 
min-1 from a 2 μL sample that consisted of 1,070 Jurkat cells. 
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Beyor and coworkers94 presented an E. coli O157:H7-detectionmicrosystem with 
integrated cell capture, sample preparation, and PCR with capillary electrophoresis analysis. 
Immunomagnetic beads were coupled to polyclonal antibodies specific to the E. coli 
phenotype of interest. Sample volumes ranging from 10 to 100 μL were introduced and 
driven through immunomagnetic bead beds to capture the target cells. A detection limit of 
0.2 colony-forming units μL−1 was achieved for an input volume of 50 μL. 
1.3.5 Microfluidic Fluorescence-Activated Cell Sorting 
Replacing the conventional flow chamber in FACS with microfabricated devices 
could allow more sensitive optical detection, easier mechanical setup, and more innovative 
sorting schemes. Another advantage is that multiple cell sorters can be fabricated in 
parallel on a single chip, allowing increased throughput or successive enrichment steps.  
Fu et al.95 demonstrated a complete microfabricated fluorescence-activated cell 
sorting (μFACS) device for E. coli HB101 cells. The chip was mounted on an inverted 
optical microscope, and fluorescence readout with a photomultiplier tube was accomplished 
at a T-shaped fluidic junction on the chip, with the cells manipulated electrokinetically. An 
advantage of the μFACS system is the small detection volume, typically 250 fL, which 
greatly reduces background fluorescence from the cell suspension and chamber material. 
Low-abundance cells are sorted by implementing a specific sorting algorithm. When a cell 
of interest is detected, the flow is stopped and the cell of interest is recovered by running 
the flow backward at a slow speed until the cell is moved into a collection channel. At that 
point, the cell is collected, and the device is once again run at a high speed in the forward 
direction. This reversible sorting method cannot be performed with standard FACS 
machines. The μFACS system offers several  advantages  over  traditional   FACS:  (a)  
Because the channels are made with micrometersize dimensions, the volume of the 
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interaction region can be precisely controlled, eliminating the need for hydrodynamic 
focusing;  (b)  the planar geometry  of the device allows for the use of high–numerical 
aperture optics, increasing the limit of detection of the optical system; and (c) the 
disposability of the sorting device obviates the need for cleaning and sterilizing the 
instrument and prevents cross contamination between samples. However, the 
throughput obtained with this μFACS is 20 cells s−1, considerably lower than that of 
conventional FACS.  
Another example of low-abundance-cell sorting via μFACS was presented by 
Simonnet & Groisman,94 who attempted to port conventional high-throughput, high-
resolution cell sorting using flow cytometry to a PDMS microsystem. The integrated cell 
sorter was incorporated with various components, including peristaltic pumps, dampers, 
and input and output wells, to perform cell sorting in a coordinated and automated 
fashion. DEP and pressure switching were used to create a valveless device for the 
separation of cells within microchannels. The standard forward and reverse sorting 
algorithms were implemented. Conventional FACS uses flow rates of ∼10 m s−1, 
corresponding to sampling rates of 1,000–50,000 cells s−1. Using this platform, the 
authors processed up to 17,000 cells s−1. An 83-fold enrichment was achieved in a 
single pass, yielding 40% recovery. As with the macroscale version of FACS, sorting 
and enumerating low-abundance cells require specific staining protocols as well as 
sample-preprocessing steps. 
1.4  Conclusions  
IMACS, FACS, and size-based selection techniques of low-abundance cells can be 
transitioned to microscale systems, and they can produce results that are similar if not 
superior to their macroscale counterparts. The high automation potential of microﬂuidic 
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systems and their ability to process samples in closed architectures provide a venue in 
which to analyze mass-limited samples, such as low-abundance cells, which is free 
from contamination.  
However, Microsystems for rare cell selection need to be designed to sample 
larger input volumes in reasonable times (i.e., higher throughput) to accommodate 
extremely low abundance cells. In this dissertation, I investigate the use of surface 
modification, rare cell enumeration and electro-manipulation techniques in polymer-
based microfluidic devices as a means of separation, enumeration and enrichment low-
abundance cells in complex matrices such as whole blood and environmental water 
samples.  The selection and enumeration of low-abundance cells are often not the 
terminal steps in the processing pipeline of these cells. For example, CTCs selected via 
immunoafﬁnity, with EpCAM as the molecular target, can originate from a variety of 
different cancers, such as colorectal, prostate, bladder, lung, or breast. To determine 
the speciﬁc type of cancer, it is necessary to molecularly proﬁle the selected cells. A 
major challenge concerns the mass-limited samples encountered when analyzing low-
abundance cells. For example, in a single eukaryotic cell two copies of the genome and 
approximately 300 copies of each different mRNA molecule are present, requiring highly 
sensitive genotyping techniques to characterize these molecular entities.   
Therefore, I also investigate to optimize genotyping techniques such as RT-
qPCR and PCR/LDR/CE for quantitation and molecular profiling of low-abundance 
genetic molecular entities. Overall, highly integrated low-abundance cell–based 
microﬂuidic devices that can molecularly proﬁle such cells will ﬁnd applications in 
medicine at the point of care; national security and counterterrorism; police, paramedics, 
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and ﬁre departments; veterinary medicine; and environmental and food safety 
monitoring. 
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CHAPTER 2 CIRCULATING TUMOR CELLS: A LITERATURE REVIEW   
 
2.1 Introduction 
The first observation of blood-borne cells shed from a solid tumor was reported in 
the 19th century from an Australian physician named Thomas Ashworth from a patient 
who died of metastatic cancer.1 Originally these cells were referred to as 
‗carcinocythemia,‘ but now they have been named circulating tumor cells (CTCs).2  A 
fraction of these CTCs originate from the primary tumor and consequently, are one of 
the initial steps in the process of metastasis, whereas a majority of these CTCs are 
derived from metastatic lesions. Because the ultimate fate of cancer patients is largely 
determined by metastases and the number of CTCs is likely to reflect the 
aggressiveness of a tumor, CTC detection, characterization and enumeration have 
been considered to have great potential in the therapeutic management of cancer-
related diseases.3 
2.2 Anatomy of Tumor Metastasis 
 Metastasis is the process by which cancer cells leave the primary tumor site, 
disseminate and form secondary tumors at anatomically remote sites.4 Understanding 
the metastatic process is indeed a critical process in cancer fatalities; 90% of cancer 
patients do not die from their primary tumor, but from metastatic disease.5 In 1889, 
Paget proposed the ‗seed and soil hypothesis‘ for understanding the process of 
metastasis. He proposed that metastatic spread was a consequence of particular tumor 
cells (‗seeds‘) finding a suitable environment (‗soil‘) in which to develop and grow.4 An 
alternative hypothesis, that of mechanical entrapment, was proposed by Ewing in1928; 
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he suggested that CTCs accumulate through entrapment in the first vascular bed they 
encounter.4 
As such, metastasis is often delineated as a ‗cascade‘ of events (Figure 2.1), 
because there are a series of steps that are involved:4,6-8 
(1) The development of a new blood supply to the proliferating tumor (angiogenesis).  
(2) The elude of tumor cells from the primary tumor mass. 
(3) Incursion of, and migration through, the basement membrane (BM) and extracellular 
matrix (ECM) surrounding the tumor epithelium and subsequent invasion of the BM 
supporting the endothelium of local blood vessels (or lymphatics).  
(4) Intravacation of the tumor cells into the blood vessel (or lymphatic), prior to 
hematogeneous (lymphagenous) dissemination to distant anatomical sites.  
(5) Adhesion of the CTCs to the endothelial cell lining at the capillary bed of the target 
organ site. 
(6) Incursion of the tumor cells through the endothelial cell layer and surrounding BM 
(extravasation) and target organ tissue. 
(7) The growth of secondary tumor foci at the target organ site.  
Angiogenesis is the formation of new blood vessels from pre-existing vasculature. 
Without the formation of an intra-tumor blood supply, tumors would be unable to obtain 
the oxygen and nutrients necessary to flourish.7 Angiogenesis is stimulated by the 
release of growth factors, such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF).9 As a result of angiogenesis, tumors gain access to a 
blood supply in conjunction with co-option of existing blood vessels and also 
vasculogenicmimicry, where the tumor cells themselves carve blood vessel-like 
conduits.10 
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Figure 2.1 The metastatic cascade. Tumor cells are released from the primary tumor mass, and 
thus become circulating tumor cells (CTCs). The CTCs in the blood are subjected to the shear 
forces generated by the flow of blood, immune response attack and anoikis. CTCs that do 
survive can reach a target organ and attach to the endothelial cell lining within the capillary bed 
of the target site. After invading the endothelium, a secondary tumor mass can develop. 
Reprinted with permission.8 
 
Loss of cell–cell adhesion within the primary tumor mass permits disaggregation 
of tumor cells and hence, aids in the initial phases of dissemination.11 Cadherin/catenin 
expression in the primary tumor is also altered resulting in the loss of cell–cell adhesion. 
It has been reported that abrogation of E-cadherin is associated with the metastatic 
phenotype.12 During metastasis, the dissolution of the ECM is achieved through the 
action of several hydrolytic enzymes, released either by the tumor cells themselves or 
by cells surrounding the tumor.13 From model systems, it has been estimated that ~1× 
106 CTCs per gram of solid tumor tissue can be introduced daily into the bloodstream.8 
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Once released from the primary tumor site, many cancer cells possess the ability 
to migrate and do so in several different ways: (1) Moving collectively as groups or as 
single cells; (2) adopting an elongated mesenchymal morphology; or (3) crawling in an 
amoeboid manner.9 Tumor cells initially attach to the BM and ECM via interactions with 
the integrin family of adhesion receptors and subsequently traverse these structures as 
proteolytic enzymes help their invasion and ultimately allow the tumor cells access to 
the vasculature. Tumor cells also move through collagenous matrices by physically 
deforming their shapes.14 
The endothelial cells can retract, thus allowing the detached tumor cells to pass 
into systemic circulation. Once tumor cells are in the blood stream, they are subject to 
events which can threaten their survival including the shear forces generated by the 
flow of blood and an immune response attack.15 Upon being shed, the CTCs are fragile 
and lack interactions with blood borne fibrin and platelets and as a result, the membrane 
can be easily destroyed by shear stress imparted by blood flow.16 In addition, natural 
killer cells, Pit cells and Kupffer cells, attack the neoplastic cells immediately upon 
release.17,18 It has been reported that the presence of CTCs in the peripheral blood 
triggers as much as an 80% increase in the number of natural killer cells present within 
peripheral blood in a matter of minutes. As such, the vast majority of carcinoma cells 
are killed within a few hours of dissemination through the natural defense system.19 Also, 
most tumor cells are either mechanically destroyed from the shear stress of blood flow 
rupturing the cells‘ membrane or the CTC undergoes a process called anoikis, a special 
form of cell death resulting from an adhesion deficiency.20 Single tumor cells are more 
likely to be destroyed compared to cells travelling in clumps because the cells at the 
center of the complex are physically shielded.21  
42 
 
Most often, tumors develop in organs proximal to capillary beds owing in part to  
metastatic CTCs surviving the natural protections provided by the circulatory system. 
Survival is further supported by the CTCs developing a protective barrier consisting of 
fibrin and platelets sufficient to prevent lysis from blood flow related shear by providing a 
stabilizing reinforcement and barrier-like protective coating from natural killer cells.  
Surviving CTCs can eventually reach the capillary bed of a target organ, where 
they can adhere to the micro-vessel endothelium, which stimulates endothelial cell 
retraction. The CTCs pass through the BM via the action of proteases and thus, 
establishing a secondary tumor at a new site. Once tumor cells reach the secondary site, 
they may be destroyed – most undergo apoptosis within 24 h, may lie dormant, or they 
may proliferate to form secondary tumors. It has been recently revealed that CTCs can 
reach the peripheral blood from tumor deposits every few hours and can remain there 
for as long as 22 years.8  Recent evidence suggests that tumor cell dormancy may 
account for the observation that some tumors – for example, melanoma and breast 
cancer – may present metastases many years after eradication of the primary tumor.7  
It has been suggested that distant sites may be pre-conditioned to become fertile 
ground for the establishment of metastases; the ‗metastatic niche‘. Hematopoietic stem 
cells migrate to tissues causing remodeling of the ECM and growth factor milieu, such 
that a microenvironment is formed that both attracts tumor cells and supports their 
proliferation.22 
2.3 Morphology of CTCs 
  Both solid tumor cells (STCs) and cultured CTCs have been found to have 
irregular nuclei. Many CTCs exhibit conspicuous intracellular compartments containing 
numerous small vesicles and large amounts of amorphous material. They are also 
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surrounded by a ribosome decorated membrane. These inclusions may have a size 
equal to or exceeding that of the nucleus and are not seen in STCs. CTCs have a 
significantly larger mean cell diameter (CTC-15 µm) and cell volume (CTC-1730 µm3) 
compared to STCs (STC-11 µm, STC-735 µm3, respectively). In contrast, STCs have a 
larger nuclear/cytoplasmic (N/C) ratio (CTCs-27.1%, STCs-28.9%) and ‗excess‘ 
membrane (CTCs-46.8%, STC-60.9%).23 
The deformability of STCs and CTCs differ significantly as well. Small 
deformations are rapid and of similar magnitudes for both cell types, but large 
deformations are considerably slower in the case of CTCs. Microscopic observations 
indicate that CTCs‘ large nucleus resists deformation. In addition, it has been 
speculated that the large, multi-vesicular intracellular accumulations of CTCs contribute 
to their low cytoplasmic deformability.24 
Marrinucci et al. investigated the morphology of CTCs using metastatic breast 
cancer cells. They observed different subcategories of CTCs within the same patient‘s 
blood sample. It was discovered that 22.9% of CTCs had a higher N/C ratio than the 
surrounding white blood cells (WBCs) (Figure 2.2). They also exhibited a scant rim of 
amphophilic to eosinophilic cytoplasm with round to oval to  occasionally  lobated nuclei 
without sharp irregularities. The chromatin was vesicular with  prominent, generally 
eosinophilic   nucleoli.  This   category   of   CTCs   was   termed  well-differentiated 
adenocarcinoma cells.25  In addition, their eccentrically located nuclei were slightly 
smaller than neighboring WBC nuclei. The chromatin was often coarse and 
hyperchromatic in these CTCs with a moderate rim  of  dense  appearing  orangeophilic 
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Figure 2.2 Example of CTC types identified from the patient with breast cancer. (A) Wright-
Giemsa–stained CTCs (100x oil). (B) Same cells as (A) showing initial fluorescent image of 
corresponding CTCs stained with anti-CK-Alexa Fluor 488 (green) and DAPI (4',6-diamidino-2-
phenylindole) (blue) (image taken at 20 and enlarged for comparison purposes). (C) Example of 
probable CTC undergoing final stages of apoptosis, with no detectable nucleus. These events 
are not counted as CTCs in our patient statistics. Reprinted with permission.25 
 
cytoplasm. This category of cells meets the cytological criteria for moderately to well-
differentiated adenocarcinoma cells.26 31.9% and 34.7% of the total CTC population 
exhibited morphologic evidence of both early- and late-stage apoptosis (Figure 2.2), 
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respectively. Early apoptotic changes included condensation and shrinkage of nuclear 
material yielding hyperchromatic glassy-appearing nuclei with loss of nuclear detail on 
Wright-Giemsa staining.26,27  Also, clusters of CTCs were noted with a 4% frequency. 
Ten doublets, one triplet, and one quartet were observed by Marrinucci et al. The 
composition within clusters was a heterogeneous mixture of cell types.25 
2.4 Biomarkers Found in CTC Membranes 
 CTCs express two distinct marker types on their membrane, which are tumor 
type-specific and epithelial-specific markers. Tumor type-specific markers are 
expressed exclusively on tumor cells that have disseminated from a particular tumor.28 
Markers of this type include mammoglobin, HER2-neu, mucin 1 (breast cancer), 
prostate specific antigen (prostate cancer), and carcinoembryonic antigen (colorectal 
and gastric cancers).3,29 Although these types of markers may offer the potential 
advantages of specifically identifying a particular organ tumor cell rather than just 
epithelial cells, they also provide some insight into their molecular characteristics.  
Epithelial-specific markers are expressed by all tumor cells of epithelial origin as 
well as by normal epithelial cells, although they are unlikely to be present in the 
peripheral blood stream. The most commonly used markers in this category include the 
epithelial cell adhesion molecule (EpCAM, also known as ESA, CD326, HEA125, TROP 
II, or TACSTD1) and cytokeratins (CK) 7, 8, 18, 19, and/or 20.30 The majority of 
leukocytes do not express epithelial markers, however, they occasionally have been 
observed to become positive for such antigens when in an activated state.3,31 
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2.5 Abundance of CTCs in Cancer Patients 
 Allard et al. evaluated the abundance of CTCs in the blood of healthy subjects 
and patients with a variety of malignant diseases (Table 2.1).32 The number of CTCs in 
metastatic cancer patients ranged from 0 to 23,618 in 7.5 mL of patient‘s blood. The  
Table 2.1 Summary of CTC counts in 7.5 mL of blood from patients with various types of 
carcinomas 
 
No. of 
patients 
No. of 
specimens 
Mean 
±SD 
Median 
with ≥2 
No. (%) 
≥2 
No. (%) 
≥5 
No. (%) 
≥10 
No. (%) 
≥50 
Subject  
Healthy 145 145 0.1±0.2 N/A 0(0) 0(0) 0(0) 0(0) 
Nonmalignant 199 199 0.1±0.3 3 1(1) 0(0) 0(0) 0(0) 
Metastatic 
cancer type 
        
Prostate 
cancer 
123 188 75±333 13 107(57) 77(41) 61(32) 27(14) 
Unknown 
cancer 
11 27 16±35 13 14(52) 13(48) 8(30) 2(7) 
Ovarian cancer 29 53 6±16 9 20(38) 12(23) 1(23) 9(17) 
Breast cancer 422 1316 84±885 10 489(37) 340(26) 256(19) 129(10) 
Gastric cancer 9 13 24±83 3 4(31) 1(8) 1(8) 1(8) 
Colorectal 
cancer 
196 333 4±11 5 99(30) 56(17) 30(9) 5(2) 
Bladder cancer 7 7 42±107 146 2(29) 2(29) 1(14) 1(14) 
Renal cancer 11 12 1±1 2 3(25) 0(0) 0(0) 0(0) 
;Lung cancer 99 168 30±178 9 34(20) 24(14) 16(10) 10(6) 
Pancreatic 
cancer 
16 21 2±6 3.5 4(19) 1(5) 1(5) 0(0) 
Assorted other 
cancer 
41 45 1±4 11 5(11) 4(9) 3(7) 0(0) 
Combined 
cancers 
964 2183 61±696 9 781(36) 530 (24) 386 (18) 176(8) 
NOTE. The group labeled unknown are patients with metastatic disease with unknown primary 
tumor; the assorted others are carcinomas with <5 specimens. 
Abbreviation: N/A, not applicable. Reprinted with permission.32 
 
highest proportion of positive specimens was seen in patients with metastatic prostate 
cancer, followed by patients with metastatic cancer of unknown origin, ovarian cancer, 
and breast cancer.33 The presence of CTCs and the mean number of CTCs varied 
widely in samples. Differences in carcinomas, vascularization of the tumors, sites of 
metastasis, and aggressiveness of the tumor were factors that contribute to these 
differences.34  
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It has also been found that the CTC frequency varies highly depending on the 
form of therapeutic treatment. Studies carried out on pancreatic and colorectal cancer 
patients indicated that decreases in CTC numbers were seen immediately after 
surgery.35  By contrast, radiofrequency ablation of liver secondaries led to an immediate 
increase in CTC number and there was speculation that coagulative necrosis caused by 
the energy waves might induce cancer cell seeding.36  
Correlation between CTC number and the response of the primary tumor to 
chemotherapy was not observed, which is unusual given the fact that CTCs levels are 
normally correlated to treatment response.37 This  observation was explained by the 
discovery that CTCs can be different from the  primary  tumor  in  terms  of  their  
genome  and  protein expression patterns, such as p53 mutations and expression of 
Bcl-2, heat shock proteins, topo-isomerase II-a, ER/PR, and HER2.38 For example, a 
subset of patients with HER2-negative primary tumors developed HER2-positive CTCs 
during disease progression and this change might have consequences as to the 
response of the tumor cells to therapy.30 
2.6 Clinical Significant of CTCs 
 Elucidating the presence and number of CTCs in peripheral blood is emerging 
as an effective tool for differential diagnosis and prognosis, risk determination, disease 
recurrence, screening, and prediction of specific benefits from particular therapies for 
the management of cancer-related diseases.20 Moreover, the growing ability to detect 
and analyze CTCs could galvanize the development of drugs designed to block 
metastasis.  Compared to waiting for secondary tumors to appear, monitoring CTC 
numbers may provide a simple way to determine whether an anti-metastasis drug works 
for a particular patient.30 
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The initial primary tumor specimen may not always be representative of 
metastatic deposits. A primary example is prostate cancer, which often presents itself 
with multifocal localized disease and may recur many years later with bony lesions that 
are not readily biopsied.39 CTCs can reflect the molecular changes in a person‘s cancer 
that would point toward particular and effective treatments (i.e., personalized medicine). 
For example, only women with breast cancer whose tumor cells express the receptor 
HER2 respond to the drug Herceptin. It has been found that some women whose 
primary tumors were HER2-negative later had CTCs that were positive for HER2, 
suggesting their cancer had mutated.40 Monitoring CTCs might therefore identify women 
who were initially ineligible for Herceptin but who would later qualify for the drug. These 
important observations support the argument that the detection of CTCs and 
determination of their gene amplification, mutation or expression can be used for better 
tailoring therapies.   
Researchers have also begun to analyze CTCs for certain gene variants or 
proteins that indicate a patient‘s tumor is susceptible to a particular drug.41 This kind of 
―liquid biopsy,‖ will allow physicians to follow cancer changes over time and tailor the 
treatments. Also driving the interest in CTCs has been the recent development of 
molecularly targeted cancer therapies that work best on patients whose tumors have a 
particular mutation.42 
Receptor profiles of tumors change over time; it was noted that epidermal growth 
factor receptor (EGFR) is consistently expressed in CTCs for patients with metastatic 
breast cancer.43 In patients with non-small cell lung cancer, EGFR-activating mutations 
have been detected in CTCs as well, including the T790M mutation that confers drug 
resistance. The ability to stain CTCs directly for a variety of markers and potentially 
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analyze the mutations within them could enable therapeutic trials to be designed with 
CTC-based endpoints.39 
It was recently reported that highly tumorigenic cells possessing properties 
consistent with those of stem cells can be isolated from human cancers. These cancer 
stem cells may be detectable in the peripheral blood and bone marrow of patients.44 
The identification of these CTC subpopulations is likely to further the discovery of tumor 
stem-cell biomarkers and help resolve the issue of what exactly a cancer stem cell is. 
Hence, the development of therapies specifically targeting cancer stem cells will have 
great benefit for patients.  
2.7 Statistical Considerations for CTC Analysis 
 The success of rare CTC detection is affected by many parameters, including 
quality of the starting sample, frequency of the events of interest, sample preparation, 
specificity and expression level of the chosen markers, robustness of the assay, and 
objective and reproducible readouts.29 All of these factors contribute to the statistical 
probability of accurately detecting and quantifying CTCs and therefore, are important to 
consider when designing and interpreting CTC assays for clinical use. 
The CellSearch™ system employs the Kaplan-Meier statistic for the 
interpretation of CTC counts at baseline and follow-up blood collections of the patient 
(Figure 2.3). The survival curves are compared using log-rank testing and cox 
proportional hazards regression to determine univariate and multivariate hazard ratios 
for overall survival.45,46 For example, a threshold of 5 CTC/7.5 mL was used to stratify 
patients with metastatic breast cancer into those with favorable outcomes (CTC <3 or 
<5) and those with unfavorable outcomes (CTC ≥3 or ≥5). These statistical outcomes on 
CTC levels were used to predict survival, therapeutic benefits and stratify patients into 
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low-risk, moderate-risk, and high-risk groups (Figure 2.3).35 It was found that both 
univariate and multivariate analysis of CTC levels were significantly correlated with 
overall survival.47,48 
In most cases, Poisson statistics apply when accounting for randomly distributed 
CTCs due to limitations with the volume of blood that can be sampled. Another 
important consideration is whether the blood sample volume is large enough to detect  
 
Figure 2.3 Kaplan-Meier estimates of probabilities of progression-free survival and overall 
survival in patients with metastatic breast cancer for those with <5 CTCs per 7.5 mL of whole 
blood and those in the group with >5 CTCs in 7.5 mL of whole blood at the first follow-up visit 
after initiation of a newline of therapy. All patients in the trial (n=177) are included in these 
Figures. (A) progression-free survival from baseline. (B) overall survival from baseline. 
Reprinted with permission.35 
 
and enumerate a very small number of CTCs.29 For cell-based assays, the size 
of sample (n) that will provide a given precision is given by;28 
                                                        n = (100)2  (1) 
                                                                CV 
where CV is the coefficient of variation of a known positive control. From the 
perspective of CTCs, to reduce the CV to ∼10% (and hence improve the accuracy), 
many events would need to be assessed. Therefore, analysis of multiple blood samples 
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from the same patient at the same time significantly improves the probability of 
accurately detecting rare CTCs.  
These statistical factors also suggest that some caution should be employed 
when using a threshold number (i.e., ≥5 CTC versus <5 CTCs) to stratify cancer 
patients into poor prognosis versus good prognosis groups for the purposes of clinical 
decision making. From a statistical point of view, there is a higher probability of correctly 
identifying CTCs when >5 are detected, and/or there is a greater probability of incorrect 
identification when 1–4 CTCs are detected.48  
2.8 Conclusions   
CTC presence is one of several crucial steps in the metastatic process of solid 
malignancies. CTCs are detected in peripheral-blood samples, which are easy to obtain 
(with minimal discomfort for patients) compared with other sites, such as bone marrow 
and lymph nodes, where minimal residual disease might be present. Therefore, the 
detection of CTCs is emerging as an attractive strategy for tailoring cancer treatment on 
a single-patient basis. Because metastatic cells can have a very different molecular 
profile from the solid tumor of origin, sensitivity to conventional chemotherapeutic drugs 
and molecularly targeted anticancer agents might be better tested in CTCs than in the 
primary tumor. Accordingly, any advance in the knowledge of CTC biology might lead to 
significant progress in both anticancer drug development and better definition of patient 
diagnosis and prognosis.  
However, many investigators have reported a positive correlation between 
detection of CTCs and patient diagnosis and prognosis, but the number of clinical trials 
enrolled in each case is low (50-1,000 patients). Therefore, implementation of CTC 
detection in biological studies of large-scale clinical trials must prove the prognostic 
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power of CTC detection. In addition, CTCs are low-abundance cells scattered among 
millions of peripheral-blood mononucleated cells. The application of novel technologies, 
such as high-throughput technologies, single-cell genomics and proteomics must fulfill 
the promise of comprehensively describing the molecular signature of CTCs of solid 
malignancies. Dissection of CTC biology should define the molecular profile of those 
CTCs that can metastasize. These insights should enable investigators to identify an 
ideal marker (or set of markers) to detect only prognostically informative CTCs and/or to 
design more effective anticancer drugs. 
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CHAPTER 3 HIGHLY EFFICIENT CAPTURE AND ENUMERATION OF LOW-
ABUNDANT PROSTATE CANCER CELLS USING PROSTATE-SPECIFIC 
MEMBRANE ANTIGEN APTAMERS IMMOBILIZED TO A POLYMERIC 
MICROFLUIDIC DEVICE  
 
3.1 Introduction 
 
 Prostate cancer is the most common non-cutaneous malignancy, accounting for 
9% of all male cancer-related deaths in the US; there is a 1 in 6 probability of men in the 
US developing prostate cancer.1,2 In 2007, ~220,000 new cases of prostate cancer were 
recorded and 27,050 prostate cancer related deaths occurred in the US alone.3 For 
more than a decade, determinations of prostate-specific antigen (PSA) levels in human 
serum followed by digital rectal examination have been the predominate diagnostic 
methods for prostate cancer screening.4 Men with an abnormal digital rectal 
examination, as evidenced by the existence of poll ups, or elevated PSA levels are 
typically referred for biopsy to assess the presence of prostate cancer. The five-region 
prostate biopsy technique is typically utilized in conjunction with a sextant biopsy.5 
Using these rather invasive diagnostic strategies, up to 30% of prostate cancers are still 
undiagnosed.6 Unfortunately, certain medications (e.g. Finasteride), ejaculation, and 
prostate manipulation (e.g. catheterization, prostate massage) can alter PSA levels and 
as such, the determination of PSA levels in clinical settings remains controversial.4  
Mortalities associated with malignant tumors are primarily due to metastasis, 
which results from the invasionof tissues and organs distant from the primary tumor.7 
The early detection of metastasis is a critical factor for determining the probability of 
survival for many cancers.8 At present, reports have noted that circulating tumor cells 
(CTCs) can be present in peripheral blood for many adenocarcinomas prior to detection 
                                                 
 Reproduced with permission from Electrophoresis 
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of the primary tumor via conventional screening modalities.9 Therefore, elucidating the 
presence and number of CTCs in peripheral blood is emerging as an effective tool for 
risk determination, screening, differential diagnosis and prognosis, disease recurrence, 
and prediction of specific benefits from particular therapies for the management of 
cancer-related diseases.10  
CTCs are an extremely rare component within human blood (~101 cells mL-1 of 
whole blood) with the majority cellular components being erythrocytes (~109 cells mL-1 
of whole blood) and leukocytes (~106 cells mL-1 of whole blood).11 To discriminate CTCs 
from these highly abundant species, morphological or chemical differences between the 
target CTCs and normal hematopoietic components have been exploited,12 but typically 
provide low recovery and/or purity. 
 Disseminated prostate tumor cells can infiltrate the bone marrow, peripheral 
blood, lymph nodes, stomach, or the penis and the question becomes; can these 
disseminated tumor cells be used as a clinical marker for prostate cancer staging? 
Certain cell lines derived from prostate cancers can be used as model systems for the 
design and evaluation of new assays directed toward prostate cancer using for example 
CTCs as the diagnostic marker. These cell lines are categorized as to their final 
metastatic destination, such as bone metastasis – PC3, lymph node metastasis – 
LNCaP, and those localized to prostate – 22Rv1.13 Lymph node based metastasis occur 
in the very early stages of prostate cancer where high cure rates abound, whereas bone 
metastasis typically occur in the advanced stages of this disease and is accompanied 
by significantly reduced quality of life.14 It has been hypothesized that tumor cells 
released from a primary tumor site into peripheral blood can be correlated with patient 
survival or other indicators, such as the presence of regional lymph node metastases. 
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But the use of CTCs as a diagnostic marker is unclear due to the lack of efficient tools 
for their isolation and enumeration.15 Therefore, the development of highly efficient CTC 
isolation and detection systems to search peripheral blood for LNCaP type cells can 
potentially generate an effective diagnostic/prognostic tool for prostate cancer. 
 LNCaP-like cells typically possess a high-expression level of the integral 
membrane protein, prostate-specific membrane antigen (PSMA). PSMA is a 
homodimeric type II transmembrane glycoprotein consisting of 750 amino acids having 
a molecular weight of 100 kDa,16 making PSMA an excellent candidate for tracking 
LNCaP-type cells to diagnose prostate cancer or to monitor its progression and/or 
therapeutic response to treatment.17–19  
Due to the low abundance nature of CTCs in peripheral blood with respect to 
erythrocytes and leukocytes, the efficiency of CTC isolation is basically characterized by 
throughput, recovery and purity.20 Until now, different techniques, such as flow assisted 
cell sorting and immunomagnetic selection have been employed for the isolation of rare 
cells from complex clinical samples and are typically fraught with the limitation of 
choosing between high purity with poor recovery or high recovery with low purity.21,22 
 While microfluidic systems are emerging as effective tools for biomedical 
research and diagnostics having such advantages as low reagent consumption, short 
analysis times and process integration,22 they are fraught with some limitations, for 
example the inability to exhaustively sample large input volumes required to search for 
extremely rare events, such as CTCs in peripheral blood. Two recent examples have 
appeared in which rare cellular events were accumulated from clinical samples using a 
microfluidic platform. Nagrath et al. described an immunoaffinity approach in which anti-
epithelial cell adhesion molecules (EpCAM) antibodies were affixed to micropillars 
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poised within a microfluidic chip capable of extracting CTCs from peripheral whole blood 
samples with ~50% purity.11 A polymer-based high-throughput microfluidic system was 
described by Adams et al. in which EpCAM-specific monoclonal antibodies were 
tethered to parallelized-high-aspect ratio microchannels, which were employed to 
isolate breast cancer cells (MCF-7) from whole blood demonstrating a recovery of 97% 
and nearly 100% purity.20 A compelling attribute of this microfluidic device was its ability 
to specifically enumerate the CTCs on-chip using an integrated conductivity sensor, 
which demonstrated a single-cell detection efficiency of 100% without requiring cell 
labeling.20 
Though various techniques have been applied to isolate and characterize CTCs, 
many of them share a similar principle, they use antibody-based selection with integral 
membrane protein antigens. Application of this molecular recognition strategy for CTC 
detection is limited by the availability and specificity of antibodies directed against the 
necessary biomarkers, such as membrane proteins found on different tumor cells.9 In 
addition, most of these cell selection tools require surface immobilization of an antibody, 
which can result in reduced cell recoveries or adhesion strength between the cell and 
the surface-tethered antibody due to the stochastic nature of the immobilization 
chemistry.  
Aptamers, single-stranded nucleic acid oligomers, possess highly specific 
recognition affinities to molecular targets through interactions other than classical 
Watson-Crick base pairing.23 Compared with antibodies, aptamers have lower 
molecular weights, demonstrate faster tissue penetration, remain stable during long-
term storage, sustain reversible denaturation, low toxicity, and can be produced against 
targets, such as membrane proteins, using highly automated technologies (i.e. 
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SELEX).24 In addition, a wealth of literature exists on the immobilization of aptamer 
recognition elements to solid supports, such as glass,25 polymers,26 and gold.26 
Additionally, the immobilization chemistry is highly oriented with end-point attachment 
occurring exclusively through the 50- or 30-end of the aptamer, which bears a functional 
group, such as a primary amine. These advantages make aptamers highly desirable as 
potential molecular probes for diagnostics.27  
Many aptamers have been developed to target the extracellular domains of 
integral membrane proteins that are over-expressed on cancer cells.28 Lupold et al. first 
reported RNA aptamers directed against the tumor-associated PSMA membrane 
antigen and the first application of RNA aptamers that targeted LNCaP cells via the 
PSMA biomarker. The affinity of this aptamer for PSMA was quantified and suggested 
that the aptamer identified a unique extra-cellular domain of PSMA.29  
Herein, we report on the use of PSMA-specific aptamers tethered to a high-
throughput micro-sampling unit (HTMSU) with an integrated conductivity sensor 
employed for the highly efficient isolation and enumeration of rare circulating prostate 
tumor cells (LNCaP used as a model in these studies) from whole blood without the 
need for preprocessing of the blood prior to introduction into the microfluidic device nor 
staining of the CTCs for enumeration. Nuclease stabilized and in vitro generated RNA 
aptamers were immobilized onto ultraviolet (UV)-modified curvilinear capture channels 
comprising the capture bed contained within the microfluidic device using carbodiimide 
coupling chemistry and the appropriate linker structure to enhance the accessibility of 
the surface-bound aptamer to the solution-borne cells.30 The linear velocity of sample 
introduction into the device was optimized in order to achieve high-CTC recovery from 
blood. After selection and isolation, the captured cells could be released from the 
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capture surface via enzymatic digestion of the extra-cellular domain of PSMA using 
trypsin for subsequent conductivity enumeration.20 Recently, Phillips et al. has reported 
on the use of aptamers decorating PDMS microchannel walls for the selection of T-cell 
acute lymphocytic leukemia cells seeded in an aqueous buffer that was also loaded with 
a noncancerous cell line.31 Unfortunately, this work did not use whole blood as the input 
sample, which contains extremely high levels of interfering cells and the cell 
concentration was much higher (~1×106 cells mL-1) than typically encountered for CTCs 
found in clinical samples (~10 cells mL-1). The results reported here used whole blood 
as the input with CTC concentrations as small as 10 cells mL-1. 
3.2 Materials and Methods 
 
3.2.1 Buffers and Reagents 
 
PMMA was used as the HTMSU substrate and cover plate (0.5 mm thickness) and 
were purchased from Good Fellow (Berwyn, PA). Platinum wires for the conductivity sensor 
were purchased from Alfa Aesar (Boston, MA). Polyimidecoated fused silica capillaries 
were purchased from Polymicro Technologies (Phoenix, AZ). Chemicals used for 
thePMMA surface cleaning and modification included reagent grade isopropyl alcohol, 1-
ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), fetal bovine serum and 2-(4-morpholino)-ethane sulfonic acid (MES) and these 
were purchased from Sigma-Aldrich (St. Louis, MO). The nuclease-resistant RNA aptamer, 
(NH2-(CH2)6-(OCH2CH2)6-(ACCAAGACCUGACUUCUAACUAAGUCUACGUUCC), was 
obtained from Eurogentec (San Diego, CA). Random sequence oligonucleotides were 
obtained from Integrated DNA Technologies (Coralville, IA). Monoclonal anti-EpCAM 
antibody was obtained from R & D Systems (Minneapolis, MN). The LNCaP (prostate 
cancer cell line), MCF-7 (breast cancer cell line), growth media, HEPES buffer, PBS and 
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trypsin were all purchased from American Type Culture Collection (Manassas, VA). 
Citrated rabbit blood was purchased from Colorado Serum Company (Denver, CO). Tris-
glycine buffer was obtained from Bio-Rad Laboratories (Hercules, CA). All solutions were 
prepared in nuclease-free water, purchased from Invitrogen (Carlsbad, CA). Nuclease-free 
microfuge tubes were purchased from Ambion (Foster City, CA) and were used for 
preparation and storage of all samples and reagents. A fluorescein derivative, PKH67, 
which contained a lipophilic membrane linker for cell staining, was purchased from Sigma-
Aldrich. 
3.2.2 Cell Suspensions 
 
LNCaP and MCF-7 cells were cultured to 80% confluence in Dulbecco‘s Modified 
Eagle‘s Medium supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate 
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A 0.25% trypsin solution 
was prepared in 150 mM PBS and used to harvest the LNCaP and MCF-7 cells from the 
culturing plate.  
LNCaP and MCF-7 cells were stained with PKH67 for microscopic visualization 
experiments using fluorescence. A modified protocol for cell staining was implemented 
whereby the dye concentration was increased twofold resulting in more evenly distributed 
fluorescent labels over the cell‘s periphery. Cell counts for seeding experiments into whole 
blood were determined by counting three aliquots of cells in succession using a 
hemacytometer. The cell count accuracy was ±10%. 
3.2.3 HTMSU with Integrated Conductivity Sensor Fabrication 
 
A detailed description of the HTMSU fabrication has been given by Adams et al. 
with a schematic of the device shown in Fig. 3.1A.20 Briefly, the HTMSU was hot 
embossed into PMMA substrates via micro-replication from a metal mold master. The 
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HTMSU consisted of a series of 51 high-aspect ratio curvilinear channels that in concert 
formed the cell capture bed. Each channel was 150 µm (depth)×30 µm (width) and 
shared common inlet/outlet ports. Curvilinear shaped capture channels were used to 
improve the cell capture efficiency. The cell-free marginal zone apparent in straight 
channels was not observed in curvilinear channels and the cell radial distribution was 
unaffected by changes in cell translational velocity. Cells migrate to the outside of the 
curved channels due to centrifugal forces acting on the cells and the cross-stream 
velocity component due to the reversal of the direction of curvature.20 The result is an 
increase in the aptamer/antigen encounter rate as the cells moved through the capture 
beds at the relatively high-linear velocities used here. The channel width of the cell 
capture bed (30 µm) was comparable with the average target cell diameter, which was 
used to increase the probability of cell–aptamer interactions with the solution-borne 
target cells. The large channel depth (150 µm) was selected to reduce the pressure 
drop in high-volume flow rates and also, to increase sample processing throughput. 
 Appropriately cleaned PMMA HTMSUs devices and cover plates were exposed 
through a mask to UV radiation resulting in the formation of carboxylate moieties only in 
the exposed areas of   the PMMA. The  exposed  areas were restricted to only the  cell 
capture bed region of the device.20 UV irradiation was performed through an aluminum 
mask for 10 min at 15 mW cm-2 to facilitate the formation of the carboxylated scaffold. 
These parts were then aligned and clamped together between two borosilicate plates. 
The cover plate was thermally fusion bonded to the substrate by placing the clamped 
pieces inside a convective oven and heating to ~101 °C, slightly above the glass 
transition temperature of the UV-modified material. The temperature was increased 
from 50 to 101 °C at a rate of 20 °C min-1 and held at 101 °C for 15 min. Polyimide-
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coated fused silica capillaries were then inserted into the inlet port of the assembled 
HTMSU to provide the introduction of samples into the device using a programmable 
syringe pump (Harvard, Holliston, MA).  
Pt electrodes (d=76 µm) served as the contact conductivity sensor in the 
detection zone of the HTMSU and were placed into guide channels that were positioned 
orthogonal to the fluidic output channel following thermal assembly. Insertion of the 
electrodes was monitored using a microscope to carefully control the inter-electrode gap 
(50 µm). The cell constant of the Pt conductivity sensor, K, was ~0.01 µm-1, which 
allowed for the specific detection of LNCaP cells based on their average size (diameter= 
25 µm). 
3.2.4 Antibody Immobilization to the HTMSU 
 
Antibody immobilization was carried out in a two-step process. The UV-modified 
thermally assembled HTMSU device was loaded with a solution containing 4 mg mL-1 
EDC, 6 mg mL-1 NHS in 150 mM MES (pH=6) for 1 h at room temperature to obtain the 
succinimidyl ester intermediate. After this incubation, the EDC/NHS solution was 
removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0 mg 
mL-1 of the monoclonal anti-EpCAM antibody solution contained in 150 mM PBS 
(pH=7.4) was introduced into the HTMSU and allowed to react for 4 h. The device was 
then rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound anti-
EpCAM antibodies. 
3.2.5 Aptamer Immobilization onto PMMA Films and the HTMSU Device 
 
A schematic of the aptamer immobilization process is given in Fig. 3.1B. Aptamer 
immobilization to PMMA surfaces was carried out in a single step. Following PMMA  
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Figure 3.1 (A) Diagram of the HTMSU made via micro-replication into PMMA from a metal mold 
master. The capture bed consisted of curvilinear channels that were 30 µm wide and 150 µm 
deep (51 channels). (B) Process operation of the HTMSU used for the positive selection of 
LNCaP cells. Also shown is the chemistry used for the immobilization of the cell selection 
elements, aptamers, to the PMMA surface. The first step involved the UV-irradiation (15 mW 
cm-2) of PMMA and in this case, the irradiation was carried out on just the capture bed so that 
positive cell selection occurred only in this region. 
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activation using UV light to generate the carboxylic acid functional scaffold, the 
activated  PMMA   surfaces  were   incubated  with  a  solution  containing  10 mM of an 
oligonucleotide with a random sequence or the PSMA aptamer, 4 mg mL-1 EDC and 6 
mg mL-1 NHS in 150 mM MES (pH=6), and allowed to incubate for 3 h at room 
temperature. For PMMA films, the planar surface was immersed in the reaction solution. 
Following reaction, the PMMA surface was rinsed with a solution of PBS (pH=7.4) to 
remove any non-specifically bound constituents.  
In the case of the HTMSUs, the assembled devices were loaded with a 10 mM 
anti-PSMA aptamer solution also containing 4 mg mL-1 EDC and 6 mg mL-1 NHS in 150 
mM MES (pH=6). This solution was allowed to incubate in the device for 2 h at room 
temperature. The device was then rinsed with a solution of PBS (pH=7.4) at 20 mL min-1 
flow rate to remove any non-specifically bound constituents. 
3.2.6 Determination of Aptamer Surface Density on UV-Modified PMMA 
 
A clean SPR gold sensor surface was coated with 300 µL of a PMMA solution 
(1.0 mg of PMMA in 10 µL of CH2Cl2) in a custom built spin coater and spun at 1500 
rpm for 1 min. The PMMA film was then subjected to UV light and aptamer 
immobilization was undertaken using identical conditions as those described in Section 
2.5. The SPR response, which was measured using a BIACORE X SPR instrument 
(Piscataway, NJ), was recorded after each treatment using DI water as a buffer. The 
difference in SPR response before and after aptamer immobilization was determined 
and the SPR response unit was converted into molecules cm-2 using the manufacturer‘s 
conversion factor of 10 response unit=1 ng cm-2 and the molecular weight of the 
aptamer.30 
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3.2.7 LNCaP Cell Capture Using the HTMSU 
 
To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV) 
was placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix, 
AZ). This was then attached to the capillary that was sealed to the input port of the 
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1 
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell 
suspension was introduced at the appropriate volumetric flow rate to produce the 
desired linear velocity in each microchannel comprising the capture bed. Next, a post-
capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1 to remove any 
non-specifically adsorbed cells.  
In cases where the cells required optical visualization to assist in the operational 
optimization of the HTMSU, the PMMA devices were fixed onto a programmable 
motorized stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) microscope and 
video images were collected during each experiment at 30 frames per second using a 
monochrome CCD (JAI CV252, San Jose, CA). A Xe arc lamp was used to excite the 
fluorescent dyes incorporated into the cells‘ membrane. 
3.2.8 LNCaP Cell Release from the HTMSU 
 
Following a post cell capture rinse performed with 0.2 mL of 150 mM PBS, a 
trypsin solution consisting of 0.25% w/v trypsin in Tris-Glycine buffer (pH=7.4) was 
infused into the HTMSU. The captured cells could be observed (microscopically) until 
they were removed by the tryptic digestion and Stoke‘s force using both brightfield video 
measurements to evaluate release efficiency.  
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3.2.9 Conductivity Enumeration of Released Cells 
 
The released cells from the capture surface were traversed at 1 mL min-1 volume 
flow rate through a set of Pt electrodes. We used a specially designed circuit as 
described earlier20 to measure the changes in solution conductivity due to single cells as 
a function of time to create the desired conductivity trace from which cell numbers were 
determined. 
3.3  Results and Discussion 
 
Although sophisticated imaging reagents and hardware have been developed for 
the diagnosis and prognosis of many cancer-related diseases, there are still significant 
advancements that need to be made that can provide earlier diagnosis and staging of 
cancers following surgical intervention or monitoring disease recurrence.15 In this work, 
we exploited the potential utility of CTCs as a diagnostic and prognostic marker for 
cancer using microfluidics for the high-efficiency recovery and subsequent enumeration 
of prostate tumor cells. The molecular recognition of these cells from clinical samples, 
such as blood, was enabled by the expression of PSMA into lymph node metastasized 
LNCaP cells. The selective isolation of these cells directly from whole blood was 
affected through the use of immobilized anti-PSMA aptamers decorating the walls of a 
capture bed poised within a HTMSU fabricated in a polymer, which could process large 
input volumes and search for extremely rare events. The HTMSU contained a 
conductivity sensor that was used to enumerate the isolated LNCaP cells following 
chemical release from the capture surface. 
3.3.1 LNCaP Cell Selectivity and Specificity Using Aptamer Recognition 
 
Specific selection of LNCaP cells was based on the recognition capabilities of 
anti-PSMA aptamers that were tethered to the HTMSU capture beds to select only cells  
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Figure 3.2 (A) Brightfield (left) and fluorescence (right) images for the positive selection of 
LNCaP cells infused into the HTMSU at a constant volumetric flow rate. The cells were 
suspended in a PBS buffer (~1000 cells mL-1) and following infusion of the cell suspension, the 
device was washed with PBS buffer prior to imaging. In all cases, the entire capture bed was 
imaged by scanning the microscope stage. The cells were stained with the fluorescein 
membrane probe prior to introduction into the HTMSU to allow fluorescence visualization. (B) 
Comparison of LNCaP cell capture efficiencies using anti-PSMA aptamers or anti-EpCAM 
antibodies cell recognition elements. In both cases, the HTMSU capture bed was modified with 
UV light to create the functional scaffold for covalent attachment of the antibody or 50-labeled 
aptamer. The graph shows the cell capture efficiency versus cells‘ translational velocity. Red 
squares and blue circles represent the capture efficiencies for anti-PSMA aptamers and anti-
EpCAM antibodies, respectively. In these experiments, ~1000 LNCaP cells were seeded into a 
PBS buffer (pH=7.4) with the number of captured cells determined via brightfield microscopy 
and subsequently verified using fluorescence microscopy. 
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that expressed PSMA even when these cells were of extremely low abundance. The 
specificity of the PSMA-mediated cell selection by aptamers was investigated by using 
different surface chemistries, pristine PMMA, UV-modified PMMA, and a capture bed 
surface decorated  with  random  DNA  sequences  or  PSMA-specific  aptamers. These 
initial experiments used the HTMSU with the adhered cells determined via inspection 
with fluorescence and brightfield microscopy. In these experiments, the LNCaP cells 
were seeded into PBS buffer (pH=7.4) at ~1000 cells mL-1 and pumped through the 
HTMSU using a syringe pump (linear velocity=2.5 mm s-1). Because fluorescence 
microscopy was used for visualization, the cells were fluorescently stained using a 
fluorescein membrane probe. From these experiments, we noticed negligible amounts 
of cell adhesion of the LNCaP cells to the channel walls of pristine PMMA. UV 
irradiation of the polymer modifies the PMMA surface by introducing carboxylic acids 
and other carbonyl groups onto its surface, making this surface more hydrophilic 
compared with pristine PMMA.32 When the LNCaP cell suspension was pumped 
through this HTMSU device, no LNCaP cells were found to adhere to the UV-modified 
PMMA surface. Repeating this experiment using a UV-activated PMMA surface that 
was reacted with 50-amine containing DNA oligonucleotides possessing a random 
sequence, no LNCaP cells were detected in the capture bed following fluorescence and 
brightfield microscopic interrogation. These results suggested that the adhesion forces 
of the LNCaP cells to these surfaces were not strong enough to withstand the 
hydrodynamic shear produced by the laminar fluid flow. The random DNA sequences 
tethered to the PMMA surface did not possess recognition capabilities for the PSMA 
integral membrane protein. However, when PSMA-specific aptamers were tethered to 
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the capture bed walls, microscopic inspection of the capture beds clearly indicated the 
presence of captured LNCaP cells (see Fig. 3.2A). 
3.3.2 Cell Translational Velocity Optimization 
 
Because the capture aptamers are tethered to the channel walls, dynamic 
interactions between the cell membrane‘s receptors and the channel wall containing the 
recognition elements is important in determining the recovery of the rare cells. Chang‘s 
model 33 of cell adhesion in flowing systems has been applied in previous reports to 
describe the encounter rate between the solution-borne cells and the surface-tethered 
cell selection elements.20 When the flow velocity is beyond an optimal value, a decrease 
in the interaction time between a particular cell‘s membrane antigen and the capture 
molecule available for binding is observed, thereby reducing the number of potential 
binding events. This model also predicts that too small of a velocity leads to a decrease 
in the encounter rate between the cell bound antigen and the immobilized recognition 
element. Therefore, an optimal linear velocity would be expected for each flowing 
system to guarantee the highest frequency of binding between capture molecules and 
antigen based on a balance between the interaction time and the encounter rate.33 In 
addition, because the solution is driven hydrodynamically through the capture bed, 
shear force can cause release of the captured cells if the shear force is greater than the 
adhesion force, which in this case is determined by the PSMA/aptamer dissociation 
constant and the number of molecular association complexes between the surface and 
cell.29  
We therefore carried out experiments to determine the optimal linear velocity to 
provide the maximum recovery of rare tumor cells found in peripheral blood using 
aptamer recognition elements. The results of these investigations are presented in Fig. 
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3.2B. From these results, the maximum cell capture efficiency was found to occur at a 
translationalvelocity equal to 2.5 mm s-1 under the conditions employed in this study. 
LNCaP cell capture studies using an EpCAM antibody-tethered HTMSU followed the 
same capture efficiency trend for that observed for the anti-PSMA aptamer, indicating 
that the cell capture efficiency is governed by the same principal as that described by 
the Chang model and seen in our previous work for anti-EpCAM captured MCF-7 cells 
using this HTMSU.20 However, the optimum linear cell translational velocity for 
maximum cell capture for the anti-EpCAM immobilized HTMSU was slightly lower (2.0 
mm s-1) than that observed for the anti-PSMA aptamer (2.5 mm s-1) indicating that the 
reaction rate for the anti-EpCAM/EpCAM interaction is slightly less than that observed 
for the anti-PSMA aptamer/PSMA interaction. The molecular weight of EpCAM, 33 
kDa ,34 is far less compared with 100 kDa for PSMA.16 The extra-cellular domain of 
EpCAM contains only 242 amino acid residues whereas PSMA contains 707 extra-
cellular amino acid residues potentially giving extended accessibility of the extracellular 
domain of PSMA to its recognition element. However, the rate of association will 
depend also on the location of the recognition epitope as well as the conformational 
reorganization occurring during a binding event. These factors may provide a faster rate 
of reaction observed in the case of the anti-PSMA aptamer/PSMA complex. In addition, 
the expression level of PSMA (1×106 molecules cell-1) is approximately twice the 
expression level of EpCAM within the LNCaP cell‘s membrane.35–37 This higher 
expression level and the bulky extra-cellular domain of PSMA may hinder accessibility 
of anti-EpCAM/EpCAM interactions due to molecular crowding effects. Moreover, the 
smaller molecular weight anti-PSMA aptamer, 10 kDa, is able to efficiently bind to the 
larger molecular weight PSMA due to its capability to quickly fold into 
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thermodynamically stable secondary and tertiary structures to form complexes through 
molecular forces that specify target interaction.38  
Another issue that must be addressed is the adhesion strength between the 
captured cell and its surface immobilized recognition element due to the fact that the 
shear force exerted by the solution can potentially dislodge the cell from the capture 
surface. This would occur if the adhesion strength (or force) was less than the shear 
force (FS). The adhesion force (FA) between the cell and the anti-PSMA aptamer 
decorated surface can be determined from the bond strength between a single antigen–
aptamer complex (fC), the cell contact area with the PMMA surface (AC) and the number 
of receptors poised on the PMMA surface within the contact area of the cell (CS) from: 
20 
                                                     FA = fC×AC×CS  (1) 
If the cell is assumed to be a non-deformable object upon adhesion to the 
capture surface, the contact area can be calculated using;39 
                                             AC = ∏(rpsin(cos
-1(rp- h’+h)/rp
2 (2) 
where rp is the cell radius and h and h’ represent the characteristic cell separation 
distances from the surface upon binding. Using h and h’ as 100 and 400 A°, 
respectively,40 the calculated contact area was determined to be 1.88 µm2 for the 
LNCaP cells (rp≈12.5 µm). If the cell is assumed to flatten and elongate after contact, as 
observed experimentally (see Figs. 3.2 and 3.3), the resulting contact area AC was 
calculated to be ~380 µm2.41  
The single PSMA-anti-PSMA aptamer adhesion force was estimated using the 
formalism by Bell,42 who developed the following expression for deriving the critical 
force required to break a single bond; 
                                                        fC=kT/roaC (3) 
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where k is Boltzman‘s constant, T is the absolute temperature, ro is the separation 
distance between receptors at the minimum breaking force and aC=KDCS (KD=PSMA-
anti-PSMA aptamer equilibrium constant). Using a value of KD=4.76×10
8 M-1,29 and 
ro=0.5 nm,
33 the value calculated for the adhesion force per association complex was  
 
 
Figure 3.3 Brightfield and fluorescence micrographs showing anti-PSMA aptamer captured 
LNCaP cells in a PMMA microchannel. (A) Brightfield micrographs taken at 40x magnification 
and (B) the corresponding fluorescence micrographs verifying the captured cell is the 
fluorescently labeled LNCaP cell. The inset shown in panel (B) is a fluorescent-stained LNCaP 
cell in a PMMA microchannel that was not decorated with anti-PSMA aptamers indicating the 
spherical shape of these cells. 
 
determined to be 4.55×10-11 N. For the LNCaP cells shown in Fig. 3.3A, FA was 
calculated to be 5.5×10-5  N.41 FS was determined from Stokes‘ law;
43 
                                                    FS = 6∏ηrpvC (4) 
where rp is the cell radius (~12.5 µm for LNCaP cells),
44 η is the solution viscosity (4.8 
CP for whole blood with a hematocrit level of 0.4)
45 and vC is the critical linear velocity 
that can induce cell detachment. Rearrangement of Eq.4 produced a value of 6.0×103 
cm s-1 for vC. This value is significantly greater than the linear velocities used in the 
present experiments for optimizing the capture efficiency. Several captured cells were 
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observed continuously during experiments in which linear velocities up to 10.0 cm s-1 
were implemented and no cell damage or disruption of cell–wall adhesion was observed. 
3.3.3 Selection of Other CTC-Types Using the HTMSU with Immobilized PSMA 
Aptamers 
 
Non-specific adsorption or recognition of other CTC-types was also evaluated 
using a breast cancer cell line (MCF-7) as an example, which does not express PSMA, 
but does overexpress the EpCAM. The existence of PSMA genes in normal and non-
prostate-specific tumor cells, such as the MCF-7 cell line, has been reported, however, 
protein assay results for the MCF-7 cell lines failed to detect the PSMA antigen.46 Our 
results indicated that no MCF-7 cells were found in the PMMA capture beds when 
decorated with the anti-PSMA aptamers as deduced from microscopic interrogation of 
these beds using brightfield microscopy (data not shown). These cell capture 
experiments were carried out under dynamic laminar flow conditions in the HTMSU 
microfluidic channels using the optimized LNCaP linear velocity of 2.5 mm s-1. Therefore, 
the presence of the hydrodynamic shear would most likely detach any non-specifically 
bound material due to weak adhesion forces exerted on these cells. 
3.3.4 Cell Detachment from the Capture Surfaces 
 
Releasing the cells intact from the capture bed was critical for the subsequent 
conductivity enumeration of the LNCaP CTCs. The mechanism we evaluated for cell 
release was the use of enzymatic digestion of the extra-cellular domain of the PSMA 
protein using trypsin to reduce the cell‘s adhesion strength to the aptamer surface. 
There are two main biosynthetic forms of PSMA within the LNCaP cell membrane, 
which are either mannose-rich PSMA (PSMAM) or the glycosylated form of PSMA 
(PSMAC). PSMAM is completely sensitive to trypsin, whereas PSMAC is trypsin resistant 
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Figure 3.4 (A) Time-lapse micrographs showing trypsin enzyme mediated release of a captured 
LNCaP cell upon application of 0.25% w/w trypsin in PBS buffer (pH=7.4). (a) At t=0 or prior to 
exposure of the captured cells to the trypsin releasing buffer. (b) At t=2.0min, disruption of the 
binding complex is evident. (c) At t=6.5min, the cell appears to be released from the capture 
surface. (d) At t=7.5min, the cell was completely released from the surface and swept away 
from the capture surface to the detection region by the hydrodynamic flow. (B) Plot of cell 
release efficiency versus time. In each experiment the number of cell releasing events, >25, in 
three curvilinear channel were counted. The error bars represents the standard deviation of the 
results obtained for three replicate experiments. 
 
 due to transport blockage at the Golgi complex associated with their secretory 
pathway.47 
Introduction of a trypsin solution into the capture bed to allow for tryptic digestion 
of PSMA to provide release of the captured LNCaP cells was found to effectively 
release these cells from the aptamer-decorated surface indicating the dominate 
component was PSMAM as the attachment partner between PSMA and the anti-PSMA 
aptamers. Figure 3.4A represents time-lapse micrographs of a captured cell that was 
processed using a trypsin digestion solution. Close investigation of the time-lapse 
micrographs  indicated  efficient  release  of  the  intact  LNCaP  cells  from  the  capture  
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surface. The cell releasing efficiency increased with increasing incubation time 
according to Fig. 3.4B. Complete cell detachment (~100%) was achieved in less than 7 
min of incubation time. We also note that brightfield inspection at the Pt electrode pair 
readout point of the device was performed of the released cells following trypsin 
processing and these inspections confirmed that the cells were intact at this point. 
3.3.5 Conductivity Enumeration of the CTCs 
 
The conductivity detector, which consists of a pair of Pt electrodes with a 50 µm 
spacing (cell constant=0.01 µm-1), was fabricated specifically to transduce the larger 
CTCs compared with the smaller leukocytes and/or erythrocytes that may appear in the 
enumeration phases of the assay providing false positive signals due to the universal 
nature of the conductivity response. Also, the CTCs possess unique electrical properties 
due to their characteristic chemical composition compared with erythrocytes and 
leukocytes to provide efficient conductivity readout.48 For example, the over-expression 
of membrane glycoproteins, such as PSMA, associated with many tumor or cancer cells 
result in an increase in the number of negatively charged sialic acid molecules that cap 
the extra-cellular domains of these integral membrane proteins.20 This can produce a 
cell with a higher electrical conductivity compared with one that does not over-express 
these types of proteins.  
One milliliter of whole blood was seeded with 20±1 LNCaP cells and was 
processed using the HTMSU. The captured cells were subsequently released using the 
trypsin releasing buffer and enumerated with the conductivity transducer with a typical 
data stream shown in Fig. 3.5A. The conductivity transducer measured changes in the 
conductivity releasing buffer induced by the presence of single CTCs between the Pt 
electrode pair. Therefore, the responses generated in the data shown in Fig. 3.5A were  
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Figure 3.5 (A) Conductometric responses generated for 1.0 mL of whole blood seeded with 20 
±1 LNCaP cells (black) or 0 LNCaP cells (red) at a linear flow velocity of 2.5 mm s-1 processed 
using the HTMSU. The captured LNCaP cells were released from the capture surface using the 
release buffer comprised of 0.25% w/w trypsin and transported through the conductivity sensor 
at a volumetric flow rate of 0.05 mL min-1. The arrows designate peaks that were identified as 
LNCaP cells based on a signal-to-noise threshold of 3. The crossed arrows represent non-
LNCaP cell events. The insets shown in the figure represent a magnified view of sections of the 
data stream. The blue line represents the threshold level, which represents 3x the average 
background level, which was used to differentiate ‗‗true‘‘ events from noise. The data presented 
here was smoothed by the Savitsky-Golay method (25 point smoothing function). Also shown in 
this plot is a sample of whole blood containing no LNCaP cell that was processed with the 
HTMSU device (red line). (B) Calibration plot (m=0.990, r2=0.99997) for the number of LNCaP 
cells seeded (10–250 cells mL-1) into 1.0 mL of whole blood versus the number of conductivity 
responses using the Pt-conductivity sensor. 
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generated from single cells. Tris-Glycine buffer was selected as the major component in 
the release buffer due to its low conductance, hence, the sensitivity of the conductivity 
detection for single cells was enhanced and the resultant peaks should exhibit a positive 
response due to the higher conductance of the LNCaP cells with respect to the release 
buffer. There were 18 peaks in the conductance response given in Fig. 3.5A that could 
be assigned to single LNCaP cells based on a signal-to-noise threshold of 3 (99.7% 
confidence level) giving a recovery of ~90% (see insets to Fig. 3.5A showing the 
discrimination threshold used). As seen in Fig. 3.5A, only positive signals were 
designated as LNCaP cells and the negative spikes were assigned to particulates due   
to their lower conductance compared with the Tris-Glycine buffer. Variation of the peak 
response for each cell is most likely due to differences in the cells‘ morphology and 
chemical composition, which is determined by the state of mitosis of the cell.  
One milliliter of a blank sample, which consisted of whole blood seeded with no 
LNCaPs cells, was analyzed by the HTMSU and enumeration via conductivity under the 
same conditions as described for the whole blood sample seeded with LNCaP cells and 
the resultant trace is shown in Fig. 3.5A. In this case, no single-cell spikes were seen in 
the data trace indicating that the signal spikes seen in the conductivity trace for the 
LNCaP seeded whole blood was indeed due to these tumor cells. Therefore, the purity 
of LNCaP cell selection was determined to be 100%.  
The HTMSU with conductivity enumeration was further evaluated for the 
detection of various seed levels of LNCaP cells into whole blood to produce a 
calibration plot. A range of 10–250 LNCaP cells per mL of whole blood was evaluated. 
The best-fit linear function to the data plotted in Fig. 3.5B had a slope of 0.990 with an 
intercept near zero (r2=0.9997). Interestingly, even at the lowest LNCaP cell load, the 
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data still fit along this linear function indicating that even at extremely low levels of 
LNCaP cells found in whole blood, we could still quantitatively analyze these cells using 
the HTMSU. We should note that for 1 mL of whole blood, ~2.5×109 erythrocytes are 
present. Therefore, the enrichment factor for this assay can be calculated as 2.5×108 for 
the lowest LNCaP cell load investigated. At the 2.5 mm s-1 employed to provide 
maximum LNCaP recovery, the processing time for exhaustively processing 1 mL of 
blood would be ~29 min. 
3.4  Conclusions 
 
The HTMSU described in this manuscript utilized an aptamer-based positive 
selection approach for the isolation of prostate-specific CTCs (LNCaP) directly from 
whole blood with subsequent quantification of these rare cells using a non-labeling 
approach. The compelling advantage of this methodology is that no sample pre-
treatment was necessary and the throughput (29 min processing time for 1 mL input), 
recovery (90%) and purity (100%) were extremely high, contrary to what is seen in other 
rare cell selection formats utilizing size or affinity capture. The ability to quantify the 
selected cells with near 100% detection efficiency using a conductivity readout format 
allows for the use of this simple system at the point-of-care for the management of 
cancer-related diseases from a simple blood test. In addition, molecular profiling of the 
selected CTCs could be used for determining therapeutic treatment regimens as well as 
identifying the organ of origin of the selected CTC from whole blood. Molecular profiling 
of rare CTCs in whole blood could not be done directly on the clinical sample due to the 
low copy number of the mutated DNA originating from the CTCs as well as potential 
interferences on downstream molecular processing by the highly abundant red and 
white blood cells found in whole blood. We are currently in the process of developing 
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sensitive genotyping assays that can be performed directly on the selected CTCs for 
providing this valuable clinical information.  
Previously, it has been reported20 a positive selection of MCF-7 breast cancer 
cells from peripheral blood using anti-EpCAM antibodies and this HTMSU. In this report, 
aptamers were used for the positive cell selection, in this case for selecting LNCaP cells 
from peripheral blood. The recovery, purity, and throughput were similar in both cases 
as well as the specificity for the target cells. The attractive features of aptamers 
compared with antibodies is the ordered nature of their attachment to the solid surface 
(50-end attachment) as opposed to a stochastic one associated with antibodies (primary 
amine groups on the antibody), the ability to carefully control the aptamer/surface 
distance to improve accessibility and the robust nature of the molecular recognition 
elements. For example, aptamers can be stored at room temperature without degrading 
their recognition performance, whereas antibodies must be stored in more controlled 
conditions to maintain their activity. 
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CHAPTER 4  ENRICHMENT  AND  DETECTION  OF  ESCHERICHIA  COLI  O157:H7 
FROM  WATER  SAMPLES  USING  AN  ANTIBODY  MODIFIED  MICROFLUIDIC 
CHIP  
 
4.1  Introduction  
Threats to human health from Escherichia coli contamination of aquatic 
environments are becoming highly prevalent. Several major waterborne outbreaks have 
been reported in aquatic systems ranging from freshwater to marine, where E. coli 
accumulates in the water column and sediments.1,2 To better understand E. coli ecology 
in aquatic environments, to provide monitoring over time scales appropriate for the 
study of E. coli outbreaks,3-5 and to protect human populations, monitoring techniques 
for E. coli are needed that have low detection thresholds even for extremely rare cells 
and rapid processing times.  
The U.S. EPA allowable levels of E. coli are 0, 200, and 1000 cfu per 100 mL of 
drinking, swimming, and recreational (boating) waters, respectively, and the minimum 
infectious dose is very low, ∼10 cells.6 To detect E. coli corresponding to doses this low, 
preenrichment of cells is required, especially in drinking and recreational waters, by 
processing large input volumes to accommodate the readout phases of the 
measurement assay. There are different technologies for isolating rare cells from 
heterogeneous samples to aid in their analysis such as fluorescence assisted cell 
sorting,7 flow-through filtrations,8 enzyme linked immunosorbent assays (ELISA),9 and 
immunomagnetic assisted cell sorting.10 These methods, however, rely on time-
consuming culturing protocols.  
The U.S. EPA has approved an E. coli detection test for the examination of 
drinking water, which is based on ß-D glucuronidase, an enzyme associated with E. coli 
                                                 
 Reproduced with permission from Analytical Chemistry 
85 
 
colonies.11 This method (EPA Method 1603) detects the presence of all coliforms but 
not specifically the E. coli O157:H7 strain due to a two-base frame shift insertion within 
its genome that yields an inactive uidA gene and lack of ß-D glucuronidase 
production.12 Detection of pathogenic E. coli O157:H7 is usually performed with EPA 
Method 9260F,13 which employs a series of incubations at low temperatures for 
extended periods of time (72 h).  
The presence of naturally and anthropogenically derived dissolved substances in 
aquatic systems, such as humic materials and residual pharmaceuticals,14 along with 
other dominant native bacterial species, can act as interfering agents that may alter the 
accuracy of the aforementioned colorimetric tests. In addition, microbiological studies 
have indicated that stressed E. coli O157: H7 become nonculturable even though they 
may be viable and still capable of producing Shiga-like toxin.15 More recently, nucleic 
acid-based methods for pathogen detection, such as polymerase chain reaction (PCR), 
have been developed to target unique bacterial genes. PCR itself, although very 
sensitive, detects the presence of bacteria but does not allow isolation of rare bacterial 
cells, which is required to determine the etiological agent responsible for an outbreak.16 
 Recent work has shown that cells can be accumulated from biological samples 
using a microfluidic platform.17-19 These microfluidic devices utilized the surface of a 
microchannel or beads trapped within a microchannel for positive cell selection. Liu et al. 
generated a device for processing E. coli cells from input volumes of 1 mL with the cell 
limit-of-detection (LOD) of ∼1 cfu μL-1.20 Beyor and co-workers reported a microfluidic 
system that could process ∼50 μL of input and search for target cells, such as K-12 or 
O157:H7 E. coli.21 The LOD reported was 0.2 cfu μL-1. With an E. coli O157:H7 
concentration level of <200 cells per 100 mL, the probability of securing a target cell in 
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50 μL would only be 0.01. Therefore, sampling statistics would require processing larger 
input volumes to provide higher confidence that a target could be processed.  
We present a method for the isolation, identification, and quantification of E. coli 
O157:H7 cells from recreational waters. Once the cells were enriched, their 
quantification was accomplished using off-chip real-time quantitative PCR (qPCR). We 
used an engineered chip consisting of high-aspect ratio capture beds decorated with 
polyclonal antibodies (pAbs) specific for antigenic membrane proteins expressed in E. 
coli O157:H7. The method was further demonstrated to be capable of detecting E.coli 
O157:H7 cells in lake and wastewater samples. The benefits of this methodology 
include: (i) preselectivity, which is extremely important because the detection is often 
difficult due to the combination of the high number of nonpathogenic bacteria and the 
low number of pathogens of interest;16 (ii) the microfluidic chip provides a cell 
purification platform (cells are washed while attached to the surface) and prepares the 
selected cells for immediate qPCR analysis free from potential interfering agents; and 
(iii) rapid analysis as compared to conventional methods relying on culturing. 
4.2  Materials and Methods 
4.2.1 Reagents and Buffers 
Heat-inactivated E. coli O157:H7 cells and goat polyclonal anti-E. coli O157 
antibodies were purchased from K & P Laboratories Inc. (Gaithersburg, MD). Reagents 
used for the PMMA microfluidic chip surface cleaning and modification included reagent 
grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride 
(EDC), N-hydroxysuccinimide (NHS), and 2-(4-morpholino)-ethane sulfonic acid (MES), 
which were purchased from Sigma-Aldrich (St. Louis, MO) and used as received. 
Phosphate buffered saline (PBS) was purchased from American Type Culture 
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Collection (Manassas, VA). Cellstripper™ was obtained from Mediatech, Inc., 
(Manassas, VA) and used as received. For the fluorescence visualization experiments, 
E. coli cells were stained with a fluorescein-based cell membrane stain, PKH67, 
according to the manufacturer‘s protocol (Sigma-Aldrich, St. Louis, MO). All bacterial 
cells used (Staphylococcus aureus, Micrococcus luteus, Bacillus subtilis, Enterobacter 
aerogenes, Escherichia coli K12) were purchased from Sigma-Aldrich (Milwaukee, WI), 
and Escherichia coli O157:H7 cells were purchased from Kirkegaard & Perry 
Laboratories Inc. (Gaithersburg, MD). A stock solution of E. coli cells was prepared at a 
concentration of 3×109 cfu mL-1 and cell suspensions required for testing were prepared 
through serial dilution.  
4.2.2 Microfluidic Chip Fabrication and Assembly 
The microfluidic fabrication procedure involved the following four major steps: (i) 
mold fabrication using high precision micromilling (HPMM); (ii) hot embossing of the 
microfluidic structures in a PMMA substrate; (iii) post-processing of the microfluidic 
including drilling of sample reservoirs, UV-photoactivation of the immobilization beds, 
cover plate assembly; and (iv) antibody attachment to the capture channel surfaces. 
Microstructures were milled onto the surface of a 6.3 mm thick brass plate (alloy 353 
engravers brass, McMaster-Carr, Atlanta, GA, USA) using a high-precision micromilling 
machine (KERN MMP 2522, KERN Micro- und Feinwerktechnik GmbH & Co. KG; 
Germany) as reported previously.22 PMMA was used as the chip substrate and cover 
plate (0.5 mm thickness) and were purchased from Good Fellow (Berwyn, PA). The 
microstructures were hot embossed into PMMA substrates via micro-replication from 
the brass mold master. Before final assembly (attachment of the cover plate to enclose 
fluidic channels), chips were washed with ~0.5% Alconox solution, rinsed with DI water, 
88 
 
2-propanol, and ultrasonicated for 10 min in DI water. PMMA devices and cover plates 
were exposed through a mask to ultraviolet radiation (254 nm, 10 min at 15 mW cm-2) 
resulting in the formation of carboxylate moieties only in the UV exposed areas of the 
PMMA, which in this case was the cell selection bed. The density of the carboxylic acid 
groups on the surface after a 10 min exposure to UV light has been determined to be 
6.6×10-10±0.8×10-10 mol cm-2.17 UV-modified PMMA parts were clamped together 
between two borosilicate glass plates and the cover plate was thermally fusion bonded 
to the substrate using a convective oven set to 101 °C, slightly above the glass 
transition temperature of the UV-modified material. The temperature was increased 
from 50 °C to 101 °C at a rate of 20 °C min-1 and held at 101 °C for 15 min. Polyimide-
coated fused silica capillaries (100 μm i.d., Polymicro Technologies, Phoenix, AZ) were 
inserted and glued into the inlet port of the assembled device to provide an interconnect 
for sample introduction into the device.  
Each of the 8 devices contained 9.5 mm long, 16 curvilinear channels that were 
15 μm in width and 80 μm in depth with a radius of curvature of 120 μm (see Figure 4.1). 
The surface area of the 16 channels, which defined the cell selection bed, was 40 mm2 
with a volume of 250 nL. The chip output following selection and release was directed 
into a PCR microtube. A precell selection rinse of the chip was performed with 100 μL of 
150 mM PBS at 50 mm s-1. A programmable syringe pump (Harvard, Holliston, MA) with 
a syringe equipped with both a luer lock (Hamilton, Reno, NV) and a luer-to-capillary 
adapter (Inovaquartz, Phoenix, AZ) were used to infuse the water sample into the chip. 
Then, a cell suspension or water sample was infused into the chip at 0.5, 1.0, 5, 10, 40, 
80, and 100 mm s-1 linear velocities. A postcapture rinse with 100 μL of 150 mM PBS at 
50 mm s-1 (55.6 μL min-1) was used to  remove any  nonspecifically  adsorbed  material.  
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Figure 4.1 (A) A picture of the PMMA fluidic system for the positive selection of rare E. coli cells 
containing 8 different devices with each device comprised of 16 selection channels. (B) 
Schematic of the entire cell selection chip and (C) an expanded via of an individual cell selection 
device. Each device contained 9.5 mm long 16 curvilinear channels that were 15 μm in width 
and 80 μm in depth with a radius of curvature of 120 μm with respect to the channel center. (D-
E) SEM of the brass molding tool. 
Cells were then stripped from the channel walls using a Cellstripper solution and eluted 
from the chip in 5 μL of PCR buffer. 
4.2.3 Antibody Immobilization 
Antibody immobilization onto the photoactivated PMMA chip surface was carried 
out in a two-step process.7 The UV-modified, thermally assembled device was flooded 
with a solution containing 4 mg mL-1 EDC, 40 mg mL-1 NHS in a 150 mM MES (pH=6) 
and kept for 1 h at room temperature to obtain the succinimidyl ester intermediate. After 
this incubation, the EDC/NHS solution was removed by flushing nuclease-free H2O 
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through the device. Then, an aliquot of 10 μL of 1.0 mg mL-1 of the polyclonal anti-E. 
coli O157 antibody solution in 150 mM PBS (pH=7.4) was introduced into the channels 
and allowed to react for 4 h in a high humidity box. The device was then rinsed with a 
solution of PBS (pH=7.4) to remove any non-specifically bound anti-E. coli O157 
antibodies. The molecular weight of pAb was provided by the manufacturer and 
reported as ~150 kDa. IgG antibodies possesses three discrete domains, two Fab 
fragments and one Fc, known to be flexible, but difficult to predict the exact 
conformation when immobilized to a solid surface.8 Roberts et al. determined IgG 
molecular dimensions of passively adsorbed IgG antibodies on a polystyrene surface to 
be 16-19 nm.23 Dong et al. determined the diameter of covalently attached IgG to a gold 
surface to be 52.4 nm and determined that ~22% of the Abs were active after covalent 
attachment.24 Assuming a 52.4 nm IgG diameter, we calculated the pAb density on the 
PMMA surface to be 4.6×1010 molecules cm-2 assuming a full monolayer coverage that 
was limited by the molecular dimensions of the pAb, which is supported by the higher 
surface density of carboxylic acid functional groups on the PMMA surface following UV 
exposure.25,26  
4.2.4 Fluorescence Microscopy 
Observations of fluorescently-labeled cells in the chip‘s selection channels were 
accomplished using a Zeiss Axiovert 200M Inverted Microscope with a 40x fluorescence 
objective equipped with a 480 nm excitation filter. The microscope was fitted with a JAI 
CV 252 monochrome video camera. The images were captured directly to the hard 
drive of a Dell Precision 500M workstation via a Pinnacle Systems DV500 video capture 
card that was interfaced to a Pinnacle Systems Bluebox (Pinnacle Systems, Inc., 
Mountain View, CA). Adobe Premiere 6.0 (Adobe Systems, Inc., San Jose, CA) was 
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used for image acquisition and processing. In order to analyze the cell flow profiles and 
cell radial distribution in the selection channels, trajectories of fluorescently labeled E. 
coli O157:H7 cells flowing in an unmodified channel were investigated. Cell trajectories 
were captured via video microscopy and micrographs containing one half of the curved 
channels were extracted from the video. One hundred cellular events were located in 
the micrographs and the distance between the center of the cell event and the channel 
wall was determined using ImageJ 1.38x software (National Institute of Health, USA).  
4.2.5 Flow Dynamics 
To evaluate the flow dynamics of bacterial cells in the microchannel operated 
with hydrodynamic pumping, the Reynolds numbers (Re) were calculated
27 using the 
equation, Re=ρUdh/μ, where, ρ, U, and μ are the density (997.04 kg m
-3), velocity (m s-1), 
and viscosity (8.9×10-4 Pa s-1) of the fluid, respectively, and dh is the hydraulic diameter, 
defined as 2wh/(w+h), where w and h are the channel width and height, respectively. 
For a rectangular channel with 15 μm×80 μm dimensions, dh=2.53×10
-5 m. Re was 
calculated to be in the range of 0.01 to 2.83, for 0.5, and 100 mm s-1 linear velocities, 
respectively, indicating fully developed laminar flow within the tested flow range.  
4.2.6 Water Sample Collection 
Lake water samples were secured from two different sites: (i) Baton Rouge 
University Lake, LA (USA), which is a small man-made lake on the LSU campus 
created in the early 1920s with the damming of Bayou Duplantier, and (ii) Lake 
Granbury, TX (USA), which is a reservoir on the Brazos River constructed in 1969. The 
sampling depth was about 6 in. below the water surface. The University Lake is a part of 
the Lakes District System, which consists of six man-made lakes located approximately 
1.2 miles east of the Mississippi River and 2.5 miles southeast of downtown Baton 
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Rouge, LA. Creation of the lakes began in the early 1920s with the damming of Bayou 
Duplantier, which flooded the old cypress swamp. There are approximately 140 outflows 
entering the lakes from storm drains of the watershed. University Lake is the largest 
lake of the system at approximately 195 acres in size. The lake has an average depth of 
1.5 feet with some areas as low as 0.5 feet and a hydraulic retention time of ~50 days 
(http://www.mvn.usace.army.mil/pd/projectsList/ProjectData/108824/reports/University%
20Lakes% 20PRP.pdf).  
Lake Granbury‘s surface area and volume are 34 km2 and 167×106 m3, with 
inflows primarily through the Brazos River. Upstream of Lake Granbury, the Brazos 
River watershed is dominated by rangeland. For extended periods of the year, inflows 
can be near-zero. When inflow events occur, they last several days and can exceed 
flushing rates of 20 d-1.28 Much of the shoreline of Lake Granbury is residential, with 
only a portion of this area serviced by a sewage system. In addition, some areas of 
Lake Granbury are protected from flushing (i.e., coves with longer hydraulic residence 
times). E. coli concentrations can become problematic in this lake system (Roelke, 
unpublished data), where the likely source of contamination is aging septic systems that 
leak into the lake. E. coli concentrations are able to accumulate in areas of low flushing. 
For this study, water samples were collected by hand from multiple coves of Lake 
Granbury. 
4.2.7 Water Sample Filtration 
Water samples from recreational lakes (100 mL) and wastewater samples (1 mL) 
were filtered using hydrophilic (PVP-coated) polycarbonate track etched membranes 
(PCTE, Sterlitech, Kent, WA) membrane filters. The pore size of the membranes used 
was 10 μm for the prefiltration to remove large particulates and 0.1 μm for further 
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filtration and volume reduction prior to input into the microfluidic device. Water samples 
were filtered through the 10 μm pore size membranes at 10 mL min-1, and the effluent 
was collected and filtered through the 0.1 μm pore size membranes at 2.5 mL min-1. 
The membrane was rinsed with ∼1 mL of pure water to exhaustively remove material 
from the surface and used as the input to the microfluidic chip. The 10 μm pore size 
membrane filter did not change the total volume of the sample; however, it did remove 
solid particulates and debris. 
4.2.8 E. coli Detection via Culturing 
E. coli were in some cases analyzed from membranes using a modified 
membrane-Thermotolerant E. coli agar (Modified mTEC EPA Method 1603), which uses 
a membrane filter procedure for the detection and enumeration of E. coli bacteria in 
ambient waters and disinfected waste waters. The modified medium contained a 
chromogen (5-bromo-6-chloro-3-indolyl-ß-D-glucuronide), which is catabolized to 
glucuronic acid producing a red- or magenta-colored compound by E. coli that produces 
the enzyme, ß-glucuronidase. A sample was filtered through a 0.1 μm pore diameter 
membrane, which retained the bacteria. After filtration, the membrane was placed on a 
selective and differential medium, modified mTEC agar, incubated at 35±0.5 °C for 2± 
0.5 h to resuscitate injured or stressed bacteria and then incubated at 44.5±0.2 °C for 
22±2 h. The target colonies on the modified mTEC agar are red or magenta in color 
after incubation and can be counted manually via visual inspection.  
4.2.9 Polymerase Chain Reaction (PCR) and Real-Time qPCR 
The primer sequences used for the PCR were as follows: slt1, forward primer 
(FP) – CAG TTA ATG TGG TGG CGA AGG (Tm=56.3 °C), reverse primer (RP) – CAC 
CAG ACA ATG TAA CCG CTG (Tm=56.2 °C) product size – 348 bp; uidA, FP – GCA 
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AAA CTG TGG AAT TGG G (Tm=54.8 °C), RP – TGA TGC TCC ATA ACT TCC TG (Tm 
=52.0 °C), product size – 252 bp. These primers were previously reported by Cebula et 
al. for recognition of E. coli O157:H7 through a mismatch amplification mutation assay.6 
PCR cocktails consisted of 0.5 μM primers, 0.2 mM dNTP‘s, 1x PCR buffer, 5 U of Taq 
DNA polymerase, DNA template and ultrapure water. The PCRs were carried out using 
a commercial thermal cycling machine (Techne, Burlington, NJ) with cycles consisting 
of an initial denaturation step at 94 °C for 5 min followed by 30 cycles of the following: 
94 °C for 30 s, 58 °C for 40 s, 72 °C for 60 s. A final extension at 72 °C for 7 min was 
followed by a cooling step at 4°C. Real-time qPCRs were performed on a Stratagene 
Mx4000 real-time PCR machine with Brilliant® II SYBR® Green QPCR Master Mix 
(Stratagene, La Jolla, CA). The reactions (50 μL) were prepared by combining 
nuclease-free water, master mix, primers (final concentration=40 nM), and reference 
dye (ex/em=584/612 nm) to a final concentration of 30 nM. The volume of the 
template/unknown sample added to the reaction was 5 μL and was the total volume of 
the pre-concentrated cells eluted from the microchip (chip pre-concentration factor = 2× 
102). The PCR protocol used involved a three-step cycling procedure: (1) 10 min at 
95 °C; (2) 46 cycles 30 s  at 95 °C, 60 s at 58 °C, 60 s at 72 °C; and (3) a dissociation 
step consisting of 81 cycles of ramping the temperature between 55 and 95 °C (0.2 °C 
s-1). Standard calibration curves were constructed and PCR amplification efficiencies 
were determined among different experiments.  
4.2.10 Slab Gel Electrophoresis 
PCR products were electrophoresed using a 2% agarose gel (Bio-Rad 
Laboratories, Hercules, CA) pre-stained with ethidium bromide. The sample volume 
loaded onto the gel was 5 μL with 1 μL of the loading dye. Amplicons were indexed 
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against a DNA sizing ladder (50-1,000 bp, Molecular Probes, Eugene, OR). Separation 
was performed at 4.8 V cm-1 in 1x TBE (Tris/Boric Acid/EDTA, Bio-Rad Laboratories). 
Gels and culturing plates were imaged using a Logic Gel imaging system (Eastman 
Kodak).  
4.3  Results and Discussion 
4.3.1 Low-Abundant E. coli O157:H7 Cell Processing 
Scheme 4.1 presents an overview of the processing strategy used for the 
selection and identification of E. coli O157:H7 cells. The processing steps involved: (i) 
chip preparation; (ii) sample filtration using PCTE membranes to remove large 
particulates from the sample and to provide pre-enrichment; (iii) sample processing on 
the chip and cell release; and (iv) benchtop real-time qPCR quantification of the 
selected cells. For the recreational water, the time required to filter a 100 mL input using 
both the 10 and 0.1 μm filters to reduce the total volume to 1 mL was 50 min, producing 
a volume reduction of 100-fold and, thus, a 102 pre-enrichment assuming 100% 
recovery. Processing a total input  volume of 1 mL  using  the  8  devices  poised on  the 
microfluidic chip (Figure 4.1) at a linear flow velocity of 5 mm s-1 (5.3 μL min-1) required 
24 min and produced an enrichment factor of 2×102. Therefore, the 0.1 μm filter and 
microfluidic chip generated a total enrichment factor of 2×104 with a processing time of 
74 min. Membranes before and after filtration were inspected under a microscope and 
showed that the majority if not all of the solid material had been  removed  from the 
sample prior to chip processing (see Figure 4.2). To achieve maximum recovery of 
bacterial cells from the 0.1 μm filter, the filter was washed with 1 mL of water and 
control experiments with known amounts of cells were performed.  Previously,  Wang et  
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Scheme 4.1 Overview for the Processing Strategy Adopted for Analysis of Extremely Low 
Abundant E. coli O157:H7 and Other Serotypes Using Positive Selection and Enrichment via a 
Microfluidic Chip with Subsequent Quantification through Real-Time qPCR 
 
al. evaluated the performance of these types of membrane filters with pore sizes 
ranging from 0.1 to 0.45 μm to determine the effect of cell shape and size on bacterial 
filterability and determined that bacterial shape, rather than their absolute size, was a 
key factor in determining cell recovery.29 We recovered 92±5% (n=4) of E. coli O157:H7 
microbial material using the 0.1 μm. Bacterial cells were not lysed while on the 
membrane because this process would not guarantee the high quality quantitative 
analysis of DNA. A DNA extraction step should be performed to free the sample from 
any potential inhibitors present on the membrane surface.30 In our approach, the 
immunocapture of the pathogens of interest using microfluidic channels followed by an 
extensive wash and subsequent release from the capture surface produced high quality  
97 
 
                         
Figure 4.2 A and C are pictures of 0.1 μm PCTE membranes after filtration and washing, 
respectively, while B and D correspond to 40x microscope images of the same membranes 
after filtration and washing, respectively. The insert in B shows a micrograph of the membrane 
before filtration. The sample processed here was that taken from Lake Granbury in Texas. 
qPCR results that were not seen in the case using E. coli washed directly from the 0.1 
μm filter (data not shown). In addition, the use of the microfluidic  device  provided  high  
preconcentration factors due to the small selection bed volume, improving the limit-of-
detection for the qPCR. 
4.3.2 Water Sample Filtration 
The water samples (100 mL) were first filtered using a 10 μm pore size 
Polycarbonate Track Etched membranes (PCTE). Using a vacuum pump with the filter 
allowed processing water samples at a volume flow rate of 10 mL min-1. This step 
ensured that large debris was removed from the sample before it entered the 
microfluidic device. Effluent from that step was subsequently filtered on a 0.1 μm pore 
size PCTE membrane, on which bacteria and debris larger than 0.1 μm and smaller 
than 10 μm were retained. Samples were processed at 2.5 mL min-1 volume flow rates. 
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The next step involved washing residual material from the 0.1 μm pore membrane using 
1,000 μL of water, which also resuspended the retained bacterial material. This was 
performed thoroughly making sure none of the retained material was left on the 
membrane. Membranes before filtration, after filtration and washing were inspected 
under a microscope. Figure 4.2 presents results from these evaluations.  
4.3.3 E. coli Flow Dynamics in Microfluidic Channels 
As we demonstrated in our previous work discussing the positive-selection of 
cells via surface-immobilized Abs, hydrodynamic flow through low Re channels can 
produce a cell-free layer near the channel wall due to focusing effects, significantly 
reducing cell:wall interactions and thus, cell recovery.17,18 This focusing effect is flow 
rate dependent, but can be reduced using a channel geometry that is sinusoidally 
configured, at least for relatively large cells such as tumor cells. Therefore, we 
investigated cell flow dynamics and possible focusing artifacts for much smaller cells, 
such as E. coli, in curved channels. Radial cell distribution histograms for 1, 5, 40, and 
100 mm s-1 linear flow velocities are presented in Figures 4.3A-D. Cell distributions 
indicated that the number of cells at the outer edge of a single curved region increased 
only slightly with flow velocity compared to the number within the inner edge. For 
example, the ratio of cells at the outer-to-inner edges of a curve were 1.6, 2.0, 2.5, 3.0, 
and 11.0 for 1, 10, 40, 80 and 100 mm s-1 flow rates, respectively. Similar observations 
were reported by Mayeed et al.31 
Previously, we reported that sinusoidal channels were more effective than 
straight channels for recovering circulating tumor cells at relatively high linear velocities 
due to the lack of a cell-free marginal zone adjacent to the outer-edge of the wall for a 
single turn. This resulted from centrifugal forces acting on the cells and increased  
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Figure 4.3 Histograms of the radial position of bacterial cells in an unmodified sinusoidally-
shaped microchannel at linear velocities of (A) 1, (B) 5, (C) 40, and (D) 100 mm s-1. The dashed 
lines designate the channel walls. The cells were imaged using fluorescence microscopy with 
the cells stained using PKH67. The coordinate system adopted used 0 as the channel centroid, 
(-) values refer to locations with respect to the outer edge of the channel and (+) values 
represent radial positions in the direction of the inner edge of the channel. 
 
cell:wall interactions  generating  higher  cell  recoveries.17  In  the data  presented in  
Figure 4.3, these effects were much less dramatic for the E. coli cells most likely due to 
the smaller size of these cells. In fact, as can be seen from Figure 4.3C, the E. coli cells 
did not cross flow lines through the turns with fully  developed  laminar  flow. Therefore, 
a much more uniform cellular radial distribution was observed, which indicates that 
higher flow rates could be used to increase sample processing throughput based solely 
on the cells‘ flow dynamics.  
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4.3.4 Nonspecific Cell Selection 
Even though the affinity purified pAb were directed against E. coli O157:H7, other 
types of E. coli serotypes such as O157:H12, O157:H42, O157:H29, O157:H19, and 
O157:H45, could potentially be selected using this reagent as well as other species, 
such as S. sonnei or C. freundii (see www.kpl.com). However, even if these bacterial 
types were selected during microchip enrichment, they would not be transduced during 
the enumeration process using real-time qPCR because of a lack of the specific marker 
genes used for reporting specifically on E. coli O157:H7.32 We tested the nonspecific 
selection of E. coli K12. Cells were infused into the microfluidic channels at 5 mm s-1, 
the same conditions used for E. coli O157:H7 selection. After a postcapture rinse, 
fluorescence micrographs indicated that no E. coli K12 cells were found in the selection 
beds when decorated with the E. coli O157 pAbs.  
 
Figure 4.4 Fluorescence images of a microchannel with (A) E. coli O157:H7 cells and (B) E. 
coli K12 cells captured on an antibody modified PMMA surface. The dashed lines designate the 
edges of the channel. 
Figure 4.4 shows fluorescence micrographs taken after introducing both types of 
cells. In Figure 4.4A, one can clearly see multiple events of anchored E. coli O157:H7 
cells (indicated with arrows), while in Figure 4.4B, there was a lack of any such events 
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for the K12 serotype. Also, minimal nonspecific cell interactions with the 
poly(methylmethacrylate), PMMA, channel surface was also found (data not shown) due 
to the weak adhesion forces and the presence of hydrodynamic shear that could 
remove any nonspecifically bound cells.17 
4.3.5 E. coli O157:H7 Cell Release from the Channel Surface 
Due to the strong adhesion between the captured cells and the antibody-modified 
capture surface, hydrodynamic release from the capture surface to provide intact E. coli 
O157:H7 cells for real-time qPCR interrogation was found to not be feasible (data not 
shown). Following a postcell capture rinse performed with 150 mM PBS, a Cellstripper 
solution was infused into the channels to dislodge antibody-induced adhesion of cells to 
the channel wall. The use of the Cellstripper™ solution, a non-enzymatic cell 
dissociation solution formulated with a proprietary mixture of chelators, for the release of 
antibody-captured cells without causing cell disassembly was investigated.  
Figure 4.5 shows time-lapse micrographs of a surface-captured cell that was 
subjected to Cellstripper™ processing. Stoke‘s forces induced by hydrodynamic shear 
produced from laminar flow in the presence of the Cellstripper™ solution allowed for 
efficient release of these cells in less than 4 min. Twenty-five cells were monitored, and 
the average time required for their release was determined to be 3.4±0.3 min. Following 
incubation with the stripper solution, the released cells were flushed from the selection 
amplification. We determined that a concentration of Cellstripper up to 10% in the real- 
time qPCR cocktail did not affect these results (see Figure 4.6A-D). 
4.3.6 Cell Recovery 
In order to maximize the recovery of E. coli O157:H7 cells from water samples 
and maintain high  sampling  throughput,  the  processing  linear  flow  velocity  thru  the  
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Figure 4.5 Time-lapse micrographs showing Cellstripper™ and hydrodynamic shear-mediated 
release of a captured fluorescently-labeled E. coli O157:H7 cell (circled in red) from the capture 
surface. (A) A brightfield image prior to exposure of the captured cell to the stripping solution. (B) 
A fluorescence image of the same spot at t=0.1 min following incubation with the Cellstripper™ 
solution. (C) A bright field image at t=3.4 min after introduction of the Cellstripper™ solution was 
infused into the channel and disruption of the binding complex was evident by the bacterial cell 
being released from the surface. (D) A fluorescence image at t=3.5 min following introduction of 
the stripping solution – the cell appears to be released from the capture surface. The stripping 
solution was hydrodynamically pumped through the fluidic chip at a linear velocity of 25 mm s-1. 
 
selection microchannels was optimized. E. coli O157:H7 capture efficiency at different 
flow rates and different cell densities (3-30×103 cfu mL-1) were determined using real-
time qPCR. Linear flow velocities were varied between 0.5 and 100 mm s-1. The results 
of these experiments are depicted in Figure 4.7A as a plot of E.coli O157:H7 capture 
efficiency (%) vs linear velocity (mm s-1). We observed that a linear flow rate of 5 mm s-1 
produced the highest recovery; 71.6±1.4% (n=5). The general trends observed in the 
plot shown in Figure 4.7A can be explained based on the Chang/Hammer model for 
mobile cell interactions with immobilized association elements.17,33 Basically, the two 
processes that primarily dictate a successful antibody/cell interaction involve: (i) the 
encounter rate, which describes the rate of delivery of cells to the channel  surface  and  
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Figure 4.6  Real-time PCR amplification plots for the slt1 gene using RT qPCR with a master 
mix containing different concentrations of Cellstripper™ in standard samples (indicated with 
arrows in the figure). The protocol involved a three-step cycle: (1) 10 min at 95 °C, 46 cycles; (2) 
30 s at 95 °C, 60 s at 58 °C; and (3) 60 s at 72 °C. The PCR products were observed in real-
time using a SYBR Green dye. 
 
is flow rate dependent with this rate increasing with linear velocity, and (ii) the reaction 
probability between the surface tethered antibody and the mobile cell antigenic target, 
which is dependent on the reaction kinetics between the antigen/antibody complex with 
this probability decreasing at high linear velocities.17 Therefore, the observed optimal 
linear velocity (∼5 mm s-1) results from a balance between the reaction kinetics and the 
encounter rate.  
Capture efficiency decreased with increasing channel width as well17,18 (see 
Figure 4.7B). We evaluated the recovery of  E. coli  cells using  channels  with  variable  
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Figure 4.7 (A) Capture efficiency data of E. coli O157:H7 as a function of the cells‘  
translational velocity using the microfluidic chip shown in Figure 4.1. The number of captured 
cells was determined via real-time qPCR. (B) Cell capture efficiency as a function of the channel 
width using a translational velocity of 5 mm s-1. Channels used contained a variable width (10, 
20, and 30 μm) but the same depth (30 μm) and length (3 cm). (C) Standard curves for the real-
time, qPCR analysis of E. coli O157:H7 using slt1 (filled squares) and uidA (filled circles) genes. 
Ct values of known samples were plotted against the corresponding cfu of the bacteria. The 
linear regression analysis for slt1: y=-3.456log(x)+37.12 (r2=0.997) and uidA: y=-
3.373log(x)+40.99 (r2=0.996). (D) A fluorescence agarose gel image of the 252 bp and 348 bp 
PCR products for uidA and slt1 genes, respectively. The amplicons were generated with 10× 
103 cfu/reaction of the E. coli O157:H7 serotype. 
 
widths but the same depth (30 μm) and length (3 cm) and cells flowing at 5 mm s-1 
linear velocity. We observed much higher recoveries for narrower channels as opposed 
to wider channels (68%±2%, 49%±2%, and 18%±5% for channel widths of 10, 20, and 
30 μm, respectively). We previously demonstrated that cell recoveries are maximized 
when the channel width approaches the average cell diameter.17 Unfortunately, we were 
limited by the micromachining technique employed here to a channel width of 10 μm, 
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but the use of narrower channels will most likely increase the recovery by increasing the 
number of cell/wall contacts. Narrower channels can be fabricated using optical 
lithography to make the molding tool as opposed to high precision micromilling.34  
4.3.7 Cell Enumeration in Water Samples  
The selective enumeration of E. coli O157:H7 used real-time qPCR and two sets 
of primers targeting the slt1 and uidA genes. Primers for these genes were reported by 
Cebula et al.34 and were extensively tested for specificity in comparison to other 
serotypes of E. coli. Additionally, we tested these primers with other microbes, some 
potentially present in the sample. No PCR products were observed for S. aureus, B. 
subtilis, E. aerogenes, M. luteus, or E. coli K12 using the uidA and slt1 specific primers. 
PCR products with the size appropriate for the particular gene being interrogated for E. 
coli O157:H7 were observed (see Figure 4.7D).  
Calibration curves for E. coli O157:H7 were generated using serial dilutions of 
standard E. coli O157:H7 cell suspensions between 1 cfu and ∼3×106 cfu (see Figure 
4.7C) in samples containing 100 mL of water. The linearity between the Ct values and 
the number of target cells was observed over 5 orders of magnitude (r2≥0.996). The 
slope of the calibration curve, which is directly related to the average amplification 
efficiency throughout the cycling reaction (efficiency) 10(-1/slope)-1), was found to be -
3.593±0.231, yielding a 98.5±1.7% efficiency (n) 5) for slt1, and -3.616±0.372, for an 
89.2± 2.4% efficiency (n=5) for the uidA gene. The limit-of-detections (expressed as the 
amount of cells detected in the 100 mL sample at least 95% of the time) were calculated 
to be 6 cfu for the slt1 gene and 10 cfu for the uidA gene. Similar or higher real-time 
qPCR limits-of-detections were reported.35  
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Plots of the real-time normalized fluorescence intensity as a function of cycle 
number for the slt1 gene for different cell numbers are presented in Figure 4.8A. The 
analysis of dissociation curves, plotted as the first derivative of the reference dye-
normalized fluorescence intensity reading multiplied by –1(–Rn´(T)), as a function of 
temperature displayed one population with a transition temperature of 80-82 °C, 
indicating the presence of only a single PCR product of the anticipated sequence 
content (see Figure 4.8B). Standard curves were generated using serial dilutions of 
standard E. coli O157:H7 cell suspensions ranging from 1 cfu to ~106 cfu per reaction 
for both slt1 and uidA genes. The linearity between the Ct values and the number of 
target cells was observed over five orders of magnitude. The Ct values of the known 
standards were plotted versus logarithm of the cell count for each standard, creating 
calibration curves from which the unknown concentrations were determined. 
Control samples (single blinded studies) were also evaluated in which E. coli 
O157:H7 samples were spiked at levels of 30-800 cfu per 100 mL input. This data was 
used to construct a calibration plot of Ct versus log (cell density, see Figure 4.7C). For 
example, the number (n=3) of E. coli O157:H7 cells determined from the calibration plot 
was 34±4 (RSD of 12%) at the 30 cfu spike level. At a 400 cfu spike level, the average 
cell count for the assay was 405±5 with an RSD of 1.2%. A blank sample was also 
analyzed, and no E. coli O157:H7 was detected.  
We next evaluated the microchip/real-time qPCR assay to assess the quality of 
different water samples. These samples consisted of samples from two lakes and sewer 
water from a purification plant in Baton Rouge. We should also note that E.coli obtained 
directly from the 0.1 μm filter and tested via  realtime  qPCR  without  processing  in  the  
107 
 
 
Figure 4.8 (A) Amplification plots for the slt1 gene using real-time qPCR for serial dilutions of E. 
coli O157:H7 (6 – 60×103 cfu/reaction). (B) Dissociation curves for amplicons obtain in (A). The 
PCR protocol used involved a three-step procedure: (1) 10 min at 95 °C; 46 cycles consisting of 
(2) 30 s at 95 °C, 60 s at 58 °C, 60 s at 72 °C; and (3) 81 cycles of ramping the temperature 
between 55 and 95 °C (0.2 °C  s-1). 
 
microchip produced failed PCR results due most likely to the presence of potential PCR 
inhibitors that were removed in the fluidic chip following cell selection and rinsing.  
In the Lake Granbury sample, the total E. coli levels were detected at 5 cfu 100 
mL-1 and E. coli O157:H7 serotype at 4 cfu 100 mL-1. Water from University Lake in 
Baton Rouge was evaluated only for the total E. coli level using EPA Method 1603 and 
was determined to be 15 cfu 100 mL-1 (see Figure 4.9A). After performing the assay 
using the microfluidic chip, we determined that for both of these water samples, the 
level of E. coli O157:H7 was below the limit of-detection. This is understandable given 
the fact that the recovery is 72%, and therefore, the approximate numbers of E.coli 
O157:H7 from Lake Granbury would be ∼3 cells, which is below the limit-of-detection 
for both the slt1 and uidA genes.  
Next, we evaluated wastewater samples using EPA Method 1603 and found E. 
coli levels  of 2.6×106  cfu 100 mL-1  (see  Figure  4.9B). In   wastewater   samples,   we  
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Figure 4.9  E. coli colonies formed on the modified mTEC agar surface. The E. coli colonies are 
respresented as dark spots. (A) Baton Rouge Lake water, filtered volumes: a – 100 mL sample, 
b – 25 mL, c – 10 mL, d – 5 mL, e – 0.1 mL, f – blank. The membrane filter in sample (a) was 
used to calculate the number of colonies of E. coli per 100 mL of water. The E. coli 
concentration was calculated as (# colonies/volume processed)×100. (B) A waste water sample 
processed using the mTEC agar surface; volumes processed: a – 1 mL; b – 0.1 mL; c – 0 mL 
(blank). The membrane filter in sample b has the acceptable number of colonies to calculate the 
number of E. coli per 100 mL of waste water. 
 
detected 0.96×106±0.2 cfu 100 mL-1 of E. coli with the serotype O157:H7. Also, we 
calculated the cell capacity of the microchip selection beds possessing a surface area of 
40 mm2, and this value was determined to be 260×106 cells. Thus, the level of cells 
collected from the wastewater sample is well below the saturation limit.  
4.3.8 Cellstripper™ Effects on Real-Time Quantitative PCR (RT qPCR) 
The effect of the non-enzymatic cell dissociation solution on the efficiency of RT 
qPCR was investigated. The amplification plots of baseline-corrected, reference dye-
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normalized fluorescence (dRn) as a function of the cycle number for the slt1 gene for 
different concentrations of Cellstripper™ with different cell numbers are presented in 
Figure 4.6A-D. Typically, the reproducibility of qPCR assays determining cell numbers 
from multiple runs in the absence of the Cellstripper solution was observed to be 2-10%. 
Based upon these results, variabilities between the Cellstripper and no Cellstripper 
qPCRs of ≤5% for concentrations of Cellstripper™ up to 10% in the RT qPCR cocktail 
were concluded to not significantly affect these results (see Figure 4.6B).  
4.4  Conclusions 
I demonstrated the ability to select and quantitatively enumerate the E. coli 
O157:H7 serotype free from other serotype interferences, which is important due to the 
large number of E. coli types and the O157:H7 serotype health-related issues. The 
strategy developed offered the ability to monitor water quality without the need for a 
time-consuming cell culture step. I also showed the ability to recover cells with ∼72% 
efficiency from 100 mL input volumes with the real-time qPCR step providing a limit of-
detection of 6-10 cfu. The entire series of processing steps can be implemented in 
under 5 h, and this could significantly be reduced by transitioning more of the 
processing steps to the chip. For example, increasing the throughput of the fluidic chip 
through the use of more fluidic vials that are deeper can provide the opportunity to 
process 100 mL of input directly without the need for the intermediate 0.1 μm filtering 
step. In addition, moving the real-time qPCR step to the chip can also reduce 
processing time significantly due to the more efficient thermal management properties 
of microscale PCR.36  
The microchip enrichment procedure provided the following advantages: (i) the 
enrichment step can recognize O157 types in intact and virulent cells and in stressed 
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and nonculturable cells; (ii) cells enriched on the chip can be isolated from potential 
contaminants that can interfere with nucleic acid-based analysis; and (iii) the chip can 
preconcentrate cells to a detectable level with an enrichment of 2×102 in its current 
rendition. I envision the potential to probe for a large number of different strains of 
enterohemorrhagic E. coli, which includes more than 100 different non-O157 strains.37-
39 By proper choice of pAbs and specific probes for the real-time qPCR, one could 
monitor a large panel of suspected E. coli strains from a single sample. 
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CHAPTER 5 HIGH-THROUGHPUT SELECTION,ENUMERATION, ELECTROKINETIC 
MANIPULATION, AND MOLECULAR PROFILING OF LOW-ABUNDANT 
CIRCULATING TUMOR CELLS USING A MICROFLUIDIC SYSTEM 
 
5.1 Introduction 
 
Colorectal cancer (CRC) accounts for nearly 1,000,000 new cases and 550,000 
deaths worldwide each year; it is the fourth most common form of cancer in the United 
States and the third leading cause of cancer-related deaths in the western world.1 
Diagnostic and/or prognostic tests of CRC consist primarily of looking for bleeding in the 
stool (fecal occult blood test, FOBT) and/or endoscopic examinations of the colon 
and/or rectum. While FOBT has reduced mortality rates by 15-33% over the last 30 
years, FOBT is more sensitive for the diagnosis of invasive cancer than it is toward 
advanced adenomas or early-stage lesions.2 On the other hand, endoscopic 
examinations, such as colonoscopy or flexible sigmoidoscopy, can detect early stage 
lesions but misses proximal lesions when the distal colon is examined. Even in cases 
where both stool samples and endoscopy are employed, 25% of cases are expected to 
be missed.3 
In cancer patients with either metastatic or localized disease, there is growing 
evidence that the presence of circulating tumor cells (CTCs) in the blood may be an 
important indicator of the potential for metastatic disease and thus, poor prognosis.4 
Various epithelial-based cancers are known to release CTCs into circulation for 
example breast, bladder, prostate, lung, colorectal, cervical, and pancreatic cancers. 
The attractive attribute associated with CTCs is their ease of securing the sample; a 
simple blood draw (~7.5 mL) can be used to allow for the selection and enumeration of 
these cells.5 CTCs can provide valuable clinical information as well, such as early 
diagnosis of relapse, monitoring the effectiveness of adjuvant therapy and serving as an 
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independent prognostic factor. For example, while surgical resection of the diseased 
tissue in conjugation with chemotherapy is seen as an effective mode of treatment for 
highly localized CRC diseases, 30-50% of these patients ultimately experience 
recurrence and die.6 
The high rate of recurrence for CRC could be due to heightened levels of CTCs 
in peripheral blood following surgery; indeed elevated levels of CTCs were found post-
operatively for CRC patients.7 Finally, tumors contain genetically heterogeneous cell 
subpopulations with different propensities to spawn metastatic disease and therefore, if 
the CTC population responsible for metastasis could be identified through unique 
genetic profiles, oncologists could match proper therapy to the individual patient.8  
Early results for CTCs as a biomarker for CRC have been somewhat 
controversial due to the proximity of the colon to the liver, which can act as a filter to 
remove malignant cells. In spite of this controversy, promising results have appeared in 
the literature.9 For example, progression free survival and overall survival for metastatic 
CRC patients with less than 3 CTCs per 7.5 mL of peripheral blood was significantly 
longer than those with CTC numbers >3 per 7.5 mL of blood. In addition, the diversity of 
targeted therapies is often times hampered by the acquisition of solid biopsy samples 
and the use of CTCs has been demonstrated to serve as an important, noninvasive 
biomarker for pharmacodynamic assessment of new treatment regimens for CRC.5 
The challenge in any platform directed towards the isolation and pre-
concentration of low abundance cells begins with the selection of the target cells from a 
heterogeneous population in which the target is a minority. However, technological 
advances have now facilitated the selection, enumeration, and characterization of CTCs 
using methods such as PCR,10 flow cytometry,11 image-based immunologic 
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approaches,12 immunomagnetic techniques,13 and microchip technology.14 The FDA 
accepted modality for CTC selection has been the use of the Veridex CellSearch™ 
system, which uses magnetic beads coated with monoclonal antibodies directed against 
the epithelial cell adhesion molecule, EpCAM. The processed sample is incubated with 
ferromagnetic particles coated with anti-EpCAM antibodies and the 
immunomagnetically-labeled cells are isolated by an external magnetic field. A rigorous 
evaluation of the performance metrics associated with the CellSearch™ system has 
indicated that the CTC recovery is ~85%.4 Challenges with this technology are the low 
throughput (8 samples per day) it affords and the high cost per assay.15 In addition, 
once selected, the cells must be extracted from the isolation cassette and placed in the 
imaging station for enumeration. This requires the vessel containing the cells to be 
opened to the environment, which can run the risk of contamination, especially in a 
centralized laboratory where many samples are processed. 
  Microchip technology has the potential to select with high recoveries, enumerate, 
and characterize rare CTCs in cancer patients, which will provide opportunities for 
identifying the potential for metastatic disease at very early stages, managing risk 
stratification in the adjuvant setting, monitoring response to treatment, identifying 
disease recurrence, and the prospective development of targeted therapies based on 
molecular characterization of CTCs (i.e., personalized medicine). For example, Nagrath 
et al. developed a microfluidic device for selecting CTCs directly from peripheral 
blood.16 The CTCs originated from a variety of epithelial-based tumors and were 
selected through the use of anti-EpCAM monoclonal antibodies tethered to a fluidic 
channel containing 78,000 microposts. Anti-EpCAM monoclonal antibodies provided the 
specificity for CTC selection from unfractionated blood because EpCAM is 
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overexpressed only by adenoma carcinomas. The potential utility of this CTC chip in 
monitoring response to anti-cancer therapy was also investigated.16 RT-PCR analysis of 
the selected CTCs indicated the opportunity for CTC-based molecular analyses.  
Adams and Dharmasiri et al. generated a polymer–based fluidic device for the 
high-throughput and high recovery selection and enumeration of CTCs directly from 
peripheral blood using either anti-EpCAM antibodies or PSMA-specific aptamers as the 
molecular/cellular recognition elements.17,18 The cells were selected directly from whole 
blood in less than 40 min of processing time with recoveries exceeding 90%. In addition, 
the selected CTCs could be released from the capture surface and counted 
quantitatively using a contact conductivity sensor.  
Unfortunately, the aforementioned work did not perform any type of molecular 
analyses on the selected CTCs with the selected CTCs simply dumped to waste 
following their selection from whole blood. Molecular profiling of CTCs can provide 
important clinical information that cannot be garnered simply by enumerating the 
selected cells. As noted, mutations in certain gene fragments carried by CTCs can be 
used to guide therapy and provide opportunities for personalized treatment of a patient. 
In the case of colorectal cancer (CRC), patients with mutated K-ras oncogenes do not 
benefit from anti-EGFR mAB therapy, whereas patients with wild-type K-ras genotypes 
do benefit from cetuximab and panitumumab-based treatments.20 Yang and coworkers 
recently found that 90% of metastatic CRC patients had a K-ras mutational status of 
CTCs similar to the primary tumor as determined by genotyping mRNA surrogates. In 
addition, it has been noted that non-tumor epithelial cells can also be present in the 
blood and express antigens that would select these cells. Therefore, to discern 
differences between CTCs and normal epithelial cells shed into peripheral blood, 
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molecular profiling is necessary.21 The significant challenge with genotyping gDNA from 
mass-limited samples, such as CTCs isolated from cancer patients, is the small copy 
number of the assays input material. Indeed, most studies in which molecular profiling 
has been invoked on CTCs, in particular CRC, has focused on using reverse 
transcription PCR with mRNA surrogates to record gene activity or the 
presence/absence of mutations due to the higher copy number of the transcripts 
compared to the gDNA.22 Therefore pre-concentration of the selected CTCs in a 
microfluidic for subsequent molecular profiling is crucial for detecting low copy number 
gDNA mutations. 
Many techniques exist to physically manipulate and pre-concentrate cells such 
as blood, tumor and bacterial cells using microfluidics including optical tweezers,23 
acoustic forces,24 magnetic forces, electromagnetic fields, dielectrophoresis (DEP) and 
surface modification.25 Magnetoquasistatic fields have been used to manipulate cells 
either due to their intrinsic magnetizability, such as the iron found in red blood cells,26 or 
by attaching magnetic materials to the cells for magnetically activated cell sorting.27 The 
resulting force is due to the interaction of a magnetic dipole with a non-uniform magnetic 
field and is known as magnetophoresis. Magnetophoresis has the important attribute of 
being highly specific because the vast majority of material does not respond strongly to 
magnetic fields. The drawback is that the technique requires a label (except for red 
blood cells). Electromagnetic fields are the most general case and are commonly used 
to manipulate particles when used as optical tweezers.28 At low frequencies or in 
systems that are small compared with the wavelength of the field, the electric and 
magnetic components of the electromagnetic field decouple and one will dominate.23 
Optical tweezers typically are able to handle only one or a few cells at once. DEP 
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systems are less suitable due to potentially cytotoxic buffers and/or high temperatures 
induced by Joule-heating.29,30 
Overall, cell manipulation techniques thus far are rather inefficient with the 
efficiency, defined as the ratio of the number of cells successfully collected to the total 
number of input cells, is only 10-20%.31,32 The low efficiency may not be a problem in 
many cell assays, but it is a concern when working with cell-limited samples, such as 
the case with CTCs. To address these limitations, a family of emerging technologies, 
such as microfluidic, and electrophoresis, can be combined for CTC handling with the 
potential for high-throughput processing with efficient collection of the target cells for 
molecular profiling. Electrophoresis has already been demonstrated for the manipulation 
of biological particles, such as cells, bacteria and viruses.30  Electrophoresis is based on 
the intrinsic electrical properties of the particles being manipulated and does not require 
a label, thus it can potentially be more universal and simpler to implement. The small 
volume liquid handling capability of microfluidic chips should also permit the 
manipulation of only a few cells within a network of channels with highly efficient 
recovery. 
Detecting mutations in cancer patients can be difﬁcult due to the highly variable 
nature of the cancer cells in terms of their mutational status with respect to the stage of 
tumorigenesis and the location and proximity of the sampling site with respect to the 
primary tumor site.32,33 The success and accuracy of genotyping many cancers, such as 
CRC, depends on the ability to detect low copy numbers of mutated sequences in a 
vast majority of wild-type DNA. However, through the use of a microfluidic device that 
can enrich low-abundance CTCs from a mixed-population and recover them with high 
efficiency and their subsequent release can provide effective molecular profiling results 
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from low-copy number inputs and alleviate the problem of large wild-type DNA 
backgrounds.  
Ligase detection reaction (LDR) coupled to a primary PCR can be used to 
identify extremely low abundant mutant DNA due to the double amplification steps the 
assay employs, even when implemented in a multiplexed fashion.33 Following PCR 
ampliﬁcation of the appropriate genes containing the loci of interest, the amplicon is 
mixed with two complementary primers (a common primer and a discriminating primer) 
that ﬂank the mutation locus of interest. The discriminating primer contains a base at its 
3‘ end that coincides with the single-base mutation site being interrogated. Facilitated by 
a highly speciﬁc thermally stable ligase, the allele-specific LDR primers become 
covalently ligated to adjacent fluorescently labeled primers  to form an LDR product if 
and only if the nucleotide at the potential mutation site is complementary to the 3‘ end of 
the discriminating primer. This LDR can then linearly amplify the products during 
subsequent thermal cycles. The ﬂexible design of the primers used for the LDR assay 
has allowed for the detection of successful ligation events via a variety of analytical 
formats,34 such as low-density DNA microarrays,35 high-resolution electrophoresis,36 
and spectroscopic techniques employing ﬂuorescence resonance energy transfer.37-39  
In this report, we describe a microfluidic electrokinetic micromanipulation method 
for the selection and electrokinetic collection of low-abundance CTCs affinity-selected 
from whole blood for subsequent molecular profiling of point mutations in the gDNA of 
the CTCs. The electric field strength and hydrodynamic flow velocity were optimized for 
the effective collection of CTCs released from the surface containing antibodies specific 
to the CTCs. The CTCs were directed into a reservoir (2 µL) for molecular interrogation 
of potential point mutations within their gDNA. Finally, the optimized system was 
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integrated to a micro-scale high-throughput microsampling unit (HTMSU) for CTC 
selection and enumeration directly from whole blood. We recovered SW620 cells, a 
CRC cell line used as a model, following seeding into peripheral blood. The selected 
cells were enumerated using an on-chip conductivity sensor and the enumerated cells 
directed into a reservoir for pre-enrichment. The enriched CTCs were lysed and their 
DNA was extracted for genotyping gDNA for potential K-ras mutations. Because most 
K-ras mutations are localized to codon 12 and to a lesser extent, codons 13 and 61, the 
PCR/LDR assay was performed on codon 12 of the K-ras oncogene to detect the 
presence/absence of point mutations possessing clinical relevance for the 
diagnosis/prognosis of colorectal cancers.  
5.2 Materials and Methods 
5.2.1  Reagents and Cells 
PMMA substrates and cover plates (0.5 mm thickness) were purchased from 
Good Fellow (Berwyn, PA). Platinum wires were purchased from Alfa Aesar (Boston, 
MA). Polyimide-coated fused silica capillaries were purchased from Polymicro 
Technologies (Phoenix, AZ). Chemicals used for the PMMA surface cleaning and 
modification included reagent grade isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), fetal bovine serum and 
2-(4-morpholino)-ethane sulfonic acid (MES) and these were purchased from Sigma-
Aldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody was obtained from R & D 
Systems (Minneapolis, MN). The SW620 (colorectal cancer cell line), growth media, 
HEPES buffer, phosphate buffered saline (PBS) and trypsin were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). Citrated rabbit blood was 
purchased from Colorado Serum Company (Denver, CO). Tris-Glycine buffer was 
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obtained from Bio-Rad Laboratories (Hercules, CA). All solutions were prepared in 
nuclease-free water, Invitrogen (Carlsbad, CA). Nuclease-free microfuge tubes were 
purchased from Ambion (Foster City, CA) and were used for preparation and storage of 
all samples and reagents. A fluorescein derivative, PKH67, was purchased from Sigma-
Aldrich. Oligonucleotide probes and primers were obtained from two different sources, 
Integrated DNA technologies (Coralville, IA). 
5.2.2 Cell Culturing 
SW620 cells were cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s 
Medium supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate 
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper solution 
was prepared in 150 mM PBS and was used to harvest the SW620 and HT29 cells from 
the culturing plate. SW620 cells were stained with PKH67 for microscopic visualization 
experiments using fluorescence microscopy. A modified protocol for cell staining was 
implemented whereby the dye concentration was increased twofold resulting in more 
evenly distributed fluorescent labels over the cell‘s periphery. Cell counts were 
determined by counting three aliquots of cells in succession using a hemacytometer. 
The cell count accuracy was within 10%. 
5.2.3  Microscopy 
In cases where the cells required optical visualization to assist in the operational 
optimization of the CTC selection, enumeration and manipulation assay, the PMMA 
devices were fixed onto a programmable motorized stage of an Axiovert 200M (Carl 
Zeiss, Thornwood, NY) inverted microscope and video images were collected during 
each experiment at 30 frames s-1 using a monochrome CCD (JAI CV252, San Jose, 
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CA). A Xe arc lamp was used to excite the fluorescent dyes incorporated into the cells‘ 
membrane. 
5.2.4  Fabrication of HTMSU 
The HTMSU and electro-manipulation unit were hot embossed into PMMA 
substrates via micro-replication from a metal mold master. Fabrication of the HTMSU 
followed steps previously reported.17 The HTMSU consisted of a series of 51 high-
aspect ratio curvilinear channels that in concert formed the cell selection bed. Each 
channel was 150 µm (depth)×30 µm (width) and shared common inlet/outlet ports 
(Figure 5.1A). Curvilinear-shaped capture channels were used to improve the cell 
capture efficiency as described previously.17,18 The cell-free marginal zone apparent in 
straight channels was not observed in curvilinear channels and the cell radial 
distribution was unaffected by changes in cell translational velocity. Cells migrate to the 
outside of the curved channels due to centrifugal forces acting on the cells and the 
cross-stream velocity component due to the reversal of the direction of curvature.17 The 
result is an increase in the antibody/antigen encounter rate as the cells moved through 
the capture beds at the relatively high-linear velocities used here, which resulted in high 
recoveries of the CTCs. The channel width of the cell selection bed (30 µm) was 
comparable to the average target cell diameter, which was used to increase the 
probability of cell–antigen interactions with the solution-borne target cells. The large 
channel depth (150 µm) was selected to reduce the pressure drop in high-volume flow 
rate operation and also to increase sample processing throughput.  
The electro-manipulation unit possessed one entry, through (a), (see Figure 5.1A) 
and two exits, via (b) and (c). Entry (a) was connected to a T intersection labeled (e) in 
Figure 5.1A. All of the channels were rectangular in shape with dimensions of 50 µm× 
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100 µm, width and depth, respectively. Before final assembly, 1 mm holes were drilled 
into the electro-manipulation unit for reservoirs, input port and electrodes. Then, the 
electro-manipulation unit chips were washed with ~0.5% Alconox solution, rinsed and 
ultrasonicated with DI water followed by rinsing with 2-propanol, and again 
ultrasonication for 15 min in DI water. The channels were examined under a microscope 
to ensure they were not filled with debris.  
Appropriately cleaned HTMSU substrates and cover plates were exposed 
through a mask to UV radiation resulting in surface photooxidation only in the exposed 
areas of the PMMA. The exposed areas were restricted to only the cell selection region 
of the device. UV irradiation was performed through an aluminum mask for 10 min at 15 
mW cm-2 to facilitate the formation of the activated surface, which also included a 
carboxylic acid scaffold.18  
Pt electrodes (d=76 µm) served as the contact conductivity sensor in the 
detection zone of the HTMSU and were placed into guide channels that were positioned 
orthogonal to the fluidic output channel following thermal assembly. Then, Pt wires 
positioned in the HTMSU and the cover plate were aligned and clamped together 
between two borosilicate plates. Insertion of the electrodes was monitored using a 
microscope to carefully control the inter-electrode gap (~50 µm). The cell constant of 
the Pt conductivity sensor, K, was ~0.01 µm-1, which allowed for the specific detection of 
SW620 cells based on their average size (diameter≈23 µm).17 
The embossed devices were assembled by heat annealing a cover plate made 
from the same material to the substrate. The cover plate and substrate were clamped 
together and placed in a convection oven for ~20 min at 101 °C for the UV-modified 
HTMSU and 105 °C for pristine PMMA electro-manipulation unit. After successful heat 
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annealing, 125 µm diameter Pt wires/electrodes wrapped Cu electrodes were placed 
into the drilled holes in the electro-manipulation unit.  
5.2.5 Antibody Immobilization to the HTMSU 
Antibody immobilization was carried out in a two-step process. The UV-modified 
thermally assembled HTMSU device was loaded with a solution containing 4 mg mL-1 
EDC, 40 mg mL-1 NHS in 150 mM MES (pH = 6) for 1 h at room temperature to obtain 
the succinimidyl ester intermediate. After this incubation, the EDC/NHS solution was 
removed by flushing nuclease-free water through the device. Then, an aliquot of 1.0 mg 
mL-1 of the monoclonal anti-EpCAM antibody solution contained in 50 mM PBS (pH= 
7.4) was introduced into HTMSU and allowed to react for 4 h. The device was then 
rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound anti-
EpCAM antibodies.17 
5.2.6 SW620 Cell Capture/Release and Enumeration Using the HTMSU     
To connect the HTMSU to the pump, a luer lock syringe (Hamilton, Reno, NV) was 
placed on the pump equipped with a luer-to-capillary adapter (Inovaquartz, Phoenix, 
AZ). This was then attached to the capillary that was sealed to the input port of the 
HTMSU. A pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1 
linear velocity to maintain isotonic conditions. Then, the appropriate volume of a cell 
suspension was introduced at the 27.5 µL min-1 (2 mm s-1) volumetric flow rate, which 
was optimized by Adams et al.17 Next, a post-capture rinse was performed with 0.2 mL 
of 150 mM PBS at 50 mm s-1 to remove any non-specifically adsorbed cells. 
Following a post cell capture rinse, a 0.25% trypsin solution in 0.2 mM Tris/19.2 mM 
Glycine buffer (pH=8.3) was infused into the HTMSU. The captured cells could be 
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observed using a microscope until they were enzymatically removed with Stoke‘s forces 
acting on the cells as well to facilitate release.     
5.2.7 Electrokinetic Cell Manipulation 
The released cells from the cell selection surface were subjected to electrokinetic 
cell manipulation after the enumeration. The released cells from the selection surface 
were traversed into the electro-manipulation unit at 1 µL min-1 (3.3 mm s-1) transport 
rate from inlet (a) (see Figure 5.1A). The electric field was applied between (b) and (c) 
reservoirs in the electro-manipulation unit when the buffer solution containing cells were 
introduced from the inlet reservoir.  
The programmable high voltage power supply was assembled in-house. The unit 
consisted of 4 individual power supplies (Model UR5PN, Matsusada Precision Inc., 
Santa Clara, CA) capable of delivering -5 to +5 kV. Each power supply was equipped 
with an independent Reed relay (Model RR1A07P06, Ross Engineering Corporation, 
Campbell, CA) that was used to toggle the polarity, ground, and floating states of the 
power supply. The power supply was computer controlled with a 4 channel 12 bit digital-
to-analog board (Model CYDDA 04P, CyberResearch Inc., New Haven, CT) with 
peripheral component interface (PCI) and software written in Labview (National 
Instruments, Austin, TX). All experiments were carried out at room temperature. Caution: 
The electrophoresis uses high voltages and special care should be taken when handling 
the electrodes. 
Cell migration velocities in the present study were calculated by measuring 
consecutive cell events observed in the video, which had a frame capture rate of 30 
frames s-1. The average velocity was based on values obtained from 5 different cell 
events. 
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5.2.8 Measurement of the Electroosmotic Flow  (EOF) 
The EOF in assembled devices was measured using the method described by 
Zare and co-workers.40 EOF values in 0.2 mM Tris/19.2 mM Glycine buffer (pH=8.3) 
and 0.25% trypsin in 0.2 mM Tris/19.2 mM, Glycine buffer (pH=8.3) were calculated. 
The procedure involved filling the entire chip with a 0.2 mM Tris and 19.2 mM Glycine 
buffer. After filling, one reservoir was emptied and filled with the same type of buffer, but 
of lower ionic strength (0.2 mM Tris/19.2 mM Glycine). An electric field (100 V cm-1) was 
applied to the reservoirs containing the low and high ionic strength buffers. The current 
was monitored continuously using a strip-chart recorder (Kipp and Zonen Inc., Bohemia, 
NY). The time needed for the current to reach a plateau was measured from the plot 
and the linear velocity calculated. Dividing the linear velocity by the electric field 
strength produced EOF values (cm2 V-1 s-1). The electric field was supplied by a 
Spellman high-voltage power supply (CZ1000R, Plainview, NY). The electroosmotic 
flow measurements were carried out on pristine PMMA microchips. Electroosmotic 
mobility data were obtained at room temperature. Each data point was the average of 
five measurements.  
5.2.9 DNA Extraction from SW620 Cells 
Genomic DNA (gDNA) was extracted from CTCs using Lyse-and-Go PCR 
reagent (Pierce Biotechnology, IL, USA). Following manufacturer‘s recommendations, 5 
µL of Lyse-and-Go PCR reagent was added to the selected CTCs and thermocycled 
using the following temperatures: 65 °C  for 30 s; 8 °C for 30 s; 65 °C  for 90 s; 97 °C  
for 180 s; 8 °C for 60 s; 65 °C for 180 s; 97 °C for 60s; 65 °C for 60 s. Prior to the 
addition of the PCR cocktail, the samples were placed at 80 °C.  
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5.2.10 PCRs, LDRs, Gel Electrophoresis and Capillary Electrophoresis 
PCR ampliﬁcations were carried out to generate 300 bp amplicons from SW620 
CTCs using the gene-speciﬁc primer sequences: exon 1 forward –5‘ TTA AAA GGT 
ACT GGT GGA GTA TTT GAT A 3‘, (Tm=55.4 °C ) and exon 1 reverse – 5‘ AAA ATG 
GTC AGA GAA ACC TTT ATC TGT 3‘(Tm=56.3 °C).  Forty-five µL of PCR cocktail 
consisting of 10 mM Tris–HCl buffer (pH=8.3) containing 50 mM KCl, 1.5 mM MgCl2, 
200 µM dNTPs, 0.4 µM of each forward and reverse primers was added to the lysate 
previously held at 800C in the thermocycler. After a 2-min initial denaturation, 1.5 U of 
AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) was added 
under hot-start conditions and ampliﬁcation was achieved by thermally cycling for 30 
cycles at 95  °C for 30 s, 60 °C for 2 min, and a final extension at 72 °C for 3 min.  
To test the fidelity and yield of the PCR, slab gel electrophoresis was run on an 
aliquot of each reaction. From each aliquot, either 2 µL PCR product for standard cell 
solutions or 3 µL PCR product from microchip processed solutions was mixed with 1 µL 
loading dye and 3 µL of 1x TBE buffer for the standard cell solution or 2 µL of 1x TBE 
buffer for a microchip-processed solution. The mixture was then loaded into an 
individual well of an ethidium bromide prestained 3% agarose gel (Bio-Rad Laboratories, 
Hercules, CA). The slab gel electrophoresis was typically run at 5 V cm-1 for 30 min. The 
developed slab gel images were captured using Gel Logic 200 Visualizer (Carestream 
Molecular imaging, New Haven, CT) 
LDRs were executed in a total volume of 20 µL in 0.2 mL polypropylene 
microtubes using a commercial thermal cycling machine (Eppendorf Thermal Cycler 
(Brinkmann Instrument, Westbury, NY, USA). The reaction cocktail typically employed 
in this work consisted of 10 mM Tris–HCl (pH=8.3), 25 mM KCl, 10 mM MgCl2, 0.5 mM 
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NAD+ (nicotinic adenine dinucleotide, a cofactor for ligase enzyme), and 0.01% Triton 
X-100, 2 µL of 100 nM of the discriminating primer: 5‘ 
AAACTTGTGGTAGTTGGAGCTGT 3‘ (Tm=71.3 °C) and fluorescently labeled freshly 
phosphorylated common primer: 5‘ Phos/TGGCGTAGGCAAGAGTGCCT/Cy5.5Sp 3‘ 
(Tm=63.5 °C) and 2 µL of the PCR product as template.  40 U of Taq DNA ligase (New 
England Biolabs) was added to the cocktail under hot-start conditions and the reactions 
were thermally cycled 20 times for 30 s at 94 °C and 2 min at 65 °C. The LDR products 
were stored at 4 °C until needed for capillary gel electrophoresis (CGE). The LDR 
products were separated using a CEQ 8000 Genetic Analysis System (Beckman 
Coulter, Fullerton, CA, USA). Data acquisition was performed using the Beckman 
P/ACE software.  
5.3  Results and Discussion 
In the present work, we were interested in the ability to enumerate and enrich 
CTCs using a microfluidic system with their subsequent molecular characterization by 
looking for point mutations within certain gene fragments. In these studies, the SW620 
cell line was used as a model for CTC selection, enumeration, and enrichment via an 
integrated HTMSU. SW620 cells over-express the EpCAM membrane antigen and 
harbor K-ras c12.2V oncogene mutations. Circulating colorectal cancer cell line, HT29, 
which do not harbor K-ras c12.2V oncogene mutation, was used as the wild-type for 
comparison. SW620 and HT29 cells are typically 15-30 μm in diameter (Avg≈23 μm)41 
and EpCAM occurs at a frequency of 1×106 and 2.5×105 molecules per cell, 
respectively.42 In the work presented herein, we focused on: (1) The selection and 
enumeration of low-abundance SW620 cells from peripheral blood; (2) release of the 
cells from the antibody selection surface; (3) electrokinetic enrichment of the selected 
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SW620 cells; and (4) molecular profiling of low-abundance cells using a 
PCR/LDR/electrophoresis assay (see Scheme 5.1).  Release of the cells intact is critical 
because the enumeration process depends on counting via conductivity whole cells and 
the molecular profiling is performed on rare cells selected from peripheral blood and as 
such, the genetic material to be analyzed should not be diluted extensively or mixed 
with potential interfering materials.   
 
 
Scheme 5.1 Overview for the cell selection, enumeration, electrokinetic enrichment and 
molecular profiling strategy adopted for analysis of extremely low-abundant SW620 cells 
resident in peripheral blood. 
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5.3.1 SW620 Cell Selection 
The highly specific selection of SW620 CTCs was based on the recognition 
capabilities of anti-EpCAM antibodies that were tethered to the HTMSU selection beds. 
Dynamic interactions between the CTC membrane‘s receptors and the channel wall 
containing the recognition elements are important in determining the recovery of these 
rare CTCs from blood. Curvilinear-shaped channels were employed to provide high 
recovery.17 As such, the cell-free marginal zone apparent in straight channels was not 
observed in these curvilinear channels and the cell radial distribution was unaffected by 
changes in cell translational velocity.17 Chang‘s model of cell adhesion in flowing 
systems has been applied in previous reports to describe the encounter rate between 
the solution-borne cells and the surface-tethered cell selection elements.43 Therefore, 
an optimal linear velocity would be expected to guarantee a high probability of binding 
between the target molecules and the antigen based upon a balance between the 
interaction time and the encounter rate. The optimum linear velocity for selection of 
MCF-7 CTCs, which has the same mean diameter as SW620 CTCs, using EpCAM/anti-
EpCAM antibodies (KD=3.3×10
8 M-1)44 was found to be 2.0 mm s-1. Thus, according to 
the Chang and Hammer model for cell adhesion, efficient CTC/mAb adhesion was 
determined by two factors; the encounter rate (ko) and the probability (P) of interaction 
between the membrane bound antigen and the channel wall‘s tethered antibody.43 As 
such, MCF-7 and SW620 CTCs should have a similar optimum linear cell selection 
velocity of 2 mm s-1, which we employed in these experiments for the selection of 
SW620 CTCs. The selected cells were observed using fluorescence and brightfield 
microscopy as shown in Figure 5.1B.  As  Adams et al.  and  Dharmasiri  et al.  reported 
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Figure 5.1 Diagrams of the microfluidic system made via micro-replication into PMMA from a 
metal mold master. (A) Cell selection HTMSU. The capture bed consisted of curvilinear 51 
channels that were 30 µm wide and 150 µm deep. (Electro-manipulation unit consists of 80 µm 
wide, 100 µm deep and 5 cm long linear channels. The solution flow H arriving from HTMSU is 
divided at the T junction into a major flow (Heb) and a minor flow (Hec). Conductometrically 
enumerated SW620 cells were introduced to system at ‗a‘ entrance port. The ‗a‘ entrance port 
connects with b-c channel at the T intersection. ‗b‘ exit is the sample waste reservoir and c exit 
is cell reservoir. Both ‗b‘ and ‗c‘ reservoirs host Pt external electrodes; cathode and anode 
embedded in sample reservoir, ‗b‘ and waste reservoir,‗c‘, respectively. (B) Brightfield (left) and 
fluorescence (right) micrographs (43x) for the positive selection of SW620 cells infused into the 
HTMSU at a constant linear velocity flow of 2 mm s-1. The cells were suspended in a whole 
blood (100 cells mL-1) and following infusion of the cell suspension, the device was washed with 
PBS buffer prior to imaging. In all cases, the entire capture bed was imaged by scanning the 
microscope stage. The cells were stained with the fluorescein membrane probe prior to 
introduction into the HTMSU to allow visualization. (C) The selected SW620 cells enriched in 
the sample reservoir at the end of c channel. Positive Pt electrode is also in the Figure. Total 
volume of the reservoir is 2 µL. 
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that the CTCs appear to be flattened and elongated upon capture giving better adhesion 
between the CTC and selection wall. As observed experimentally (see Figure 5.1B), the 
resulting contact area was determined to be 448±18 μm2. The anti-EpCAM antibody 
density on the selection bed wall was reported to be 2.3×1011 molecules cm-2.17 
Therefore, 2.4×105 EpCAM/anti-EpCAM antibody interactions were involved in one 
cell/antibody binding event. A CTC recovery of 96±4% was found at a translational 
velocity of 2.0 mm s-1 under the conditions employed in this study. 
5.3.2 Cell Detachment from the Capture Surface 
Release of intact CTCs from the capture bed is critical for the subsequent 
conductivity enumeration followed by electrokinetic manipulation and molecular profiling 
as noted above. Enzymatic digestion of EpCAM and anti-EpCAM was achieved using 
the proteolytic enzyme, trypsin. Microscopic investigations (data not shown) revealed 
that the average time for release of the captured SW620 CTCs was ~16 min, which was 
higher than the values recorded for MCF-7 CTC release (~7 min).17 This difference 
could be accounted for by the EpCAM expression level difference between the two cell 
lines (MCF-7=5×105 and SW620=1×106 EpCAM molecules per cell).18 Due to the higher 
expression level of EpCAM present within the SW620 membrane, higher numbers of 
EpCAM/anti-EpCAM interactions must be degraded.  
5.3.3 Conductivity Enumeration of the CTCs 
The selected and released CTCs were subsequently enumerated using a 
conductivity sensor. A typical data streams are shown in Figure 5.2A. The transducer 
measured changes in the conductivity of the release buffer with respect to the buffer in 
the presence of a single CTC between the Pt electrode pair. It was found that the peak 
width for a single CTC was ~150 m s (see inset to Figure 5.2A). Tris-Glycine buffer was  
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Figure 5.2 (A) Conductometric responses generated for 1.0 mL of whole blood seeded with 10 
SW620 cells (a) 0 SW620 cells (ash) (b) and 32 HT29 (c) at a linear flow velocity of 2.0 mm s-1 
processed using the HTMSU. The captured SW620 cells were released from the capture 
surface using the release Tris-Glycine buffer comprised of 0.25% w/v trypsin and transported 
through the conductivity sensor at a volumetric flow rate of 1 µL min-1. Peaks were identified as 
SW620/HT29 cells based on a signal-to-noise threshold of 3. The insets shown in the figure 
represent a magnified view of sections of the data stream. The data presented here was 
smoothed by the Savitsky-Golay method (25 point smoothing function). The conductometrically 
enumerated cell samples were subjected to PCR followed LDR analysis. Two µL of amplicons 
from PCR were used for analyzing point mutation in the K-ras gene. The LDR products were 
analyzed using capillary electrophoresis. The capillary electrophoresis responses for the sample 
after processing blood with no SW620 (B), Sample after processing blood with 50 HT29 cells (C) 
and sample after processing blood with 10 SW620 cells (D). Peak ‗a‘ represents the primer and 
peak ‗b‘ is the LDR product for SW620.  
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selected as the major component in the release buffer due to its low conductance, 
which improved the SNR for the conductivity detection of single CTCs. There were 10 
peaks observed in the conductance response shown in Figure 5.2A (a) that could be 
assigned to SW620 cells based on a SNR threshold of 3 (99.7% confidence level) 
giving a recovery and detection efficiency of ~100% in this case (seed level=10 CTCs 
mL-1). Enumeration of HT29 cells followed cell capture showed 32 events (seed level= 
50 CTCs mL-1) in the conductivity response attributed to HT29 cells as shown in Figure 
5.2A (b).  HT29 recovery was found to be 72% likely due to its lower EpCAM expression. 
The variations in the peak response for CTC was most likely due to differences in the 
cells‘ morphology and chemical composition.  
One milliliter of a blank sample, which consisted of whole blood seeded with no 
SW620 CTCs, was analyzed by the HTMSU and enumeration via conductivity under the 
same conditions as described for peripheral blood seeded with SW620 CTCs. The 
resultant trace c is shown in Figure 5.2A. In this case, no single-cell spikes were 
observed in the conductivity data trace indicating that the signal spikes seen for the 
SW620 seeded peripheral blood sample was indeed due to CTCs.  
The trace for the SW620 spiked blood sample showed a higher background level 
as well as a slight response drift compared to the blank sample. These artifacts may 
have been due to non-specific accumulation of dissolved membrane proteins on the Pt 
electrode surface. Because these deposits are subjected to Joule effects, the electrode 
surface temperature could change during the readout phases of the measurements, 
affecting the conductance response.45  
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5.3.4 Electrokinetic Enrichment of SW620 Cells 
In the electro-manipulation unit, the total flow (H) arriving from the inlet (a) was 
divided at the T junction into a major flow (Heb) and a minor flow (Hec) (see Figure 5.1A). 
The ratio between Heb and Hec was equal to 9:1, which was set by the pressure drop 
ratio (ΔPeb/ΔPec=0.1 at 1 µL min
-1) between the two channels. As such, the device was 
designed to have only 10% of the hydrodynamic driven input volume from the HTMSU 
entering the CTC collection reservoir ((c) in Figure 5.1A). Therefore, 90% of the 
hydrodynamic driven fluid would flow into reservoir (b) as seen in Figure 5.3A-C.  
To provide efficient pre-concentration of the selected CTCs, we applied an 
electric field to specifically select solution-born CTCs from the hydrodynamic flow and 
divert them into the collection reservoir (c). As shown in Figure 5.1C, cells were 
electrophoretically diverted from the hydrodynamic flow into (c) due to their intrinsic 
electrophoretic mobility and the applied electric field, which overcame the force exerted 
on the cell by the pressure-driven flow. The volume of reservoir (c) was 2 µL in this case, 
providing a 500x enrichment factor for the CTCs (input volume=1 mL). The electric field 
applied between (b) and (c) generated an electrokinetic flow. We placed the anode at 
the exit reservoir of channel (c) and the cathode at reservoir (b).  
According to the Smoluchowski  equation, the electrophoretic mobility of cells is 
determined by the surface bound charged groups, such as the sialic and carboxylic acid 
groups, lysine side chain amino groups, sulfhydryl groups and alkaline phosphatase-
susceptible phosphate groups.46 Thereby CTCs possess a net negative surface charge 
(Q) at pH=8.3 of; 
                                           Q=4 ρ ∏rp
2   (1) 
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whereas ρ is the charge density, -5.8×10-14 C µm-2,48 and rp is the cell radius, 11.5 µm 
for CTCs. Therefore, the average net surface charge (Q) of a typical CTC is 
approximately -9.6×10-11 C. Because Q is set by protonation/deprotonation of 
membrane-bound proteins and other groups, the CTCs‘ charge can be controlled by 
altering the properties of the buffer solution (i.e., pH, ionic strength, salt composition). 
This along with the size of the CTC and its zeta potential will determine its 
electrophoretic mobility.  
The electrophoretic force acting on a particle with a net charge Q under an 
electric field strength of V/q is given by;52  
                                         FEP=Eq=QV/d   (2) 
where V is the applied voltage and d is the distance between cathode and anode. 
Therefore, the electrophoretic force acting on the cell was calculated to be 9.6×10-9 N. 
In this study we used PBS (50 mM) and Tris-Glycine buffer in preliminary cell 
manipulation studies. It was observed that SW620 cells resident in 50 mM PBS were 
subjected to lysis at the electric field strength of 100 V cm-1. The cell migration velocity 
calculated to be 100±16 µm s-1  at 100 V cm-1 electrical field strength. On the other hand, 
utilization of Tris-Glycine buffer (0.2 mM Tris/19.2 mM Glycine) improved the CTC 
manipulation conditions dramatically. Tris-Glycine buffer is a lower ionic strength buffer 
and it has been found to increase the target cells‘ zeta potentials and mobility.49 Buffers 
of low ionic strength have the additional advantage of minimizing ohmic losses50 and 
consequently, heating effects.  
In addition, because electrolysis occurs at the electrodes, the buffer must negate 
possible changes in pH and maintain a constant charge on the cells being manipulated. 
Therefore, the SW620 cells were not found to lyse at 100 V cm-1 throughout the course  
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Figure 5.3 Micrographs (43x) showing SW620 cell manipulation in the elecro-manipulation unit. 
The SW620 cells resident in Tris-Glycine buffer were introduced from inlet of channel ‗a‘. A, B, 
C) The cells are travelling at 1 µL min-1 flow rate. The hydrodynamic flow direction is given in 
white arrow.  The majority (90%) of the cells are travelling from a-b, which has less pressure 
drop (0.7 psi at 1 µL min-1) compared to the pressure drop of a-c (7 psi at 1 µL min-1). D, E, F) 
The SW620 cells movement in the presence of electric field strength of 100 V cm-1. The 
electrophoretic movement direction of cells is given in red arrow. 
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of the cell manipulation and the cell migration velocity was calculated to be 130±15 µm 
s-1.  This field may cause membrane permeation but did not result in cell lysis.51 It took 
approximately 5 min for the cells to migrate from the T junction to the (c) sample 
reservoir. We applied higher electric field strengths to speed up the cell migration rate, 
however, an electric field ≥200 V cm-1 resulted in a higher velocity 160±17 µm s-1, but 
also extensive cell lysis. We also found that applying an electric field strength of 100 V 
cm-1 along with a hydrodynamic flow rate of 1 µL min-1 (linear velocity=3.3 mm s-1) was 
sufficient for the CTCs to be effectively collected into (c) reservoir with nearly 100% 
efficiency.  Figure 5.3 D-F illustrates two cells moving in the direction toward the anode. 
Above 1 µL min-1 flow rate, cells were not diverted toward the anode and they 
maintained their traveling direction with the hydrodynamic flow towards the waste 
reservoir.  
For an incompressible Newtonian fluid of low Reynolds number, the fluid motion 
is governed by the Stoke‘s equation. In the T junction, The Stoke‘s frictional force on a 
charged particle is due to the relative motion of the particle with regard to the EOF and 
is given by;52   
                                   FStoke’s = -6∏ηrp(Uh+UEOF)  (3) 
For the present experiments, η the solution viscosity is 7.98×10-4 N s m-2,54 rp is the 
radius of the cell, and Uh is linear velocity of the hydrodynamic flow of Heb  (3.0×10
-3 m s-
1), which is the 90% of optimum linear velocity (3.3×10-3 m s-1) for cell manipulation into 
reservoir (c). The EOF value for 0.25% w/v trypsin/0.2 mM Tris/19.2 mM Glycine buffer 
solution has been determined to be 3.1×10-4±0.23×10-4 cm2 V-1 s-1 at pH=8.3. Therefore, 
the linear velocity (UEOF) for corresponding EOF is 3.1×10
-4 m s-1. For pristine PMMA, 
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the apparent surface pKa value was found to be 4.2, indicative of carboxylic acid 
functional groups present on the surface. At pH=8.3, the PMMA surface consists of 
negatively charged functional groups producing a cathodic EOF53 in the same direction 
as the hydrodynamic flow of Uh in the e-b section of the channel. The total Stoke‘s force 
on the SW620 cell at the T junction was calculated to be 5.0×10-10 N.  
 At junction T, the electrophoretic force (9.6×10-9 N) is larger than the Stoke‘s 
force (5.0×10-10 N) acting on the cell. Therefore, CTCs are diverted into the collection 
reservoir (c) (see Figure 5.3D-F). In addition, the linear velocity (U’h) of the 
hydrodynamic flow of Hec  (3.0×10
-4 m s-1), which is the 10% of optimum linear velocity 
(3.3×10-3 m s-1) for cell manipulation into reservoir (c) is in opposite direction to the 
linear velocity (3.1×10-4 m s-1) of EOF in the e-c section of the channel. As such, 
hydrodynamic flow force is cancelled out by the electroosmotic flow in the e-c section of 
the channel. The apparent electrophoretic mobility of the SW620 cells was calculated to 
be 1.23 cm2 V-1 s-1. This value is closely correlated to the experimental value of 1.30 
±0.15 cm2 V-1 s-1.  
Chip-to-chip reproducibility of the measured cell flow velocities varied slightly 
however, the direction of the cell transport was reproducible from chip-to-chip. For 
example, in 3 different PMMA devices, the RSD for the velocities were 10–15%.  
 It was found that smaller cells moved slightly faster and thus could climb over 
the larger cells moving in front, if the centers of the cells were not located on the same 
line parallel to the applied electric field. The net charge on the cell also depends on its 
mitosis stage and surface area.46 Thus, cells with different negative surface charge 
densities migrated at different speeds.  
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In preliminary studies, we used channels of 80 µm×100 µm and 50 µm×100 µm 
of width and depth, respectively. We observed a near-wall enhancing effect, which was 
reported by Xuan et al.55 As such, the cell velocity observed for the 80 µm×100 µm 
channel was lower (110 µm s-1±10) at 100 V cm-1 than the velocity observed for 50 µm 
×100 µm channels (130 µm s-1±15) at 100 V cm-1.  When the particle–wall separation 
distance became smaller, the local electric field in the gap became stronger and hence, 
the electric force dominated over the viscous friction and the electrophoretic motion 
increased. In addition to the translational electrokinetic motion, the spherical particle 
also has a rotational motion due to the asymmetry of the electric field and the flow field. 
The particle rotational motion was more obvious in the 80 µm×100 µm channels, where 
the boundary effect was more dominant.56 
Downstream PCR and LDRs required very sensitive analysis of low-abundant 
point mutations in the gDNA, and this could be inhibited by the presence of trypsin. 
However, we were able to perform PCR/LDR reactions effectively; we noted that the 
trypsin did not inhibit PCR/LDR assays. The cell releasing agent, 0.25% trypsin, 
possessed a net positive charge at pH=8.3 (pI=10.3).57 Therefore, trypsin migrated 
toward the cathode with the EOF facilitating efficient separation of the CTCs and trypsin. 
In addition, the surface ―softness‖ (i.e., the rigidity and ion permeability of glycocalices) 
may be influenced by trypsin treatment of the CTCs.58 We did not observe significant 
variation of the electrophoretic mobility of the CTCs with and without treatment of trypsin 
for ~30 min; it appeared that proteases may remove negative charges from the cell 
surface but still maintain the electrophoretic mobility.59  
Because fluorescence microscopy was used for initial cell visualization, the cells 
were fluorescently labeled using fluorescein derivative, fluorescein isothiocyanate 
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(FITC), which has a net negative charge at pH=8.3.60 In the cell staining process, FITC 
conjugates with membrane lipids could produce more net negative charges on the cell 
surface, producing a greater electrophoretic mobility 1.35±0.11 cm2 V-1 s-1  than for cells 
that were stained.  
From these experiments, we noticed negligible amounts of cell adhesion of the 
SW620 cells to the channel walls of the electro-manipulation unit. It was noticed during 
device operation that some of the immobilized/adsorbed cells could be removed by 
applying higher electric fields. This was partially caused by an increase in the number of 
collisions between the flowing and stagnant cells as well as stronger fields that were 
able to ‗‗lift‘‘ cells from the polymer surface, suggesting that the adhesion forces of the 
cell to the polymer surface were not strong enough to withstand the electric force. We 
have observed less cell adhesion for devices with 50 µm×100 µm channel dimensions 
compared to those of 80 µm×100 µm dimensions. This effect may arise from higher 
frequency of collisions between moving cells and the adhered cells in the smaller 
channels.  
5.3.5 PCR and LDR Mutation Profiling 
A method that can detect single point mutations in DNA is the ligase detection 
reaction (LDR) coupled to a PCR (see Scheme 5.1) and this was used to search for 
point mutations in the enriched CTCs.35,61-68 Following PCR amplification of the 
appropriate gene fragments, which contain sections of the gene with point mutations, 
the amplicon is mixed with two LDR primers, a common and discriminating primer that 
flank the point mutation of interest. The discriminating primer contains a base at its 3‘-
end that coincides with the single base mutation site. If bases are mismatched, ligation 
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of the two primers does not occur. A perfect match, however, results in a ligation of the 
two primers and a product length that is the sum of the two oligonucleotides primers.  
In our experiment, enriched CTCs were lysed and the PCR/LDR assay was 
performed to search for point mutations in codon 12 of the K-ras gene (c12.2V). Most K-
ras mutations for colorectal cancer patients are localized within codon 12, but are also   
               
Figure 5.4 Agarose gel electrophoresis of the PCR products. PCR was set for 32 cycles, with 
initial denaturation of 2 min and final extension of 7 min. Each cycle consisted of: 94 °C (30 s), 
60 °C (30 s), 72 °C (40 s). Gel stained with ethydium bromide were run at 4.8 V cm-1. (A) Gel 
electropherogram for PCR performed on  standard SW620 samples (a) no gDNA template, 
Negative control;  (b) DNA from 10 SW620 cells; (c) DNA from 20 SW620 cells; (d) DNA from 
50 SW620 cells; (e) DNA from 100 SW620 cells; (f) DNA from 500 SW620 cells; (g) DNA from 
1,000 SW620 cells; (h) DNA from 5,000 SW620 cells; (i) gDNA template from SW620, Positive 
control; Lanes a-i contains  3 µL of DNA amplicons. (B) Gel Electropherogram for PCR 
performed on SW620 cells obtained from HTMSU selection followed by electrokinetic 
enrichment (a) gDNA template from SW620, Positive control; (b) PCR product from 10 SW620 
cells selected from whole blood using HTMSU (c) PCR product from whole blood with no 
SW620 cells (d) no gDNA template, negative control. Lanes a-d contains 3 µL of DNA 
amplicons. 
 
present in codons 13 and 61;69-76 they are found in nearly 35–50% of all patients with 
colorectal cancer.77-79 Once acquired, K-ras mutations are conserved throughout the 
143 
 
course of disease progression. The PCR phase of the assay was first evaluated using 
different numbers of SW620 cells, ranging from 10-5,000 cells in control experiments. In 
these experiments, the required number of cells was added to a PCR tube, thermally 
lysed and the PCR reagents added to the tube. As shown in Figure 5.4A, cells ranging 
from 5,000 to as low as 10 were successfully amplified to yield 300 bp PCR products 
based on the primers used for the PCR amplification of codon 12 of the SW620 cells.  
To demonstrate the capability of our integrated HTMSU with cell enrichment for 
subsequent molecular profiling, 1 mL of whole blood containing low-abundance CTCs 
was processed. Ten SW620 cells were selected and enriched from 1 mL of whole blood 
and subjected to PCR yielding the results shown in the Figure 5.4B lane (b). The 
success of the PCR reaction on 10 CTC was confirmed by the positive and negative 
control experiments as shown in the Figure 5.4B lane (a) and (d) respectively. As 
expected, no PCR amplicon was generated from the whole blood as shown in Figure 
5.4 lane (c). The presence of mutations within the amplicon (~300 bp) was analyzed by 
LDR. The LDR common primer possessed a Cy5.5 ﬂuorescent label and a 5‘ 
phosphorylation modification to facilitate covalent coupling with the discriminating primer 
for the detection of successful ligation events produced as a result of the LDR and the 
subsequent analysis using capillary gel electrophoresis with laser-induced fluorescence 
detection. Point mutations were identified through the observation of a 43 nt product. 
The capillary gel electrophoresis results of LDR products generated from different 
numbers of CTCs processed using the HTMSU and electro-manipulation unit are shown 
in Figures 5.5A-G. Clearly, the results indicated the ability to identify point mutations 
from as few as 10 CTCs seeded into the whole blood sample and subjected to CTC 
selection and enrichment. The HT29 (wild-type) lacks K-ras c12.2V point mutation in the 
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K-ras gene, which was confirmed by  the absence of 43 nt LDR product, as shown by  
capillary gel electrophoresis results of the LDR products generated from 50 HT29 cells 
in Figure 5.5H. Three samples, one containing whole blood without CTCs, a second one 
 
Figure 5.5 The LDR mixtures with a discriminating and common primers for K-ras c12.2V, could 
selectively detect this mutation. Two µL of amplicons from PCR with SW620 (mutant) and HT29 
were used for analyzing point mutation in the K-ras gene. LDR was set for 20 cycles. Initial 
denaturation 95 °C for 2 min. Each cycle consisted of: 95 °C (30s), 65 °C (2 min), and 4 °C as 
final hold. LDR was performed at capillary temperature of 60°C, denaturation temperature of 
90 °C (3 min),  Injection at 2.0 kV (30 s) and separation at 6.0 kV (20 min).  Peak a represent 
the primer and peak b represents the LDR product. Capillary electrophoresis products for A) 0 B) 
10 C) 20 D) 50 E) 100 F) 500 and G) 5000 cells of SW620. The insets in A and B show the 
magnified scaled plot of products. H) LDR product for 50 cells of HT29. 
 
containing 32 cells from HT29 cells, and a third sample containing 10 SW620 cells were 
processed via the HTMSU and enriched with the electro-manipulation unit. The three 
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samples were subjected to PCR/LDR/capillary gel electrophoresis and yielded the 
results shown in Figures 5.2B-D. As expected, our results showed the presence of no 
mutations in the whole blood that contained no CTCs (Figure 5.2B) which served as a 
negative control. The sample containing 34 HT29 cells did not show any product (Figure 
5.2C) because it does not harbor 12.2V point mutation and served as a wild-type in this 
assay. Conversely, the results of whole blood that contained 10 SW620 cells produced 
43 nt long LDR product indicative of 12.2V point mutation as shown in Figure 5.2D.  
5.4  Conclusions 
Previously, it has been reported a positive selection of MCF-7 and LNCaP cancer 
cells from peripheral blood using affinity agents such as antibodies and aptamers 
immobilized HTMSU. In here, I have integrated HTMSU with electrokinetic enrichment 
microfluidic unit for performance of single recombinant low-abundance CTC cell-based 
assay. A series of analytical processes were carried out, including immunoaffinity 
selection of rare CTCs, quantification of selected cells via conductivity impedance and 
electrophoretic enrichment of selected cells for PCR/LDR/CE interrogation for detection 
of low abundant point mutations in genomic DNA. We also showed the ability to recover 
cells with ∼96±4% efficiency from the whole blood and ~100% efficient electrokinetic 
enrichment of selected CTCs for molecular profiling. The strategy developed offered the 
ability to effectively profile low-abundant point mutations harbored in rare CTCs in 
patients‘ blood without the interferences of highly abundant leukocytes.  The entire 
series of processing steps can be implemented in under 40 min for 1 mL of blood 
sample, and the processing volume could significantly be increased by increasing the 
throughput of the fluidic chip through the use of more fluidic vials that are deeper can 
provide the opportunity to process 10 mL of input blood directly. In addition, moving the 
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PCR/LDR step to the chip can also reduce processing time significantly and improve the 
sensitivity due to the more efficient thermal management properties of microscale 
molecular profiling. 
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CHAPTER 6 FUTURE WORK: HIGHLY EFFICIENT SEPARATION OF PURE 
HEMATOPOIETIC STEM CELLS FROM WHOLE BLOOD  
 
6.1  Introduction  
The stem cells that generate blood and immune cells are termed as 
hematopoietic stem cells (HSCs). Recently, it has been found that HSCs are able to 
form epithelial cells, such as muscle, blood vessels, and bone.1 Lagasse et al. 
demonstrated that the liver can be repaired by purified HSCs; therefore, HSCs have the 
potential to integrate into and grow in some epithelial tissues. This may eventually make 
it possible to use HSCs to replace a wider array of cells and tissues.2 In addition, there 
have been suggestions that umbilical cord blood contains stem cells having the 
capability of developing cells of multiple germ layers (multipotent) or even all germ 
layers, e.g., endoderm, ectoderm, and mesoderm (pluripotent).3 Another potential use 
of HSCs is in the treatment of hereditary blood disorders such as aplastic anemia, beta-
thalassemia, Blackfan-Diamond syndrome, globoid cell leukodystrophy, sickle-cell 
anemia, severe combined immunodeficiency, X-linked lymphoproliferative syndrome, 
and Wiskott-Aldrich syndrome.4 Also, HSCs can be utilized for the replacement of blood 
cells that are destroyed by chemotherapy. Thus, these cells can be stored while the 
patient undergoes intensive chemotherapy or radiotherapy that is used to destroy the 
cancer cells. Once the drugs are washed out of the patient's body, the patient receives 
a transfusion using the stored HSCs.5 One problem with the use of autologous HSCs 
transplants in cancer therapy is that circulating tumor cells (CTCs) are sometimes 
inadvertently collected and reinfused into the patient along with the HSCs. 
Reintroduction of CTCs can be eliminated by specific selection and separation of HSCs 
from whole blood.6 
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To harvest HSCs, an intravenous tube is inserted into the donor's vein and the 
blood is passed through a filtering system that pulls out CD34 white blood cells (WBCs) 
and returns the red blood cells (RBCs) to the donor. The most common approach to 
identify HSCs is to utilize membrane markers such as CD34, CD59, CD38, Thy1 and/or 
SCA-1.9 Unfortunately, these markers are non-specific for HSCs and they have been 
occasionally expressed in WBCs and RBCs when in an activated state.10 Therefore, of 
the cells collected, only 5-20% are genuine HSCs and the remainder are a mixture of 
WBCs of various degrees of maturity.7  
In addition, another major issue with selection of HSC levels is the low-
abundance or rare-event nature of these cells among a higher number of spectator cells 
in peripheral blood. For example, ~1,000 HSCs are in whole blood, which is composed 
of >109 erythrocytes and >106 leukocytes per mL. In addition, there are multiple types of 
stem cells with rare, long-term replicating ability, which are morphologically similar to 
WBCs or bone marrow cells.8 
SELEX (systematic evolution of ligands by exponential enrichment) is a method 
used to generate DNA or RNA aptamers from a combinatorial library. Aptamers with 
high affinity and specificity for cells have already been produced successfully, 
demonstrating that complex targets, including tumor cells and tissues, are compatible 
with the SELEX process.12 Guo et al. generated aptamers for the isolation of HSCs from 
whole bone marrow. When bound to a surface, the aptamers could be used for HSCs 
tracking. Furthermore, they found that after immobilizing the aptamers targeted against 
osteoblasts on titanium, the aptamer-coated titanium surface could enrich osteoblasts 
quickly and efficiently.11  
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Aptamer technology has been used for protein-protein interaction research and 
for molecular recognition. It is a robust technology to identify specific targets. The cell-
SELEX process allows the selection of highly specific aptamers with high binding 
affinities without prior knowledge of any biomarkers or proteins on the cell membrane.13 
It has been reported that cell-SELEX can be used to identify minor molecular-level 
differences among similar categories of cells.14 In addition, The cell-SELEX process 
allows for aptamers to be selected from cells in their native state. In fact, through 
biomarker discovery, the molecular nature of the membrane can then be explored to 
derive even more information by the selected aptamers for an understanding of the 
molecular foundation of the cell membrane, which has been preliminarily demonstrated 
by Blank and co-workers.18 
On the other hand, improved performance of microsystem technologies is 
emerging as fundamental to high-sensitivity cellular analysis technologies. In particular, 
microsystem platforms enable one to handle small numbers of cells without loss.15 
Already, aptamers and antibodies have been incorporated into microsystems to 
effectively isolate low-abundance CTCs.13,16,17 The challenge for imposing low-
abundance cell–selection assays to microsystems is sampling; to generate a high 
statistical probability of selecting the low-abundance cells, large input volumes must be 
processed and most microsystems cannot handle large-volume inputs in reasonable 
times. Adams et al. recently reported a microsystem having high-throughput 
capabilities.16,17 In this system, 1 mL of blood could be processed in ~30 min.  
Therefore, proposed herein is a novel approach to selectively isolate HSCs from 
peripheral blood using an ultra-high-throughput microsystem. The cell-SELEX 
procedure will be implemented to generate HSCs specific aptamers.  The developed 
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HSCs specific aptamers will be immobilized onto ultra-high aspect ratio microstructures 
for high-throughput selection of HSCs from whole blood. The isolated HSCs will be 
released into solution a using complementary oligonucleotide, pH or ionic strength 
changes in the medium. As such, viability and physiological integrity of the selected 
HSCs will be conserved for downstream clinical applications.  
6.2  Materials and Methods  
6.2.1  Cell Suspensions  
HSCs (ATCC) will be cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s 
Medium supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate 
(NaHCO3), 15 mM HEPES buffer, and 10% fetal bovine serum. A cell stripper 
(Mediatech, Inc.) solution will be used to harvest the HSCs from the culturing plate. 
HSCs will be stained with PKH67 for microscopic visualization experiments using 
fluorescence. Cell counts for seeding experiments into whole blood will be determined 
by counting three aliquots of cells in succession using a hemacytometer.  
6.2.2  Cell-SELEX Library and Primers 
The HPLC-purified library will contain a central randomized sequence of 45 
nucleotides (nt) flanked by 20-nt primer hybridization sites 
(ACGCTCGGATGCCACTACAG-45nt-CTCATGGACGTGCTGGTGAC) (Applied 
Biosystems). 5‘-primer (5‘-FITC- ACGCTCGGATGCCACTACAG-3‘) and a biotinylated 
(Bio) 3‘-primer (5‘-Bio- GTCACCAGCACGTCCATGAG-3‘) (Applied Biosystems) will be 
used in the PCR reactions for the synthesis of DNA molecules. After denaturing in 0.2 M 
NaOH, the ssDNA aptamer will be separated from the biotinylated antisense ssDNA 
strand by streptavidin-coated sepharose beads (Amersham Bioscience) and used for 
next round selection.14  
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6.2.3 Cell-SELEX Procedures for Generation of Panel of Aptamers for HSCs 
The ssDNA pool will be dissolved in a binding buffer. The binding buffer will be 
prepared by adding yeast tRNA (0.1 mg mL-1; Sigma) and BSA (1 mg mL-1) (Fisher) into 
wash buffer. Then, the ssDNA pool will be incubated with a target HSCs (ATCC) 
monolayer in a T25 flask on ice for 30 min. The adherent cells will be scraped from the 
culturing medium and washed. The bound DNAs on the cells‘ membrane will be eluted 
by heating at 95 °C for 5 min in a binding buffer. The eluted DNAs will then be incubated 
with a WBC and RBC monolayer in a dish (control cells) for counter selection on ice for 
1 h. The supernatant will be desalted with a NAP 5 column (GE Healthcare) and then 
amplified by PCR with biotin-labeled primers (10-20 cycles of 0.5 min at 94 °C, 0.5 min 
at 58 °C, and 0.5 min at 72 °C, followed by 5 min at 72 °C; Taq-polymerase and 
dNTP‘s). The selected sense ssDNA will be separated from the biotinylated antisense 
ssDNA strand by streptavidin-coated sepharose beads. In the first round, the amount of 
initial ssDNA pool will be dissolved in 1 mL of binding buffer and the counter selection 
step will be eliminated. In order to acquire aptamers with high affinity and specificity, the 
wash strength will be enhanced gradually by extending wash time (e.g. from 1 to 10 
min), increasing the volume of the wash buffer (e.g. from 1 to 5 mL) and the number of 
washes (e.g. from 3 to 5). Additionally, 20% FBS and 50-300-fold molar excess of an 
88-mer random DNA library will be added to the incubation solution to reduce the 
nonspecific binding of the selected pool. After 16 rounds of selection, the selected 
ssDNA pool will be PCR-amplified using unmodified primers and cloned into 
Escherichia coli using the TA cloning kit (Invitrogen). Cloned sequences will be 
determined by genome sequencing.14  
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6.2.4 ultra-High-Throughput Microsampling Unit (uHTMSU) Fabrication 
The proposed microfluidic will consist of multiple fluidic conduits (460) to reduce 
the pressure drop across the device while allowing for high volume throughput. (e.g. 10 
mL of blood in 20 mins at 2 mm s-1 linear velocity flow). The device will consist of a 
series parallel high-aspect ratio channels sharing common input/output ports. Initially, 
microstructures will be milled onto the surface of a brass plate with a high-precision 
micromilling machine (KERN MMP 2522, KERN Micro-und Feinwerktechnik GmbH & 
Co.KG; Germany). The devices will be replicated from a mold masters using hot 
embossing. The substrate selected for the HTMSU will be PMMA due to its high fidelity 
of forming structures with high-aspect ratios via micro-replication, minimal non-specific 
adsorption of biological components to its surface and its ability to generate functional 
surface-scaffolds through UV irradiation for the attachment of a variety of biological 
moieties.  
6.2.5 Aptamer Immobilization 
The uHTMSU devices will be loaded with a 10 mM aptamer solution also 
containing 4 mg mL-1 EDC and 40 mg mL-1 NHS in 150 mM MES (pH=6). The solution 
will be allowed to incubate in the device for 2 h at room temperature. The device will 
then be rinsed with a solution of PBS (pH=7.4) to remove any non-specifically bound 
constituents. 
6.2.6 HSCs Selection Using the uHTMSU 
The blood/reagent container will be made up in 50 mL thin wall plastic tubes. 
Helium gas will be used to pressurize the system for infusing the solution into the 
uHTMSU. The reagent/blood container will be connected to a helium gas regulator and 
to the input port of the HTMSU via a plastic tube with 250 µm internal diameter. The 
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flow rate of the system will be proportional to the helium gas pressure applied. 
Therefore, the flow rate of the input blood/solution can be controlled by regulating   the 
helium gas pressure. 
 The aptamer immobilized uHTMSU will be subjected to a pre-cell capture rinse 
with 0.2 mL of 150 mM PBS at 50 mm s-1 linear velocity. Then, the appropriate volume 
of cell (~10 mL) suspension will be introduced into the uHTMSU at the appropriate 
linear velocity to isolate the HSCs. Next, a post-capture rinse will be performed with 0.2 
mL of 150 mM PBS at 50 mm s-1 to remove any non-specifically adsorbed cells. In 
cases where the cells require optical visualization to assist in the operational 
optimization of the uHTMSU, the PMMA devices will be fixed to a programmable 
motorized stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) microscope and 
video images were collected during each experiment at 30 frames per second using a 
monochrome CCD (JAI CV252, San Jose, CA). 
6.2.7 HSCs Release from the uHTMSU 
Following a post cell capture rinse performed with 0.2 mL of 150 mM PBS, the 
cell releasing step can be implemented. The released cells should be viable and have 
conserved physiological integrity for downstream clinical applications. It has been 
reported that aptamer-target complexes can be disrupted by changing medium pH, ionic 
strength or introducing the complementary oligonucleotide. Each method will be 
implemented to find the ideal conditions for releasing viable HSCs into solution. The cell 
releasing process will be observed via microscopy. 
6.3  Expected Results and Significance 
The HSCs specific aptamers will be tethered to the channel walls, dynamic 
interactions between aptamer specific cell membrane‘s receptors and the channel wall 
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is important for the recovery of HSCs. An optimal linear velocity would be expected to 
guarantee the highest frequency of interaction between surface bound aptamers and 
HSCs. The optimum linear velocity depends upon the association constant between cell 
membrane antigen and the aptamer. Here, panel of aptamers will be utilized and 
multiple cell surface biomarkers will be targeted. Therefore, determination of optimum 
linear velocity for maximum cell recovery in the presence of multiple interactions will be 
an interesting factor to investigate. 
The panel of aptamers will selectively and specifically immobilize HSCs without 
prior knowledge of any cell membrane biomarkers. Isolated cells will be released using 
the complementary aptamers,13 changing pH or changing ionic strength of the 
medium.14 These cell releasing methods will have minimal impact on the integrity and 
viability of the cell. Therefore, the cells harvested will be suitable for downstream 
applications such as clinical cell implantations. 
6.4  Dissertation Summary 
After brief overview of low-abundance cell selection techniques in chapter 1 and 
circulating tumor cells in chapter 2, this dissertation initially focuses on the development 
of aptamer incorporated high-throughput microfluidic techniques to select rare 
circulation prostate cancer cells (LNCaP) directly from whole blood. The compelling 
advantage of this methodology was that no sample pre-treatment was necessary and 
the throughput, recovery, and purity were extremely high, contrary to what has been 
seen in other low-abundance cell selection formats utilizing size or affinity capture. The 
ability to quantify the selected cells with near 100% detection efficiency using a 
conductivity readout format allows for the use of this simple system at the point-of-care 
for the management of cancer-related diseases from a simple blood test.  
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Then, we extended the technology to environmental samples to improve  
sensitivity and portability of traditional groundwater assessment. As a model bio- 
pathogen, E. coli O157:H7 was chosen due to its toxicity and adverse impact on 
recreational waters. Low-abundance (<100 cells mL-1) E. coli O157:H7 cells were 
isolated and enriched from environmental water samples using a microfluidic chip that 
its capture beds were covalently decorated with E.coli O157:H7 specific polyclonal  
antibodies. After cell selection, the cells were released and enumerated using bench-top 
real-time quantitative polymerase chain reaction (PCR), targeting genes which 
effectively discriminated the O157:H7 serotype from other nonpathogenic bacteria. The 
strategy developed offered the ability to monitor water quality without the need for a 
time-consuming cell culture step. We subsequently performed analysis of lake and 
wastewater samples. The simplicity in manufacturing and ease of operation makes this 
device attractive for the selection of pathogenic species from a variety of water supplies 
suspected of containing bacterial pathogens at extremely low frequencies. We envision 
the potential to probe for a large number of different strains of enterohemorrhagic E. coli, 
which includes more than 100 different non-O157 strains. By proper choice of pAbs and 
specific probes for the real-time qPCR, one could monitor a large panel of suspected E. 
coli strains from a single sample. 
Finally, we have integrated HTMSU with electrokinetic enrichment microfluidic 
unit for performance of single recombinant low-abundance CTC cell-based assay. A 
series of analytical processes were carried out, including immunoaffinity selection of 
rare CTCs, quantification of selected cells via conductivity impedance and 
electrophoretic enrichment of selected cells for PCR/LDR/CE interrogation for detection 
of low-abundance point mutations in genomic DNA. The HTMSU was equipped with a 
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conductivity sensor utilized for CTC selection and automatic quantitation. Following 
enumeration of the CTCs, they were hydrodynamically transported to an on-chip 
electro-manipulation unit for preconcentration of the CTCs into a receiving reservoir in a 
controlled manner.  The preconcentrated CTCs could then be genetically profiled to 
search for point mutations using a PCR/LDR/CE assay. The DNA was extracted from 
the CTCs and subjected to a primary polymerase chain reaction (PCR) with the 
amplicons used for a ligase detection reaction (LDR) to probe for K-ras G12.2V 
oncogene mutations. This system directs towards a self-contained and fully integrated 
fluidic system for the molecular profiling of low-abundance CTCs (~10 cell mL-1 of whole 
blood)  scattered among peripheral-blood nucleated cells (~106 cells mL-1 of whole 
blood). 
6.5  Immediate Projections 
With minor modifications to the techniques, such as increasing the number of 
capture channels, changing the channels dimensions, changing the immobilized affinity 
agents, changing the releasing agent and changing the electric field strength of the cell 
manipulation section, this technology will be widely applicable for different cell selection, 
and enrichment assays. In addition, moving the PCR/LDR step to the chip can also 
reduce processing time significantly and improve the sensitivity greatly due to the more 
efficient thermal management properties of microscale molecular profiling. In addition, 
the cells can be subjected to further investigations such as viability and culturing for 
development of new array of personalized cell lines. Experimental optimization of the 
parameters will have significant impact on extending the applicability in disease 
diagnostics and prognostics. Further, in the environmental regime, investigation with 
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these devices will yield assessment of environmental samples for low-abundance bio-
pathogens.  
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